Modr a Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V 3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
 
 
 
 
CLINICAL TRIAL  PROTOCOL  
Protocol  Title  “A multicentre  Phase II b trial to evaluate the efficacy and 
tolerability of ModraDoc006/r in subjects with metastatic 
Castration Resistant Prostate Cancer (mCRPC), suitable for 
treatment with a taxane”  
EudraCT  / IND   2019 -000582 -21 / IND 140355  
Clinical Phase  IIb 
Protocol No.  M18MDP  
Compound  ModraDoc006/r  
Sponsor  Modra Pharmaceuticals  
Barbara Strozzilaan 201  
1083 HN  Amsterdam,  The Netherlands  
Phone:   +31 (0)  20-205 0188  
 
Version  Final  Version 3.0 
Date  31 Mar 2020 
 Confidential  
This document contains Modra Pharmaceuticals information that is confidential, a trade –secret and/or 
proprietary in nature. It is provided to you for your confidential review on behalf of Modra 
Pharmaceuticals and is not to be photocopi[INVESTIGATOR_530], disclosed or transmitted to an y other person or party 
who is not covered by a Confidential Disclosure Agreement with Modra Pharmaceuticals except that 
the document may be disclosed to appropriate Institutional Review Boards (IRB) or Ethics 
Committees (EC) as long as they are required t o maintain its confidentiality. As the Principal 
Investigator [INVESTIGATOR_364731]. You will be sent updated information and/or amendments as they 
become available.  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    2 
PROTOCOL SIGNATURE [CONTACT_364861].:  M18MDP  
Compound:  ModraDoc006/r  
Title:  “A multicentre  Phase IIb trial to evaluate the efficacy and 
tolerability of ModraDoc006/r in subjects with metastatic 
Castration Resistant Prostate Cancer (mCRPC), suitable for 
treatment with a taxane”  
Issue Date / Version  31 Mar 2020 / Final  V3.0 
Sponsor name:  [CONTACT_364862]:  Barbara Strozzilaan 201  
1083 HN Amsterdam, The Netherlands  
Phone: + 31 (0)  20-205 0188  
  
By [CONTACT_31300], the Sponsor agrees to the content of the Protocol  as outlined.  
 
 
J.H.M. Schellens, MD, PhD   01-Apr-2020  
Chief Medical Officer   Signature   [CONTACT_1782]  
[PRINT IN BLOCK CAPI[INVESTIGATOR_364732]]  
 
 
C. Freund, MA  01-Apr-2020  
Chief Executive Officer    Signature   [CONTACT_1782]  
[PRINT IN BLOCK CAPI[INVESTIGATOR_364732]]  
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    3 PROTOCOL SIGNATURE [CONTACT_364863].:  M18MDP  
Compound:  ModraDoc006/r  
Title:  “A multicentre Phase IIb trial to evaluate the efficacy and 
tolerability of ModraDoc006/r in subjects with metastatic 
Castration Resistant Prostate Cancer (mCRPC), suitable for 
treatment with a taxane”  
Issue Date / Version : 31 Mar 2020 / Final  V3.0 
Institution Name (Site #):   
Institution Address:  
  
I have read this protocol and agree to conduct this trial in accordance with all stipulations of the 
protocol and in accordance with all relevant local regulations, the current International 
Conference on Harmonization (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use Guideline fo r Good Clinical Practice (GCP), and with the 
principles of the most recent version of the Declaration of Helsinki.  
 
 
 
 
Investigator Name   [CONTACT_155436]  
[PRINT IN BLOCK CAPI[INVESTIGATOR_364732]]  
 
 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    4  
 
 
 
DOCUMENT HISTORY  
 
M18MDP * 
Document  Protocol  
version  Issue date  Amendment 
type Comments  
Clinical Trial 
Protocol  1.2 31 Jan 2019  - New Protocol  
Amendment 1  2.0 05 Mar 2019   Includes clarifications on exclusion 
criteria, dose modifications and 
administrative aspects.  
Amendment 2  3.0 31 Mar 2020   Includes change  from O bjective  Response 
Rate (ORR)  to radiographic Progression 
Free Survival (rPFS) as primary endpoint; 
adaption of starting dose for 
ModraDoc006/r (arm B); harmonization of 
assessments for both arms; widening of 
screening window; minor clarifications 
and corrections.  
     
     
*This overview only lists general amendments to the protocol. Site - and country -specific amendments to the protocol 
are not included.  
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455595] DETAILS  
At Modra Pharmaceuticals (Sponsor)  
 
Company Address  Barbara Strozzilaan 201  
1083 HN Amsterdam  
The Netherlands  
Phone: +31 (0)  20-205 0188  
Email: [EMAIL_6979]  
 
Head of Oncology 
Development  Edwin de Wit, MD  
Mobile phone: [PHONE_7537]  
Email: [EMAIL_6980]  
Project Director  Marianne Keessen  
Mobile phone: [PHONE_7538]  
Email: [EMAIL_6981]  
Chief Medical Officer  Jan Schellens, MD PhD  
Mobile phone: [PHONE_7539] 436  
Email: [EMAIL_6982]  
Chief Executive Officer  Colin Freund  
Mobile phone: +[PHONE_7525]  
Email: [EMAIL_6983]   
 
 
At Covance (Contract Research Organi sation)  
 
Project Management  Covance Inc.  
www.covance.com  
Pharmacovigilance  
 
 Szymon Wroblewski  
Drug Safety Project Manager  
Phone : [PHONE_7540]  
E-mail : [EMAIL_6984]  
www.covance.com  
Covance (Polska) Sp. z o.o., Wspólna 47/49, 00 -684 Warsaw, 
Poland  
Medical Monitoring  
 
 Oxana Bzhadug , MD  
Tel. [PHONE_7541] -16-41 
E-mail: [EMAIL_6985]  
www.covance.com  
Millenium House Business Center, 4th Floor, Office A,  
[ADDRESS_455596] of all participating investigators is available in the Trial Master File and Investigator File.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455597] (IMP)  ................................ .....26 
1.1.1.  ModraDoc006  ................................ ................................ ................................ ............. 26 
1.1.2.  Ritonavir  ................................ ................................ ................................ ..................... 27 
1.1.3.  Pre-Clinical Information  ................................ ................................ ............................. 27 
1.2. Clinical Data  ................................ ................................ ................................ ............... 27 
1.2.1.  Trial 1: Once daily, once weekly ModraDoc006/r  ................................ ..................... 27 
1.2.2.  Trial 2: Bi -daily, once weekly ModraDoc006/r ................................ .......................... 28 
1.2.3.  Trial 3: Bi -daily, once weekly ModraDoc006/r in pat ients with mCRPC .................. 28 
1.3. Trial and Dosing Rationale  ................................ ................................ ......................... 32 
1.3.1.  Ritonavir  ................................ ................................ ................................ ..................... 32 
1.3.2.  ModraDoc0 06/r ................................ ................................ ................................ ........... 32 
1.3.3.  ModraDoc006/r in mCRPC  ................................ ................................ ........................ 33 
1.4. Potential Benefits and Risks  ................................ ................................ ....................... 34 
1.4.1.  Benefits of IMP  ................................ ................................ ................................ ........... 34 
1.4.2.  Management of Risks  ................................ ................................ ................................ .34 
1.4.3.  Benefit/Risk Ratio  ................................ ................................ ................................ ......35 
2. TRIAL OBJECTIVES AND ENDPOINTS  ................................ ............................... 36 
2.1. Primary Objectives  ................................ ................................ ................................ .....36 
2.2. Secondary Objectives  ................................ ................................ ................................ .36 
2.3. Endpoints  ................................ ................................ ................................ .................... 36 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    7 2.3.1.  Efficacy  ................................ ................................ ................................ ....................... 36 
2.3.2.  Safety  ................................ ................................ ................................ .......................... 37 
2.3.3.  Health Related Quality of Life (HRQoL)  ................................ ................................ ...[ADDRESS_455598] (Trial Drug)  ................................ .......[ADDRESS_455599] of care ............................ 46 
5.4.2.  Dose Modifications i.v. docetaxel  ................................ ................................ .............. 47 
5.5. Administration of ModraDoc006/r  ................................ ................................ ............. 47 
5.5.1.  Dose and Schedule of ModraDoc006/r  ................................ ................................ .......47 
5.5.2.  Premedication and supportive care for ModraDoc006/r ................................ ............. 48 
5.5.3.  Dose Modifications of ModraDoc006/r  ................................ ................................ ......51 
5.6. End of Treatment  ................................ ................................ ................................ ........ 55 
5.7. Prior and Concomitant Treatments  ................................ ................................ ............. 55 
5.8. Contraception  ................................ ................................ ................................ .............. 57 
5.9. Drug accountability  ................................ ................................ ................................ ....58 
6. INVES TIGATIONAL PLAN  ................................ ................................ ..................... 59 
6.1. Trial Assessment Specifications  ................................ ................................ ................. 59 
6.2. Screening Visit(s) and Registration of Patients  ................................ .......................... 61 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    8 6.2.1.  Screening Visit(s)  ................................ ................................ ................................ .......61 
6.3. Patient Registration and Randomization  ................................ ................................ ....62 
6.4. Treatment Visit(s)  ................................ ................................ ................................ .......62 
6.5. End of Treatment Visit  ................................ ................................ ............................... 62 
6.6. Follow -up Visit  ................................ ................................ ................................ ........... 62 
6.7. Assessment of Safety  ................................ ................................ ................................ ..63 
6.8. Withdrawal, Discontinuation and Replacement of Patients  ................................ .......65 
6.8.1.  Withdrawal  ................................ ................................ ................................ ................. 65 
6.8.2.  Discontinuation  ................................ ................................ ................................ ........... 65 
6.8.3.  Replacement of Patients  ................................ ................................ ............................. 65 
6.9. Assessment of Efficacy  ................................ ................................ ............................... 66 
6.9.1.  Clinical efficacy assessments ................................ ................................ ...................... 66 
6.9.2.  Determination of Radiographic Disease Progression  ................................ ................. 67 
7. ADVERSE EVENTS  ................................ ................................ ................................ ..68 
7.1. Definitions  ................................ ................................ ................................ .................. 68 
7.1.1.  Adverse E vent (AE)  ................................ ................................ ................................ ....68 
7.1.2.  Adverse Drug Reaction (ADR)  ................................ ................................ .................. 69 
7.1.3.  Unexpected Adverse Drug Reaction ................................ ................................ ........... 69 
7.1.4.  Serious Adverse Event (SAE)  ................................ ................................ .................... 69 
7.1.5.  Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  ................................ .....[ADDRESS_455600] for Reporting SAEs ................................ ........................ 72 
8. STATISTICAL METHODS  ................................ ................................ ....................... 73 
8.1. Data Analysis Considerations  ................................ ................................ ..................... 73 
8.2. Population for Analysis  ................................ ................................ .............................. 75 
8.2.1.  Safety analysis  ................................ ................................ ................................ ............ 75 
8.2.2.  Population evaluable for radiological response  ................................ .......................... 75 
8.3. Clinical Efficacy  ................................ ................................ ................................ ......... 75 
8.4. Safety  ................................ ................................ ................................ .......................... 76 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    9 8.5. Interim Analysis  ................................ ................................ ................................ .......... 76 
9. DATA MANA GEMENT AND MONITORING  ................................ ....................... 77 
9.1. Data Collection, Validation and Handling  ................................ ................................ ..77 
9.2. Data Review  ................................ ................................ ................................ ................ 77 
9.3. Medical Coding  ................................ ................................ ................................ .......... 78 
9.4. Quality C ontrol and Quality Assurance  ................................ ................................ ......78 
10. ADMINISTRATIVE ASPECTS  ................................ ................................ ................ 79 
10.1.  Maintenance of Patient Records  ................................ ................................ ................. 79 
10.2.  Investigator Site File (ISF)  ................................ ................................ ......................... [ADDRESS_455601]  ................................ ................................ ........... 79 
10.4.  Drug Accountability  ................................ ................................ ................................ ...79 
10.5.  Protocol Deviations  ................................ ................................ ................................ ....80 
10.6.  Procedures for Protocol Amendments  ................................ ................................ ........ 80 
11. ETHICAL AND LEGAL CONSIDERATIONS  ................................ ........................ 81 
11.1.  Regulatory Authority / Independent Ethics Committees  ................................ ............ [ADDRESS_455602] OF TABLES  
Table 1:  Overall and progression free survival and PSA response in mCRPC patients 
treated with first line docetaxel in different studies.  ................................ ................... 24 
Table 2  Adverse Events Reporte d During ModraDoc006/r Study with BIDW (Twice 
Daily, Once Weekly) Dosing in mCRPC patients  ................................ ...................... 29 
Table 3  Pharmacokinetic results of Mod raDoc006/r (docetaxel and ritonavir) with 
BIDW (Twice Daily, Once Weekly) dosing in mCRPC  ................................ ............ 31 
Table 4:  Dose modifications for i.v. doc etaxel  ................................ ................................ ......... 47 
Table 5:  ModraDoc006/r treatment  ................................ ................................ .......................... 48 
Table 6:  Premedication before ModraDoc006/r  ................................ ................................ .......49 
Table 7:  Anti-emetic therapy  ................................ ................................ ................................ ....49 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    10 Table 8:  Diarrhea - Supportive treatment and Dose Modifications  ................................ .......... 50 
Table 9:  Dose modifications for ModraDoc006/r in case of hematological toxicity ................ 52 
Table 10:  Dose modifications for ModraDoc006/r in case of non -hematological 
toxicity  ................................ ................................ ................................ ........................ 53 
Table 11:  Dose modifications for ModraDoc006/r  ................................ ................................ .....54 
Table 12:  Dose modifications f or ModraDoc006/r under amendment 1  ................................ ....54 
Table  13: Trial Assessments  ................................ ................................ ................................ .......60 
Table 14:  Overview of Safety Assessments  ................................ ................................ ................ 63 
Table  15:  Overview of Clinical Efficacy Assessments  ................................ ............................... 66 
Table 16:  Protocol -Specified Documentation for Radiographic Evidenc e of Disease 
Progression  ................................ ................................ ................................ ................. [ADDRESS_455603] OF FIGURES  
Figure 1:  Structural formula of docetaxel.  ................................ ................................ ................. 26 
Figure 2  Efficacy of ModraDoc006/r in mCRPC patients  ................................ ........................ 32 
Figure 3:  Schematic of study design.  ................................ ................................ ......................... 39 
Figure 4:  Study schedule cohort 1  ................................ ................................ .............................. 47 
Figure 5:  Study schedule cohort [ADDRESS_455604] OF APPENDICES  
Appendix I:  Assessments  ................................ ................................ ................................ ............ 84 
Appendix II:  WHO Performance Status Scale ................................ ................................ ............ 86 
Appendix III:  Common Terminology Criteria for Adverse Events (CTCAE) v5.0  ................... 87 
Appendix IV:  RECIST v1.1 - Tumor Evaluation Criteria  ................................ .......................... 88 
Appendix V:  PCWG3 Recommendations  ................................ ................................ .................. 93 
Appendix VI:  Quality of life Questionnaires  ................................ ................................ ............ 101 
Appendix VII:  Structured Risk Analysis  ................................ ................................ .................. 114 
Appendix VII I: Drug -Drug Interactions  ................................ ................................ ................... 116 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455605]  Adverse Drug Reaction  
ADT  Androgen Deprivation Therapy  
AE Adverse Event  
ALAT  Alanine Amino Transferase  
ANC  Absolute Neutrophil Count  
ASAT  Aspartate Amino Transferase  
ASI Additional Safety Information  
AUC  Area Under the Plasma Concentration -Time Curve  
BID Bis In Die (twice daily)  
BIDW  Twice daily once weekly  
Cmax Maximum Concentration in Plasma Concentration -Time Curve  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CR  Complete Response  
CRA  Clinical Research Associate  
CRF  Case Record Form  
CRO  Contract Research Organisation  
CRPC  Castration Resistant Prostate Cancer  
CYP  Cytochrome P450 – main drug metabolizing enzyme system  
DSMB  Data Safety Monitoring Board  
EC Ethics Committee  
ECG  Electrocardiogram  
EEA  European Economic Area  
EMA  European Medicines Agency  
eCRF  Electronic Case Report Form  
EOT  End of Treatment  
EU European Union  
EudraCT  European Union Drug Regulating Authorities Clinical Trials  
FAS Full Analysis Set  
FDA  US Food and Drug Administration  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulations  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455606]  
IV (or i.v.)  Intravenous  
LDH   Lactate Dehydrogenase  
LPLV  Last Patient Last Visit  
m (in mCRPC)  metastatic  
MDRD  Modification of Diet in Renal Disease  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic Resonance Imaging  
MTD  Maximum  Tolerated Dose  
NCI-CTCAE  National Cancer Institute – Common Terminology Criteria of Adverse 
Events  
ORR  Objective Response Rate  
OS  Overall Survival  
PCWG3  Prostate Cancer Clinical Trials Working Group 3  
PD Progressive disease (or also Pharmacodynamics)  
PFS Progression -Free Survival  
P-gp P-glycoprotein  
PK Pharmacokinetics  
PP Per Protocol  
PR Partial Response  
PSA Prostate Specific Antigen  
PSA RR  PSA Response Rate  
QW Once every week  
r (in rPFS)  radiographic  
/r (in ModraDoc006/r)  ritonavir  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455607] Characteristics  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
t1/[ADDRESS_455608]  Upper Limit of Normal  
WBC  White Blood Cell  
WHO  World Health Organisation  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    14    PROTOCOL SYNOPSIS  
Protocol Title  “A multicentre  Phase IIb trial to evaluate the efficacy and tolerability 
of ModraDoc006/r in subjects with metastatic Castration Resistant 
Prostate Cancer (mCRPC), suitable for treatment with a taxane”  
Protocol Number  M18MDP  
Clinical Phase  IIb 
Trial Background  Modra Pharmaceuticals has developed an oral tablet formulation of 
docetaxel, which is called ModraDoc006. ModraDoc006 is 
co-administered with ritonavir (/r), a CYP3A4 and P -glycoprotein 
(P-gp) inhibitor, to increase the bioavailability of docetaxel. This 
results in increased exposure, as measured by [CONTACT_364776] -time curve (AUC). The combination  is denoted 
ModraDoc006/r. By [CONTACT_364777]006/r combination is designed to have a lower to xicity 
than i.v.  docetaxel, but at least comparable efficacy. The lower 
toxicity of ModraDoc006/r can be explained by [CONTACT_110039] >10-fold lower 
maximum plasma concentration (Cmax) compared with i.v. 
docetaxel at a comparable AUC over a time period of three weeks , 
which is defined as one cycle. ModraDoc006/r has been evaluated in 
several clinical trials in which patients have been treated for up to 72 
weeks.  
The proposed Phase IIb trial aims to investigate the efficacy and 
tolerability of the ModraDoc006/r combina tion in subjects with 
metastatic Castration Resistant Prostate Cancer ( mCRPC) versus  i.v. 
docetaxel.  
Trial Rationale  For patients with mCRPC, prognosis remains poor with a median 
survival of between [ADDRESS_455609] 
line systemic chemotherapy, with a survival benefit of 2.4 months. 
Considering the milder safety profile of oral ModraDoc006/r , with 
less neurotoxicity and less neutropenia than docetaxel i.v., togethe r 
with comparable systemic exposure and higher patient convenience, 
oral docetaxel in the form of ModraDoc006/r may offer a better 
treatment option to these patients.  
Primary Objective  To determine the efficacy of ModraDoc006/r,  as measured by 
[CONTACT_364778] (rPFS), compared to standard 
treatment with i.v. docetaxel in subjects with mCRPC.  
Secondary Objectives  • To evaluate the efficacy of ModraDoc006/r, as measured by 
[CONTACT_43877]3 -modified RECIST v1.1 criteria of objective response 
rate (ORR), disease control rate (DCR) and duration of response 
(DOR) compared to standard treatment with i.v. docetaxel in 
subjects with mCRPC.  
• To evaluate the clinical outcome in terms of rPFS at 6 months 
and time to progression (TTP) of ModraDoc006/r compared to 
i.v. docetaxel  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    15 • To evaluate the outcome in terms of PSA tumor marker 
evaluation for PSA response, PSA -PFS and time to PSA 
progression of ModraDoc006/r compared to i.v. docetaxel  
• To compare the time to first ske letal-related event between 
ModraDoc006/r and i.v. docetaxel  
• To determine the safety and tolerability of ModraDoc006/r 
compared to i.v. docetaxel  
• To compare subject’s Health Related Quality of Life (HRQoL) 
response of ModraDoc006/r and docetaxel i.v.   
Trial Design  This is an open label 1:1 randomized Phase IIb trial to determine the 
efficacy and tolerability of oral ModraDoc006/r versus  i.v. docetaxel 
in mCRPC subjects. Cohort 1 will receive i.v. docetaxel at 75 mg/m 2 
Q3W. Cohort 2 will receive 20 mg Modra Doc006 in combination 
with 200 mg ritonavir in the morning and 20 mg ModraDoc006 in 
combination with 100 mg ritonavir in the evening (7 -12 hours after 
the morning dose), on Day 1, [ADDRESS_455610] discontinued trial 
treatment and ha ve been given follow -up for safety measurements 
according to the trial assessment schedule.  
Trial Endpoints  Primary endpoints:  
• Radiographic Progression Free Survival (rPFS) according to 
PCWG3 criteria  
Secondary endpoints:  
Efficacy endpoints:  
• Objective Response Rate (ORR)  
• Disease control rate (DCR)  
• Duration of response (DOR)  
• Radiographic Progression Free Survival (rPFS) at 6 months 
according to PCWG3 criteria  
• Time to progression (TTP)  
• PSA response rate according to PCWG3 criteria  
• Progression  free survival (PFS) at 6 months  
• PSA-PFS according to PCWG3 criteria  
• Time to PSA progression  
• Time to first skeletal event  
Safety endpoints:  
• Adverse events (AEs) and serious adverse events (SAEs), 
according to the current National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) 
v5.0 
• Assessments of e.g.: physical examinations, body weight, vital 
signs, WHO performance status, changes in hematology and 
biochemistry, electrocardiogram (ECG)  
HRQoL endpoints:  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    16 • Health Related Qualit y of Life (HRQoL) as assessed by [CONTACT_364779], FACT -P and FACT -taxane, Treatment Satisfaction and 
EQ-5D questionnaires : 
• Overall HRQoL improvement  
• Improvements in the individual HRQoL domains  
• Time to HRQoL deterioration  
• Overall Health Related Utility  
Number of Subjects  A total of 100 subjects evaluable for radiological response according 
to PCWG3  will be included in the trial and randomized 1:1 into 
cohort 1 and cohort 2.  
Subjects will not be replaced unless they fail to receive any 
administration of docetaxel i.v./ oral ModraDoc006/r or they fail to 
undergo  any efficacy assessment after baseline measurement.  
Trial Population  This trial will include subjects with metastatic castration resistant 
prostate cancer (mCRPC) eligible for first line systemic 
chemotherapy  with docetaxel according to standard of care, 
following progression on hormonal therapi[INVESTIGATOR_014].   
Inclusion Criteria  To be eligible to participate  in this trial, subjects must meet all of the 
following eligibility criteria:  
1. Age ≥ 18 years  
2. Histologically or cytologically proven prostate cancer with 
evidence of progressive mCRPC, defined as:  
a. Castrate levels of testosterone, defined as ≤ 50 ng/dL (or ≤ 
0.50 ng/mL or 1.73 nmol/L)  
b. Evidence of progressive metastatic disease as defined by 
[CONTACT_364780]   
c. With an indication for systemic treatment with docetaxel 
according to the standard of care  
3. Evaluable disease, defined as nodal or visceral lesions as 
evaluated with CT -scan or MRI, and measured according to 
RECIST v1.1. and/or bone metastasis as evaluated with 
99mTc-methylene diphosphonate (MDP) radionuclide bone 
scintigraphy by [CONTACT_43877]3 criteria  
4. Resolution of toxicity of prior therapy to < grade 2 (except 
for alopecia), as defined by [CONTACT_3989] v5.[ADDRESS_455611] ing gastro -intestinal toxicities (diarrhea or 
nausea/vomiting) and mucositis, full resolution is required 
prior to study start.  
5. Adequate haematological, renal and hepatic functions:  
a. Haemoglobin   mmol/l ( >9.6 g/dL)  
b. ANC ≥ 1.5 x 10 9 /L 
c. Platelet count ≥ 1 00 x 10 9 /L 
d. Hepatic function defined by [CONTACT_7406]  ULN, 
ALAT and ASAT  1.[ADDRESS_455612]  concomitant with 
alkaline phosphatase  2.5 × ULN.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    17 e. Renal function defined by [CONTACT_89408]  1.[ADDRESS_455613] or creatinine clearance  50 ml/min (by 
[CONTACT_3158] -Gault formula, or MDRD).  
6. WHO performance status of [ADDRESS_455614] 12 weeks  
8. Able and willing to swallow oral medication  
9. Able and willing to undergo radiologic scans ( CT scan)  
10. Able and willing to give writt en informed consent according 
to local guidelines  
Exclusion Criteria  Subjects who meet ANY of the following criteria at screening will 
be excluded from trial entry:  
1. Any treatment with investigational drugs, chemotherapy or 
immunotherapy within [ADDRESS_455615] dose 
of investigational treatment. Palliative radiotherapy (1x8 Gy 
dose) is allowed before and during the study, but not in the week 
prior t o start of study treatment.  
2. Subjects who have had prior treatment with taxanes.  
3. Subjects with symptomatic brain metastases. Subjects 
asymptomatic in the absence of corticosteroids and 
anticonvulsant therapy for ≥[ADDRESS_455616] been completed ≥[ADDRESS_455617] be stable with verification by 
[CONTACT_9661] (e.g. brain MRI or CT completed at screening, 
demonstrating no current evidence of progressive brain 
metastases). Subjects are not permitted to receive anti -epi[INVESTIGATOR_364733]. 
Subjects with a history of leptomeningeal metastases are not 
eligible.  
4. Current malignancies other than mCRPC with exception of 
adequately treated  basal or squamous cell carcinoma of the skin , 
or adequately treated non -muscular invasive bladder cancer.  
5. Absence of highly effective method of contraception as of cycle 
one day one (C1D1). Men enrolled in this trial must agree to use 
a highly effective c ontraceptive method throughout the study.  
6. Uncontrolled hypertension (systolic > 150 mm Hg and/or 
diastolic > 100 mm Hg)  
7. Grade ≥ 2 motor or sensory neuropathy symptoms (as defined by 
[CONTACT_30828] 5.0)   
8. Known hypersensitivity to any of the study drugs or excipi[INVESTIGATOR_364734]  
9. Concomitant use of P -glycoprotein (P -gp , MDR), CYP3A, 
OATP1B1, OATP1B3 and MRP2 modulating drugs such as 
Ca+- entry blockers (verapamil, dihydropyridines), cyclosporine, 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    18 quinidine a nd grapefruit juice, concomitant use of HIV 
medications, other protease inhibitors, (non) nucleoside 
analogues, or St. John’s wort  
10. Bowel obstruction or motility disorder that may influence the 
resorption of drugs as judged by [CONTACT_1963]  
11. Major s urgical procedures within 21 days prior to providing 
informed consent  
12. Active acute or chronic infection, which is not controlled by 
[CONTACT_364781] (at the discretion of the treating 
physician)  
13. Known positivity for Human Immunodeficiency Virus HIV -1 or 
HIV-2 type  
14. Patients with known active infection of hepatitis B, C, or E 
(patients who are anti -HBC positive but HBsAg negative are 
eligible to participate in this study)  
15. Clinically significant (i.e. active) cardiovascular di sease defined 
as stroke, transient ischemic attack (TIA), myocardial infarction, 
unstable angina, or congestive heart failure within  ≤ [ADDRESS_455618] trial treatment  
16. Evidence of any other medical conditions (such as treatment -
resistant peptic ulc er disease, erosive oesophagitis or gastritis, 
infectious or inflammatory bowel disease, diverticulitis, or 
pulmonary embolism within 4 weeks of randomization, or 
psychiatric illness, drug or alcohol abuse, physical examination 
or laboratory findings) that  may interfere with the planned 
treatment, affect subject compliance or place the subject at high 
risk of treatment -related complications  
17. Legal incapacity  
Trial Duration  The trial will include four weeks of screening (max.) and three 
weeks per treatment c ycle in both trial cohorts. Subjects may 
continue to receive study medication until the subject experiences 
disease progression, unacceptable toxicity, request by [CONTACT_364782], death, or termination of the trial 
by [CONTACT_19457]. The duration of the trial for each individual subject 
may therefore be different. Each subject should attend an end of 
treatment (EOT) visit and a follow up (FU) visit as described in the 
trial schedule. The end of trial will be reached when all subje cts have 
discontinued trial treatment , or [ADDRESS_455619] .  
Dosage and Schedule  Subjects eligible for the trial will receive:  
• Cohort 1: on Day 1 of each cycle docetaxel i.v. Q3W at 
75 mg/m 2. Each treatment cycl e consists of [ADDRESS_455620] will be 
allowed.   
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    19 • Cohort 2: twice daily on Day 1, 8 and 15 of each cycle 
ModraDoc006/r at 20/20 mg (morning/evening) in combination 
with ritonavir 200/100 mg  (morning/evening) . Each treatment 
cycle consists of 21 days.  Premedication with dexamethasone is 
not necessary.  
• Continuous prednisone 2dd 5mg will be given in both cohorts.  
 
Note : Patients enrolled under protocol amendment 1 , who are dosed 
with 30 mg of ModraDoc006 combined with 200 mg ritonavir in the 
morning and 20 mg of ModraDoc006 combined with 100 mg 
ritonavir in the evening, will, at the investigator’s discretion, be able 
to continue a t this dose.  
Dose Modification Criteria  Dose reductions should  be implemented due to toxicities as defined 
in section 5.4.[ADDRESS_455621] been assessed by [CONTACT_364783], probably or definitely related to study drug . 
These toxicities  may occur during the study despi[INVESTIGATOR_364735].  
One dose reduction of i.v. docetaxel  is allowed from 75 mg/m2 to 
60 mg/m2 , as described in Section 4.4 . If a patient  requires more 
than the allowed dose -reduction, study treatment needs to be 
discontinued.  
One dose reduction of ModraDoc006/r  is allowed according to the 
step described  in the table below. If a patient requires more than the 
allowed dose -reduction, study t reatment needs to be discontinued.  
  
Dose  Standard dose  Dose reduction  
Morning dose  
ModraDoc006  20 mg  20 mg  
Ritonavir  200 mg  200 mg  
Evening dose  
ModraDoc006  20 mg  10 mg 
Ritonavir  100 mg  100 mg  
 
Note:  For patients enrolled under protocol amendment 1 , two dose 
reductions of ModraDoc006/r will be allowed , see Table 12. 
Safety Assessments  Safety will be assessed by [CONTACT_364784], weight, 
vital signs, WHO performance status, laboratory evaluations 
(haematology, biochemistry), electrocardiograms (ECG), and 
recording of concurrent illness/ therapy and adverse events (using 
CTCAE v5.0, Appendix III) . All assessments will be perf ormed as 
indicated in the Schedule of Assessments ( Appendix I ). Additional 
assessments may be performed as clinically indicated.  
Efficacy Assessments  Efficacy measurements will include tumor assessments, consisting of 
clinical examination and appropriate imaging techniques (computed 
tomography  [CT] scans per RECIST v1.1, Appendix IV  and bone 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    20 scan per PCWG3, Appendix V ). Other imaging tests (magnetic 
resonance imaging [MRI] and X -ray) may be performed, if required, 
and if compliant with RECIST v1.1  and PCWG 3. 
Tumor assessments will be performed at screening; every [ADDRESS_455622] 24 weeks (i.e. during week 9, 17 and 25) and thereafter 
every 12 weeks during active treatment; and at the End of Treatment 
(EOT) visit, if disease progression has not been docume nted 
previously. Imaging will follow PCWG3 recommendations to 
include nodal/visceral and bone metastatic variables. A  radiological  
response will be confirmed after ≥ 4-6 weeks. Analysis of PSA blood 
levels will also be used for efficacy assessment as per PCWG3 
criteria at screening, Day 1 of every cycle and at the EOT visit. A 
PSA response will be confirmed after 3-4 weeks.  
Additional Assessments  Health Related Quality o f Life (HRQoL) endpoints will be assessed 
by [CONTACT_364785], FACT -P and FACT -taxane and EQ -5D-5L 
questionnaires at baseline and at the end of cycle 3, 6 and 10, or at 
End of Treatment (EOT) if this would occur earlier; HRQoL 
assessment by [CONTACT_364786] 3, 6 and 10, or at End of Treatment (EOT) if this 
would occur earlier ( Appendix VII). 
Statistical Procedure s Analysis Populations:  
• Safety Population (SAF): All subjects receiving at least one 
dose of trial medication in either study arm will be included 
in the evaluation of safety.  
• Efficacy Population (Full Analysis Set (FAS)): All subjects 
who received at least one dose of docetaxel i.v. (cohort 1) or 
one full three -week cycle of ModraDoc006/r (cohort 2) and 
have at least one post -baseline tumour assessment (+PSA 
levels) will be inc luded in the evaluation of efficacy and 
HRQoL evaluation.  
• Per Protocol (PP) population includes all subjects in the FAS 
population with the exclusion of subjects who are not 
compliant to study treatment or have at least one major 
protocol deviation that w ill affect the interpretation of 
efficacy.  
Safety Analysis:  
Safety data will be summarized for the safety population.  
Efficacy Analysis:  
Radiographic Progression -Free Survival : Defined as time from 
randomization to the first objective evidence of radiologi c 
progression or death due to any cause after treatment 
discontinuation, whichever occurs first will be assessed, per PCWG3 
criteria.  
Objective Response Rate:  The best overall soft tissue response as 
assessed by [CONTACT_364787] 1.1 will be summa rized. 
Only patients with measurable soft tissue disease at screening (i.e., at 
least [ADDRESS_455623] 1.1) will be included in this 
analysis. Tumor response for target lesions will be assessed at 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455624] version 1.1. The 
calculation of ORR as primary endpoint is based on disease status as 
determined by [CONTACT_364788].  
Disease Control Rate:  Defined as proportion of patients who have 
achieved complete response, partial response and stable disease 
using RECIST 1.1.  
Duration of Response:  Defined as time from documentation of 
tumor response using RECIST 1.[ADDRESS_455625] objective evidence of 
radiologic progression.  
Radiographic Progression -Free Survival at 6 months:  Defined as 
probability of rPFS at [ADDRESS_455626] objective evidence of radiologic progression or death due 
to any cause.  
Time To Progression : Defined as time from randomization to the 
first objective evidence of radiologic progression  
PSA Response:  Confirmed PSA responses will be defined as ≥50% 
reductions in PSA from  baseline to lowest postbaseline PSA result, 
with a consecutive assessment co nducted at least 3 weeks later 
required to confirm the PSA response. PSA response ≥50% will be 
calculated by [CONTACT_364789] 1 postbaseline assessment. The 
analysis of the tumor marker PS A will be performed on the efficacy 
population as per PCWG3 criteria 81. The variables will be evaluated 
using appropriate descriptive statistics for each assessment point and 
for the changes from baseline.  
PSA Progression -Free Survival / Time to PSA Progre ssion:  PSA 
progression according to PCWG3 criteria is defined as the first PSA 
increase that is ≥25% and ≥2 ng/mL, either above the nadir (if PSA 
decline after baseline) or from baseline beyond 12 weeks (if no PSA 
decline from baseline), and which is confi rmed by a second value ≥ 
[ADDRESS_455627] Skeletal -Related Event:  Time from randomization to 
first skeletal -related event will be assessed. A skeletal -related event 
is defined as radiation therapy or surgery to bone, pathologic bone 
fracture, s pi[INVESTIGATOR_13377].  
Health Related Quality of Life Endpoints:  
FACT Quality of Life:  The FACT global, FACT -P and FACT -
taxane data will be summarized descriptively by [CONTACT_15449].  
Treatment Satisfaction Questionnaire for Medication:  TSQM 
data will be sum marized descriptively by [CONTACT_15449].  
EQ-5D-5L Quality of Life : The EQ -5D-5L data will be summarized 
descriptively by [CONTACT_15449].  
Planned Data Analysis : 
All data collected in this trial will be documented using summary 
tables, figures, and patient data listings .  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    22 • Continuous variables will be summarized using descriptive 
statistics (N, mean, standard deviation, quartiles, median, 
minimum, and maximum).  
• Categorical variables will be summarized using counts, 
frequencies and percentages.  
• ORR will be reported  as proportion of subjects per cohort who 
have presented response  at fixed time intervals and separately at 
the end of trial  
• Response rates and 95% CIs will be calculated for the ORR and 
DCR by [CONTACT_1570]  
• PSA values will be reported as percentage change from baseline 
every cycle and as absolute change in PSA over time from 
baseline to best response  
• Differences between the cohorts will be compared using 
parametric techniques for continuous variables (only i n case of 
severe deviations of normality will the Wilcoxon -Mann Whitney 
test be used)  and Fisher’s exact test for categorical variables.   
PFS, TTP-DOR, PSA-PFS and time to PSA progression will be 
summarized using Kaplan -Meier estimates and differences will  be 
determined via the log -rank test. Univaria te Cox proportional 
hazards models, multivaria te models, and propensity score -weighted 
multivaria te models may be constructed to evaluate the effect of 
confounding variables on PSA -PFS, PFS and time to PSA 
progression. All tests will be two -sided and considered significant 
at P<0.05. With the design that compares treatment with 
ModraDoc006/r versus standard i.v. docetaxel, the treatment 
outcome will be estimated and used as the basis for the design of the 
future  pi[INVESTIGATOR_16076]. The sample size of 50  evaluable patients per 
cohort will provide a sufficiently precise point estimate of the 
primary endpoint rPFS  in both groups to calculate the sample size 
for the pi[INVESTIGATOR_2397].  
Number of Centres  Approximately 40 cent res in the US and Europe.  
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    23 1. INTRODUCTION  
Prostate cancer  
Prostate cancer (PCa) is the most frequently occurring malignancy in men in the Western world, 
with more than  1,000,[ADDRESS_455628] been identified 2,3. After progression on hormonal 
therapy in the metastatic castration resistant prostate can cer (mCRPC ) setting, the prognosis is 
poor ( OS of 9 to 13 months) and morbidity can be severe because of pain or complications 
related to bone metastases 4. The presence of anaemia, development of new bone metastatic 
lesions, significant pain and the presence of visceral metastases were identif ied as pre -treatment 
risk factors that predict for PSA declines and survival in men with mCRPC 5. 
First line docetaxel treatment  
According to current guideline s, systemic therapy with docetaxel should be reserved for the 
metastatic castration resistant setting 2,3, although increasingly,  based on recent trial outcomes , 
docetaxel is applied earlier in metastatic high -volume hormone sensitive prostate cancer 
(HSPC)  6,7. Treatment with docetaxel every three week s in combination with predniso ne, led to a 
survival benefit of 2.4 months, improved rates of response in terms of pain, serum PSA level and 
quality of life, as compared with mitoxantrone plus prednisone 8.  For docetaxel plus 
estramustine, comparison with a similar control group showed an improvement in median 
survival of nearly two months in patients with mCRPC 9. Table 1 describes the median PFS and 
OS in patients with mCRPC with docetaxel treatment in several studies. Because of current 
longer prior treatment before start of docetaxel (with abiraterone and enzalutamide), the PFS for 
mCRPC patients may be shorter than the estimated PFS of 7 to 8 months in Table 1. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    24 Table 1: Overall and progression free survival and PSA response in mCRPC patients 
treated with first line docetaxel in different studies.   
Study  N Median 
OS 
docetaxel 
arm (mo)  Median PFS 
docetaxel 
arm (mo)  Response rate Docetaxel arm  
Total 
number 
in trial  Number in 
Docetaxel 
arm 
(75 mg/m²  
cycle 3 wks. ) >50% PSA 
decline  RECIST 
Tumor  
response  
Tannock 8 
Docetaxel/P vs 
mitoxantrone/P  1006  335 18.9 Not reported   45% 12%  
Petrylak 10 
Docetaxel/P +/ - 
lenalinomide  1046 526 Not 
reported  10.6 58% 25% 
Kelly 11 
Docetaxel/P  
+/- bevacizumab  1052  526 21.5 7.5 57.9%  35.5%  
Fizazi 12 
Docetaxel/P  
+/- zibotentan  1052   528 19.2 7.9 56.4%  Not reported  
Meulenbeld 13 
Docetaxel /P +/- 
risedronate  592 301 18.4 6.5 66.3%  20.8%  
Sonpavde 14 
Docetaxel /P +/- 
risedronate  220 110 17.8 10.3 46% 27% 
Quinn 15 
Docetaxel /P +/- 
atrasentan  994 496 17.6 9.1 49% 14% 
Tannock 16 
Docetaxel /P +/- 
aflibercept  1224 612 21.2 6.2 63% 28.1% 
Oudard 17 
Docetaxel /P vs 
cabazitaxel  1168  391 24.3 5.3 68.4% 30.9% 
Araujo 18 
Docetaxel /P +/- 
dasatinib  1522  760 21.2 11.1 Not reported  31.9 
Total  9876  4585         
Mean    20.0 8.3 57%  25%  
Abbreviations: N = number of patients, OS = overall survival, PFS = progression free survival, PSA = prostate 
specific antigen, P = prednisolone  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455629] with docetaxel 8.  
A recent randomized phase III study compared the efficacy and safety of 2 -weekly vs 3 -weekly 
doce taxel administration. Docetaxel administered every 2 weeks was associated with longer time 
to treatment failure (TTTF) and fewer occurrences of neutropenia and neutropenic infections 
than was [ADDRESS_455630] be non -inferior and 
possibly superior , and that the safety will be better with weekly treatment with docetaxel. 
Because of the improved convenience in comparison to i.v. docetaxel, a weekly schedule for oral 
docetaxel seems acceptable for patients , and this will be evaluated in this study  in the form o f 
ModraDoc006/r .  
Predniso ne treatment  
After the FDA approval for i.v. docetaxel in combina tion with predniso ne, based on trials that 
used c ombined docetaxel and predniso ne treatment in CRPC, the combination of i.v. docetaxel 
with predniso ne has become the  standard of care 8,9. Importantly however, there is no convincing 
evidence for improvement of treatment efficacy in ter ms of overall survival with addition of 
corticosteroids to docetaxel in patients with mCRPC 39,40. Earl ier studies reported a relief of pain, 
associated with suppression of adrenal androgens in patients with symptomatic metastatic 
prostate cancer 41. PSA declines during predniso ne treatment were reported, but only declines 
above 50% were corr elated with improvement of overall survival and the effect of anti -androgen 
withdrawal may have influenced the results 42-44. Administration of 20 mg dexamethasone orally 
every 6 hours for 3 doses eve ry 3 weeks did not significantly improve the PSA response rate of 
estramustine and docetaxel 45.  
A significant improvement in overall survival was achieved in patients with hormone naïve 
metastatic prostate cancer withou t addition of predniso ne to the docetaxel treatment in the 
CHAARTED study 46. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455631]  (IMP)  
1.1.1.  ModraDoc006  
Docetaxel is a chemotherap eutic agent from the  drug class of taxane s. It is a semi -synthetic 
analogue of paclitaxel. Docetaxel can be is manufactured through two methods , a Taxus Baccata 
tree-dependent or -independent method . The Taxus Baccata tree -independent method fabricates 
docetaxel through a cell fermentation process that generates a primary taxane mixture. This 
primary taxane mixture is then chemically converted into docetaxel, see Figure 1 for the 
structural formula). ModraDoc006 contains the docetaxel from the tree -independent method.  
It stimulates the polymerization of tubulin proteins into unusually stable, dysfunctional 
microtubules, consequently interfer ing with cell cycle  division . Docetaxel is clinically effective 
in multiple tumor types, for instance breast  cancer , prostate  cancer , ovarian  cancer , gastric  
cancer , head and neck cancer and non -small cell lung cancer.  
Figure 1: Structural formula of docetaxel.  
 
Docetaxel is known to be metabolized into four major metabolites: M1, M2, M3 and M4 formed by [CONTACT_364790]. The four metabolites are primarily excreted via the bile into the faeces. Docetaxel 
metabolism is prima rily catalysed by [CONTACT_2750]3A4 enzymes in hepatocytes and human liver microsomes. The metabolites of 
docetaxel are inactive and have no anti -tumor activity 47. 
 
Oral formulation of docetaxel  
For patients, oral administration of anticancer drugs has several advantages over i.v. 
administration 48-50. Besides the need for hospi[INVESTIGATOR_063], i.v. administration of docetaxel has 
the drawback of frequently observed infusion -related reactions essentially related to the excipi[INVESTIGATOR_364736] -80 that is present in its formulation. For this reason, dexamethasone is given 
prophylactically to all patients receiving i.v. docetaxel and paclitaxel . With oral docetaxel  
(ModraDoc006)  treatment, toxicity of premedication with corticosteroids can be omitted , as the 
tablets of docetaxel do not contain Tween -80. In addition to increased patient convenience, there 
is the potential for longer treatment duration due to improved tolerability .  
However, t he oral route is often hampered by [CONTACT_364791]. The low bioavailability of 
docetaxel is the result of the poor water -solubility of the drug, as the drug does not sufficiently 
dissolve in water when administered in the crystalline form , therefore ModraDoc006 uses an  
amorphous form to im prove water -solubility . Furthermore, affinity for drug transporters highly 
expressed in the epi[INVESTIGATOR_364737] -intestinal (GI) tract (e.g., P -glycoprotein (P -gp, 

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    27 MDR1, ABCB1)  and extensive first -pass metabolism by [CONTACT_35233] P450 (CYP) meta bolic 
enzymes, especially CYP3A4 in the gut wall, hamper the oral bioavailability of docetaxel 47,51.  
To improve the bioavailability  of oral docetaxel  (ModraDoc006) , a specific CYP3A4 and P -
glycoprotein (P -gp) blocker such as ritonavir (/r) is co-administered  (combination denote d as 
ModraDoc006/r) .  
1.1.2.  Ritonavir  
Ritonavir is a viral protease inhibitor that has been approved as a combination treatment to 
increase the bioavailability of other protease inhibitors including saquinavir, nelfinavir, indinavir 
and lopi[INVESTIGATOR_054] 52,53. It is a pot ent inhibitor of CYP3A and also inhibits CYP2D6 mediated 
reactions; ritonavir also exhibits P -gp inhibiting properties.  
1.1.3.  Pre-Clinical Information  
Preclinical studies showed that first -pass metabolism is the most important factor determining 
the low bioavai lability of orally administered docetaxel. Low oral bioavailability is determined 
by [CONTACT_17588] P -gp and CYP3A4 metabolizing enzymes. In preclinical studies the CYP3A4  and P -gp  
inhibitor ritonavir was used in combination with oral docetaxel to examine the oral  
bioavailability of docetaxel 47,51,54 . Ritonavir markedly increased the area under the plasma 
concentration time curve (AUC) of docetaxel in mice , primarily  due to inhibition of CYP3A4 55. 
1.2. Clinical Data  
Two phase I dose escalating trials in patients with solid tumors investigating the  
pharmacokinetics, maximum tolerated dose (MTD) and safety of ModraDoc006 /r (i.e. oral 
docetaxel as tablets of 10 mg each co -administered with one single dose of ritonavir ( Norvir®) 
of 100 mg) as once daily once weekly (QW) dosing and bi -daily once weekly dosing  (BIDW) , 
respectively, have been performed 56,57 (Section 1.2.1  and 1.2.2). In these phase I trials, patients 
have been treated with ModraDoc006/r for a duration of up to 72  weeks.  In addition, a phase Ib 
trial was conducted to assess the safety, pharmacokinetic s and efficacy of ModraDoc006/r in 
mCRPC patients  (Section 1.2.3 ). 
All three trials were conducted using a classic 3+3 dose escalation schedule.  
1.2.1.  Trial 1: Once daily, once weekly ModraDoc006/r  
In this study, several oral formulations of docetaxel were tested  once daily, once weekly (QW) , 
starting with a drinking solution and ending up with the tablet form known as ModraDoc006. 
Dose -escalation with ModraDoc006/r w as performed up to a weekly dose of 80 mg 
ModraDoc006/100 mg ritonavir . 
Adverse events (AEs) were collected according to the National Cancer Institute’s Common 
Terminology Criteria for AEs version 3.0 (NCI -CTCAE v3.0). Most frequently occurring AEs 
with an  incidence ≥10% in ModraDoc006/r Q W dosing were diarrhea ( 76%), fatigue/malaise 
(67%), nausea (61%), vomiting ( 61%), alopecia (33%), dysgeusia (33%), abdominal cramps 
(28%), abdominal pain (22%), mucositis (2 2%), weight loss ( 22%) and anorexia (1 1%). Most 
AEs were of low grade (i.e. grade 1 -2) and easily manageable with standard -of-care.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    28 The MTD was 60 mg ModraDoc006/100 mg ritonavir administered weekly. Dose Limiting 
Toxicities (DLTs) reported in the study were grade 2 nausea, diarrhea  and mucositis, resu lting in 
inability to restart within three weeks (1x), grade 3 neutropenic fever and mucositis (1x) and 
grade 3 diarrhea (1x).  
1.2.2.  Trial 2: Bi-daily, once weekly ModraDoc006/r  
Dose -escalation of ModraDoc006/r administered bi -daily once weekly (BIDW) was perfo rmed 
starting from bi-daily  20 mg ModraDoc006/100 mg ritonavir up to bi-daily  30 mg 
ModraDoc006/ 100 mg ritonavir.  
The AEs during this study were collected according to the National Cancer Institute’s Common 
Terminology Criteria for AEs version 3.0 (NCI -CTCAE v3.0). The safety profile of the BIDW 
schedule follows the observations of the QW schedule. AEs with an inciden ce ≥10% in 
ModraDoc 006/r BIDW dosing were diarrhea (64%), nausea ( 61%), vomiting (4 3%), fatigue 
(39%), mucositis (32%), alopecia (2 1%), anorexia (21%), dysgeusia (21%), nail toxicity (21%), 
abdominal cramps (14%), aspartate aminotransferase (AST) increased , (16%), alanine 
aminotransferase (ALT) increased (16%), constipation (14%) and weight loss ( 14%), mostly of 
grade 1 and 2 severity . 
For both the QW (Trial 1) and BIDW (Trial 2) dosing schedules, the reported AEs are not 
unexpected based on experience with  i.v. docetaxel , but appear to be less severe with 
ModraDoc006 /r. AEs frequently seen with i.v. docetaxel, (i.e. leukocytopenia, neutropenic fever, 
nail toxicity, and neurotoxicity) were uncommon with ModraDoc 006/r. Allergic reactions were 
not observed. Al opecia, mostly grade 1, occurred much less frequently than would be expected 
with i.v. docetaxel. The severity of the AEs was most commonly CTC grade 1 -2 and 
occasionally grade 3 -4. Diarrhea was reported approximately twice as frequently as reported in 
the docetaxel package insert.  
The MTD and the recommended dose for further clinical development in this trial was 
determined to be 30/20 mg ModraDoc006  (morning/ evening  dose, respectively) with bi-daily  
100 mg ritonavir. Docetaxel AUC observed with this dose was comparable to the AUC of a 
weekly i.v. docetaxel dose of 35 mg/m²  
DLTs reported in the study were grade 3 nausea (2x), mucositis (2x), dehydration (1x), 
neutropenic fever (1x) and inability to r estart treatment within 3 weeks due to treatment related 
toxicity (1x).  
Because of the lower interpatient variation in pharmacokinetics as compared to the once daily 
dosing the bi -daily weekly dosing of 30/20mg ModraDoc006/r was selected for further 
develo pment in solid tumors. Keepi[INVESTIGATOR_364738] -study comparison , 
the interpatient variation in pharmacokinetics of oral and i.v. docetaxel appears similar in 
patients with normal liver function when compared with historical data.  
1.2.3.  Trial 3: Bi -daily, once weekly ModraDoc006/r in patients with mCRPC  
 
Dose -escalation of ModraDoc006/r administered bi -daily once weekly was performed starting 
from bi -daily 20 mg ModraDoc006/100 mg ritonavir  in Cohort 1 . The second dose cohort of 
30/20 mg ModraDoc006  (morning/evening dose, respectively) with bi -daily 200 mg ritonavir 
resulted in a too high docetaxel exposure (1687 ng/mL*h) with 2 dose limiting toxicities (DLTs) 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455632] cohort, simultaneous evaluation of  Cohort 3A:  30/20  mg 
ModraDoc006  (morning/evening dose, respectively) with 200/100 mg ritonavir 
(morning/evening dose, respectively ) and  Cohort 3B:  20/20 mg ModraDoc006  (morning/evening 
dose, respectively) with 200/100 mg ritonavir (morning/evening dose, respectively ) was 
perfo rmed.  
 
The most common toxicities ( see Table 2) observed with the bi -daily, once weekly treatment 
schedule, all doses, consisted of diarrhea, nausea, vomiting, anorexia and fatigue. In cohort 2 
some patients experienced severe toxicities o f which 2 were considered DLTs (grade 3 diarrhea 
and mucositis). One patient in this cohort experienced grade 3 febrile neutropenia, mucositis and 
fatigue, which was considered non -evaluable toxicity , given  the concomitant use of mirabegron  
(also a CYP3A4 inhibitor) . In cohort 3A 2 patients experienced severe toxicity, of which one 
was considered a DLT (grade 3 diarrhea) and one a grade 3 febrile neutropenia and grade 2 
mucositis, which was considered non -evaluable toxicity, given  the concomitant use of ora l 
methotrexate. In cohort 3B no DLTs were observed. The MTD  was established at weekly 30/20 
mg ModraDoc006  (morning/evening dose, respectively) in combination with 200/100 mg 
ritonavir.  
 
Table 2 Adverse Events Reported During ModraDoc006/r Study with BIDW (Twice 
Daily, Once Weekly) Dosing  in mCRPC patients  
  Cohort  1:  
M: 30 -20 mg/  
R: 100 -100 mg    
(N=5)  Cohort  2:  
M: 30 -20 mg/  
R: 200 -200 mg  
(N=8)  Cohort  3A:  
M: 30 -20 mg/  
R: 200 -100 mg  
(N=7)  Cohort  3B:  
M: 20 -20 mg/  
R: 200-100 mg  
(N=3)  All 
AEs 
 
(N=23)  All 
AEs  
 
(N=23)  Mild  
AEs  Severe  
AEs 
Adverse Events  Gr 
1 Gr 
2 Gr 
3 Gr 
1 Gr 
2 Gr 
3 Gr 
1 Gr 
2 Gr 
3 Gr 
1 Gr 
2 Gr 
3 N % % % 
Diarrhea  5     4 1 2 3 2 2 1 1   21 91% 74% 17% 
Nausea  2 2   5 1   4 1         15 65% 65%   
Fatigue    2   1 3 1 1 3     1   12 52% 48% 4% 
Anorexia  1     1 3   2 1 1 1 1   11 48% 43% 4% 
Vomiting  1 1   3     2 1   2     10 43% 43%   
Dysgeusia        4     2 1         7 30% 30%   
Alanine aminotransferase 
increased      1 1     2 1   1     6 26% 22% 4% 
Dyspepsia        1 1   1 2   1     6 26% 26%   
Oral mucositis        1   1 3 1         6 26% 22% 4% 
Alopecia        1 1   3           5 22% 22%   
Gastro -intestinal mucositis 2       2   1 2           5 22% 17% 4% 
Abdominal pain        2       2         4 17% 17%   
Aspartate aminotransferase 
increased  1           1 1   1     4 17% 17%   
Eructation        2     1     1     4 17% 17%   
Nail toxicity        1 1     2         4 17% 17%   
Weight loss  1     3       1         4 17% 22%   
Anemia        1         1   1 1 3 13% 9% 9% 
Constipation          1   1       1   3 13% 13%   
Dry skin        1 1   1           3 13% 13%   
Myalgia        1     2           3 13% 13%   
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    30 Peripheral sensory 
neuropathy              1 1   1     3 13% 13%   
Rhinitis        2       1         3 13% 13%   
Dry mouth        1     1           2 9% 9%   
Febrile neutropenia 1-2           1     1       2 9%   9% 
Fever (non -neutropenic)        1     1           2 9% 9%   
Hypotension          2               2 9% 9%   
Rectal hemorrhage  1                 1     2 9% 9%   
Thrombocytopenia        1           1     2 9% 9%   
Ascites          1               1 4% 4%   
Balanitis                1         1 4% 4%   
Dizziness        1                 1 4% 4%   
Dry eye        1                 1 4% 4%   
Headache        1                 1 4% 4%   
Leucopenia            1             1 4%   4% 
Localized edema                    1     1 4% 4%   
Malaise          1               1 4% 4%   
Paronychia                1         1 4% 4%   
Rash              1           1 4% 4%   
Restless legs                    1     1 4% 4%   
Skin fissures          1               1 4% 4%   
*All CTCAE grade (Gr) adverse events (AEs) that were possibly, probably or definitely related to ModraDoc006/r. In case of 
multiple grades of the same AE, the worst grade was reported per patient. DLTs are high -lighted in bold. ¹including a non-
evaluable p atient using mirabegron, ²including a non-evaluable patient using methotrexate  
Abbreviations: N = number of patients, ALAT = serum alanine aminotransferase, ASAT = serum aspartate aminotransferase  
 
The pharmacokinetic result s of patients with mCRPC are presented in Table 3 below. In the 5 
patients in cohort 1 the mean docetaxel AUC0 -inf was (399 ng/mL*h (coefficient of variatio n 
(CV) 49.6%) in cycle 1 and 524 ng/mL*h (CV 55.5%) in cycle 2. Doubling of the ritonavir dose 
in cohort 2 resulted in an increase of the docetaxel AUC0 -inf (1554 (CV 67.9%) and 1821 (CV 
56.5%) ng/mL*h in cycle 1 and 2, respectively) in 6 evaluable patient s. In cohort 3A, a mean 
AUC0 -inf of docetaxel of 1342 (CV 39.6%) ng/mL*h was observed in cycle 1 and 1692 (CV 
40.0%) ng/mL*h in cycle 2. In cohort 3B, a mean docetaxel AUC0 -inf of 526  ng/mL*h in cycle 
1 (CV 33.2%) and 590 ng/mL*h (CV 12.1%) ng/mL*h in cycl e 2 was achieved. Treatment with 
ModraDoc006/r has previously been evaluated in patients with miscellaneous advanced solid 
tumors in two Phase I trials (see above). The ritonavir dose in the morning is higher ([ADDRESS_455633] udies in patients with solid tumors) as in the dose -finding trial 
in mCRPC with ModraDoc006/r it was observed that the systemic exposure to docetaxel as well 
as to ritonavir was lower than in the phase I studies in which no patients with mCRPC had taken 
part. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    31 Table 3 Pharmacokinetic results of ModraDoc006/r ( docetaxel and ritonavir ) with 
BIDW (Twice Daily, Once Weekly) dosing  in mCRPC  
Para -
meter   
 
 
Pt Cohort 1  
M:30 -20mg  
R: 100 -100mg  
(n=5)  Cohort 2  
M: 30 -20mg  
R: 200 -100mg  
(n=6)  Cohort 3A  
M: 30 -20mg  
R: 200 -200mg   
(n=6)  Cohort 3B  
M: 20 -20mg  
R: 200 -100mg   
(n=3)   
 
 Docetaxel  Ritonavir  Docetaxel  Ritonavir  Docetaxel  Ritonavir  Docetaxel  Ritonavir  
Cycle   1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
AUC 0-
inf  [PHONE_7526]  7402  679 877 [ZIP_CODE]  [ZIP_CODE]  289 332 [ZIP_CODE]  [ZIP_CODE]  435 666 [ZIP_CODE]  [ZIP_CODE]  
2 283 256 [ZIP_CODE]  [ZIP_CODE]  1325  1764  [ZIP_CODE]  [ZIP_CODE]  3418  3131  [ZIP_CODE]  [ZIP_CODE]  728 578 [ZIP_CODE]  [ZIP_CODE]  
3 [PHONE_7527]  9972  1029  1391  [ZIP_CODE]  [ZIP_CODE]  1468  1458  [ZIP_CODE]  [ZIP_CODE]  [PHONE_7528]  [ZIP_CODE]  
4 [PHONE_7529]  9550  1116  1158  [ZIP_CODE]  [ZIP_CODE]  1644  2239  [ZIP_CODE]  [ZIP_CODE]    
5 553 702 [ZIP_CODE]  [ZIP_CODE]  2148  2478  [ZIP_CODE]  [ZIP_CODE]  1629  2611  [ZIP_CODE]  [ZIP_CODE]  
6   1756  2484  [ZIP_CODE]  [ZIP_CODE]  873 1157  [ZIP_CODE]  [ZIP_CODE]  
 399 
 
CV% 
49.6  
 
 
 
( 524 
 
CV%  
55.5  9514  
 
CV%    
38.0  [ZIP_CODE]  
 
CV%  
19.3  1342  
 
CV%  
39.6  
 
 
 1692  
 
CV%  
40.0  
 
 [ZIP_CODE]  
 
CV%  
30.4  
 
 [ZIP_CODE]  
 
CV%  
52.1  
 1554  
 
CV%  
67.9  1821  
 
CV%  
56.5  [ZIP_CODE]  
 
CV%  
47.4  [ZIP_CODE]  
 
CV%  
52.9  526 
 
CV%  
33.2  
 
 590 
 
CV%  
12.1  
 
 [ZIP_CODE]  
 
CV%  
46.0  
 [ZIP_CODE]  
 
CV%  
25.2  
 Cmax  1 38.6  47.4  873 847 226 84.3  1750  2430  39.9  37.8  1930  1830  63.3  78.6  2130  4210  
2 24.5  14.7  1050  500 [PHONE_7530]  2830  [PHONE_7531]  9720  53 43.7  3400  1990  
3 6.21  19.9  1010  2270  97 128 4620  5710  [PHONE_7532]  5260  21.9
8 33.3  467 1080  
4 41.8  94.6  507 807 [PHONE_7533]  5650  [PHONE_7534]  4090    
5 54.1  54.1  733 1320  [PHONE_7535]  5290  205 230 [ZIP_CODE]  9890  
6   [PHONE_7536]  3170  74.8  104 2650  3880  
 33.0  
 
CV% 
55.5  
 46.1  
 
CV% 
69.3  
 835 
 
CV% 
26.5  
 1149  
 
CV% 
60.2  
 164 
 
CV%  
30.2  
 
 170 
 
CV%  
40.2  4303  
 
CV%  
43.6  
 4180  
 
CV% 
36.5  
 146 
 
CV%  
56.3  150.3  
 
CV%  
46.5  5813  
 
CV%  
60.0  5578  
 
CV%  
57.3  46.1  
 
CV%  
46.8  51.9  
 
CV%  
45.7  1999  
 
CV%  
73.6  2427  
 
CV%  
66.3  
 Abbreviations: M = ModraDoc006, R = ritonavir, n = number of patients, Pt = patient number, AUC 0-inf  = area under the plasma 
concentration versus time curve from 0 to infinity, in ng/ml*h,  Cmax = maxim um plasma concentration in ng/ml, = mean, CV% 
= coefficient of variation (percentage)  
 
The MTD  of ModraDoc006/r in mCRPC patients is different than in patients with other solid 
tumors, which is in line with the observed higher docetaxel clearance in i.v. treated mCRPC 
patients 65. This might be caused by [CONTACT_169089]3A4 in mCRPC patien ts, associated with 
low testosterone levels .  
 
ModraDoc006/r has demonstrated efficacy in mCRPC patients as shown in  2. A PSA decrease of  
≥50% was observed in 6 out of 10 evaluable patients (after ≥9 ModraDoc006/r cycles). Five 
patients had measurable disease, of which one in cohort 2 and two in cohort 3A ach ieving stable 
disease (SD) and 2 patients in cohort 3B with a confirmed partial response. One patient in cohort 
3A with radiological SD discontinued in the study because of clinical and biochemical 
progression.  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    32 Figure 2 Efficacy of ModraDoc006/r i n mCRPC patients  
Duration of treatment with ModraDoc006/r in weeks, the reason for early discontinuation if indicated and treatment response. 
Each bar represents one individual patient. Patients with PSA responses are depi[INVESTIGATOR_364739] . The striped bars indicate that the 
patient has measurable disease according to RECIST, the corresponding evaluation (SD or PR) is depi[INVESTIGATOR_364740]. Each dose level is represented by [CONTACT_364792], as stated in the legend.  
 
1.3. Trial and Dosing Rationale  
1.3.1.  Ritonavir  
In this study, 300 mg of ritonavir will be administered maximally per week: it will be 
administered as two separate doses of 200 mg in the morning and 100 mg in the evening 
(concomitant with the two doses of ModraDoc006). With this schedule, no or only minor side 
effects are expected of ritonavir, due to the low total dose given.  As context, ritonavir is 
administered in HIV treatment, because of its ability to inhibit CYP3A4 activity in the intestinal 
luminal cells, and it has been proven that ritonavir can be administered safely at doses up to [ADDRESS_455634] 
few weeks of therapy, at these higher do ses, and they are correlated with ritonavir plasma 
levels 63. Since ritonavir in our study is administered at much lower doses and frequencies, no 
serious side  effects are expected from ritonavir in this study. Furthermore, the safety of ritonavir 
was favorable at daily doses of 100 -200 mg in clinical studies with multiple combinations with 
protease inhibitors 52,53,64  – a frequency which is far higher than will be used in  this study.  
1.3.2.  ModraDoc006 /r 
Frequently occurring toxicities of i.v. docetaxel, such as neutropenia and peripheral 
polyneuropathy, have rarely been observed with ModraDoc006/r in the phase I studies 
performed to date. The  lower toxicity of ModraDoc006, in co mbination with ritonavir  can be 
explained by [CONTACT_364793] a more than 10 -fold lower maximum 

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    33 concentration  (Cmax) as compared to i.v. docetaxel. The AUC is comparable to i.v. docetaxel over 
the time course of a treatment cycle of [ADDRESS_455635] of care, toxicity of ModraDoc006/r will be lower, but 
the efficacy will be at least similar and potentially better when compared to i.v. docetaxel.  
 
1.3.3.  ModraDoc006/r  in mCRPC  
The MTD  of ModraDoc006/r in mCRPC  has been established in the Phase Ib trial in this 
population  (Section 1.2.3 ). However, this study demonstrated that based on pharmacokinetics, 
safety and efficacy data, two dose regimens could be selected for further studies in mCRPC: 
ModraDoc006 30/20 mg (morning/evening dose, respectively) with 200/100 mg ritonavir 
(morning/evenin g dose, respectively ) and  ModraDoc006  20/20 mg (morning/evening dose, 
respectively) with 200/100 mg ritonavir (morning/evening dose, respectively ). Both 
ModraDoc006/r dose levels provide a level of AUC that is in the range (or moderately above) of 
that achieved with 75 mg/m2 docetaxel by i.v. administration, with ModraDoc006  30/20 mg on 
the high end and 20 ModraDoc006  20/20 mg on the low end of the docetaxel i.v. AUC. Both 
dose levels demonstrated sufficient safety and tolerance, although the number of adverse events 
at the ModraDoc006 20/20mg dose was less compared to the 30/20mg dose. In regards to 
efficacy, both dose levels have demonstrated encouraging  response rates in PSA and in tumor 
reduction where measurable, in addition to clinical improvement.  The ModraDoc006 20/20mg 
dose level appeared remarkably well tolerated and effective, with all patients achieving the 
maximum treatment length of 30 weeks.  
 
Initially, as clinical data demonstrated that dose level ModraDoc006 30/20mg was the MTD , this 
dose was selected for further phase II evaluation in mCRPC patients. Preliminary tolerability 
information from the current study however, shows that this ModraDoc006 30/20 mg with 
200/100 mg ritonavir regimen has higher rates of (low grade) GI adver se events than aimed for 
as a convenient and tolerable oral treatment. Supported by [CONTACT_364794], 
demonstrating both good tolerance and good efficacy, a reduction to the ModraDoc006 20/20 mg 
with 200/[ADDRESS_455636] been observed. However, 
efficacy has not yet been explored sufficiently in patients with mCRPC . Therefore, the current 
trial is proposed with the primary  aim to determine the efficacy of Modra Doc006/r as measured 
by [CONTACT_364795] (rPFS)  based on the Prostate Cancer Clinical Trials 
Working Group 3 (PCWG3) recommendations [ADDRESS_455637] treatment with  i.v. 
docet axel in subjec ts with mCRPC.  Furthermore, the safety , tolerability and HRQoL of 
ModraDoc006/r in the target population will be assessed  and compared to standard i.v. 
docetaxel . In addition, Overall Response Rate  (ORR) based on  PCWG3 -modified  RECIST 1.1 
criteria,  Time to progression (TTP) , Duration of response (DOR), PSA -PFS, Time to PSA 
progression  and Disease Control Rate (DCR) based on PCWG3 -modified RECIST v 1.[ADDRESS_455638] i.v. docetaxel.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    34 If compa rable  efficacy - or trends of superior efficacy  - as well as  improved safety , quality of life  
and patient convenience can be demonstrated, ModraDoc006/r treatment will have advantages  
for patients with mCRPC. Depend ing upon the outcome of this trial a pi[INVESTIGATOR_364741] . 
1.4. Potential Benefits and Risks  
The patient risk of th is study is qualified as ‘low’. This is motivated by [CONTACT_716]:  
1. The study drug has been tested in two prior phase I trials  56,57 and one dose -finding study 
in the target population of mCRPC ([STUDY_ID_REMOVED]) . Based on the results of these trials, 
the toxicity of ModraDoc006/r is expected to be lower than standard i.v. docetaxel 
treatment.  
2. The benefit -risk profi le of ModraDoc006/r is expected to  improve with a starting dose of 
ModraDoc006 from 20/20 mg ( morning/evening dose, respectively) with 200/100 mg 
ritonavir ( morning/evening dose, respectively) , to allow for a better tolerability, while 
keepi[INVESTIGATOR_007] a sufficient level of exposure , enabling longer treatment duration  and associated 
treatment activity.  
3. The safety profile of docetax el as an i.v.  formulation in the patient population is well 
known.  
4. With t his schedule, no or only minor side effects are expected of ritonavir, due to the low 
total dose given.   
5. Treatment guidelines to decrease dose o r interrupt treatment when side -effects occur will 
be followed as specified in this protocol, based on the exper ience in the two prior phase I 
trials.  
Considering the broad experience with i.v. docetaxel and the observed lower toxicity of the study 
treatment, the remaining risks are acceptable for the patient s participating in the study . A 
structured risk analysis including all study details can be found in  Appendix VIII. 
1.4.1.  Benefits of IMP  
The principal aim of this trial is to compare safety and efficacy data on administration of 
ModraDoc006/r  with standard i.v. docetaxel as therapy in  patients with mCRPC suitable  to 
receive docetaxel  monotherapy.  This information, together with data of HRQoL , will help in 
establish ing the pi[INVESTIGATOR_364742] , and may result in an improvement 
of this  disease state.  
1.4.2.  Management of Risks  
To minimize the risk to patient s and maximize safety, the following factors have been 
incorporated into the trial design:  
• Detailed safety and laboratory assessments will be performed as outlined in 
Section  6.7 of this protocol.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    35 • Patients will be provided with diet and hydration i nstructions and a home prescription 
for loperamide, with instructions on how to use this medication in case diarrhea 
occurs at home  
• All clinical observa tions will be evaluated by [CONTACT_941] I nvestigator on an ongoing basis.  
• The trial will be planned to minimize the time interval which would influence routine 
procedure to the patient .  
1.4.3.  Benefit/Risk Ratio  
The anticipated risks are based on ModraDoc006/r  non-clinical and clinical experiences and are 
not expected to be significant. Patient s will be monitored  closely for the occurrences of any 
significant clinical events , and treatment will only continue if it is considered safe and 
appropriate to do so.  
The early clinical development of ModraDoc006/r  demonstrated that its use is generally safe and 
well tolera ted, and can justify evaluation in a larger patient  population. These studies also 
demonstrated that IMP has a strong potential for anti -tumor activity.  
In summary, the expected benefit outweighs the expected risks for patient s.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    36 2. TRIAL OBJECTIVES AND ENDPO INTS  
2.1. Primary Objectives  
To determine the efficacy of ModraDoc006/r,  as measured by [CONTACT_364796] (rPFS) , compared to standard treatment with i.v. docetaxel in subjects with mCRPC . 
2.2. Secondary Objectives   
• To evaluate the efficacy of ModraDoc006/r, as measured by [CONTACT_43877]3 -modified 
RECIST v1.1 criteria of objective response rate (ORR), disease control rate (DCR) 
and duration of response (DOR) compared to standard treatment with i.v. docetaxel in 
subjects with mCRPC.  
• To evaluate the clinical outcome in terms of rPFS at 6 month s and time to progression 
(TTP) of ModraDoc006/r compared to i.v. docetaxel  
• To evaluate the outcome in terms of PSA tumor marker evaluation for PSA response, 
PSA-PFS and time to PSA progression of ModraDoc006/r c ompared to i.v. docetaxel  
• To compare the time to first skeletal -related event between ModraDoc006/r and i.v. 
docetaxel  
• To determine the safety and tolerability of ModraDoc0 06/r compared to i.v. docetaxel  
• To compare subject’s Health Related Quality of Life (HRQoL) response of 
ModraDoc006/r and docetaxel i.v.  
2.3. Endpoints  
2.3.1.  Efficacy  
The primary efficacy endpoint  for this study is: 
• Radiographic Progression Free Survival (rPFS) according to PCWG3  criteria  
Secondary efficacy endpoints (based on PCWG3 -modified RECIST v1.1 criteria  where 
applicable) are: 
• Objective Response Rate (ORR)  
• Disease control rate (DCR)  
• Duration of response (DOR)  
• Radiographic Progression Free Survival (rPFS) at 6 months according to PCWG3 
criteria  
• Time to progression (TTP)  
• PSA response rate according to PCWG3 criteria  
• Progression free survival (PFS) at 6 months  
• PSA-PFS according to PCWG3 criteria  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    37 • Time to PSA progression  
• Time to first skeletal event  
• HRQoL as assessed by [CONTACT_364785], FACT -P and FAC T-taxane, Treatment 
Satisfaction and EQ -5D-5L questionnaire  
2.3.2.  Safety  
The following  secondary  safety and tolerability endpoints will be assessed:  
• Adverse events (AEs) and serious adverse events (SAEs), according to the current 
National Cancer Institute (NCI)  Common Terminology Criteria for Adverse Events 
(CTCAE)  v5.0 
• Assessments of e.g.: physical examinations, body weight, vital signs, WHO 
performance status, changes in hema tology and biochemistry, electrocardiogram 
(ECG)  
2.3.3.  Health Rela ted Quality of Life ( HRQoL ) 
Health Related Quality of Life (HRQoL) will be measured using the FACT global,  FACT -P, 
FACT -taxane, Treatment Satisfaction and EQ -5D-5L questionnaires. The FACT -P is a validated 
and frequently used questionnaire in metastatic prostate cancer trials  which has led to HRQoL -
based approvals by [CONTACT_3558] 67-73. A limited number of studies has  
compared HRQoL between oral and i.v. anticancer treatment  74. In this study, the validated 
FACT -taxane questionnaire will be used to compare the HRQoL related to toxicities of 
ModraDoc006/r  and i.v. docetaxel 75. The Treatment Satisfaction questionnaire is also a 
validated tool to compare different treatments 76. 
The following questionnaires will be employed to assess HRQoL (see also Appendix VII): 
• FACT global  
• FACT -P  
• FACT -taxane   
• Treatment Satisfaction  
• EQ-5D-5L 
Overall health related quality of life (HRQoL) improvement will be evaluated with weekly 
ModraDoc006/r as compared to the standard treatment with i.v. docetaxel. HRQoL response is 
defined as a [ADDRESS_455639] -baseline  assessment 
compared with baseline.  
Improvements in individual HRQoL  domains will be investigated with weekly ModraDoc006/r 
as compared to the standard treatment with i.v. docetaxel. Improvements that are considered 
significant are in subscales of FACT : 
• ≥3 for physical wellbeing (7 items; score range 0 –28) 
• ≥3 for social or  family wellbeing (7 items; score range 0 –28) 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    38 • ≥3 for emotional wellbeing (6 items; score range 0 –24) 
• ≥3 for functional wellbeing (7 items; score range 0 –28) 
• ≥3 for prostate cancer subscale (12 items; score range 0 –48) 
• ≥3 for taxane treatment subscale (16 i tems; score range 0 –64) 
The time to HRQoL deterioration with weekly ModraDoc006/r will be investigated as compared 
to the standard treatment with i.v. docetaxel. Time from date of randomization  to the date of first 
HRQoL deterioration (defined as a ≥[ADDRESS_455640]-baseline assessment compared with baseline) or death from any cause, whichever occurs 
first, is considered significant . 
The overall Health Related Utility with weekly ModraDoc006/r as compared to the standard 
treatment with i.v. docetaxel  will be assessed  by [CONTACT_20367] -5D-5L (Appendix VII). 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    39 3. TRIAL DESIGN  
3.1. Overall Trial  Design  
This is an open label 1:1 randomized  Phase II b trial to determine the efficacy and tolerability of 
ModraDoc006/r (i.e. ModraDoc006 in combination with ritonavir therapy ) versus  standard i.v. 
docetaxel  in mCRPC subjects  (Figure 3). 
Cohort 1  will receive docetaxel at 75 mg/m 2 given i.v. as a one -hour infusion  on day 1 every 21 
days plus 5 mg oral pr ednisone twice daily .  
Cohort 2  will receive ModraDoc006/r 20 mg oral docetaxel in combination with 200 mg 
ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in the 
evening (7 -12 hours after the morning dose), on Day 1, [ADDRESS_455641] enrolled 
patient, the sponsor may terminate the study. Any patient still under treatment in Cohort 1 can be 
switched to commercially available i.v. doceta xel. Patients still treated in Cohort 2 and who 
experience clinical benefit, will be offered the  opportunity for compassionate use 
ModraDoc006/r.  
Figure 3: Schematic of study design.   
 
Metastatic Castration Resistant Prostate Canc er (mCRPC) patients for whom treatment with i.v. docetaxel is indicated according 
to the standard of care w ill be randomized 1:1 to one of the two cohorts depi[INVESTIGATOR_116719].  Abbreviation s: BID W = bi-daily  once 
weekly , Q 21 days = once every 21 days  (Q3W)   
Tumor assessment will be performed (following PCWG3) by [CONTACT_364797] (i.e. CT/MRI and bone scan) after every [ADDRESS_455642] 24 weeks  (i.e. during  week 
9, 17 and 25) , thereafter  every 12 weeks and at End Of Treatmen t (EOT) , according to the 
RECIST v1.1 criteria. Both PSA response and radiological response (PR/CR) must be confirmed 
either after 3-[ADDRESS_455643] v1.1. in patients with  measurable 
disease.  Confirmation of changes in  bone lesions by [CONTACT_43877]3 criteria will occur after a minimum 
of 16 weeks (i.e. scheduled assessments during week 17  and beyond ). 

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455644] 1.1. and PCWG3 criteria  will 
be treated in this trial.  Patients may be replaced ( see Section  6.8.3 ), therefore the total number of 
treated patients may be higher than the a nticipated  number of evaluable patients . This phase II 
study is conducted to gather preliminary efficacy and safety information on the new oral 
treatment. The sample size is not based on a formal hypothesis testing. However, sample size 
sensitivity assessm ents were performed based on precision (width of 95% confidence interval) 
for the difference in the propo rtions of radiographic progression free survival (rPFS) between 
treatment at time of the 6 months follow -up. The average median rPFS in patients with m CRPC 
with docetaxel treatment in previous studies (Table 1) was 8.3 months, correspond ing to the 
proportion of patients with rPFS at 6 mo nths of  around 61% (assum ing rPFS  
follows  an exponential distribution).  It is expected that ModraDoc006/r will be at least as 
effective as i.v. docetaxel.  The following table provide s 95% confidence intervals for the 
treatment differences in proportion of rPFS at 6 month follow -up. 
 
Docetaxel   
Response  ModraDoc006/r  
Response  Treatment Difference  
(ModraDoc006/r  - Docetaxel )  
Median 
PFS % rPFS at 
6 Month  Median 
PFS % rPFS at 6 
Month  Difference  Lower  
95% CI  Upper 
95%CI  
8.3 61%  8.3 61%  0% -19.1%  19.1%  
8.3 61%  9.1 63%  2% -17.0%  21.0%  
7 55%  7 55%  0% -19.5%  19.5%  
7 55%  7.7 58%  3% -16.4%  22.4%  
6 50%  6 50%  0% -19.6%  19.6%  
6 50%  6.6 53%  3% -16.6%  22.6%  
 
Trial Stoppi[INVESTIGATOR_364743], but are not limited to, the 
following:  
• The incidence or severity of (S)AEs in this trial posing an unacceptable risk to the patients  
enrolled in the trial.  
• A decision by [CONTACT_364798], evaluation, or development 
of the product  in this indication .  
The Investigator will be notified by [CONTACT_1034], if the trial is terminated or placed on hold. The 
relevant  Institutional Ethics Committee  (IEC) and health authorities will also be informed 
according to appropriate regulatory require ments.  
3.3. End of Trial  
The end of the trial is defined as the last patient  last visit (L PLV). F or the purpose of data 
summaris ation, data analyses will be performed after the last patient  has completed their End of 
Trial  (EOT) v isit or the last enrolled patient has completed six (6)  months of trea tment, 
whichever occurs first. Patient s may still be on trial at the time of data summari sation, as all 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455645] enrolled patient, the sponsor may terminate the study. Any patient 
still under treatment i n Cohort 1 can be switched to commercially available i.v. docetaxel. 
Patients still treated in Cohort 2 and who experience clinical benefit, will be offered the 
opportunity  for compassionate use ModraDoc006/r . 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455646] i.v. docetaxel 75 mg/m2, q 
3 weeks or to ModraDoc006/r BIDW .  
Only patients who meet all of the eligibility  criteria will be enrolled.  
4.2. Inclusion C riteria  
To be eligible to participate in this trial, subjects must meet all of the following eligibility 
criteria:  
1. Age ≥ 18 years  
2. Histological ly or cytological ly proven prostate cancer with evidence of progressive 
mCRPC, defined as:  
a. Castrate levels of testosterone, defined as ≤ 50 ng/dL (or ≤ 0.50 ng/mL or 1.73 
nmol/L)  
b. Evidence of progressive metastatic dise ase as defined by [CONTACT_364799]   
c. With an indication for systemic treatment with docetaxel according to the standard 
of care  
3. Evaluable disease, defined as nodal or visceral lesions as evaluated with CT -scan or MRI,  
and measur ed according to RECIST v1.1. and/or bone metastasis as evaluated with 99mTc-
methylene diphosphonate (MDP) radionuclide bone scintigraphy  by [CONTACT_43877]3 criteria  
4. Resolution of toxicity of prior therapy to < grade 2 (except for alopecia), as defined by 
[CONTACT_3989] v5.0 . For any pre-existing gastro -intestinal toxicities (diarrhea or 
nausea/vomiting)  and mucositis , full resolution is required prior to study start.  
5. Adequate hematological , renal and hepatic functions:  
a. Hemoglobin    mmol/l ( >9.0 g/dL)  
b. ANC ≥ 1.5 x 10 9 /L 
c. Platelet count ≥ 100 x 10 9 /L 
d. Hepatic function defined by  
i. Total bilirubin ≤ 1.[ADDRESS_455647], except for patients with familial 
bilirubinemia (Gilbert’s disease)  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    43 ii. Serum ASAT and ALAT ≤ 2.[ADDRESS_455648] ( ≤ [ADDRESS_455649] with liver 
metastases)  
e. Renal function defined by [CONTACT_89408]  1.[ADDRESS_455650] or creatinine clearance  
50 ml/min (by [CONTACT_3158] -Gault formula, or MDRD [Modification of Diet in  Renal 
Disease] ). 
6. WHO performance status of [ADDRESS_455651] 12 weeks  
8. Able and willing to swallow oral medication  
9. Able and willing to undergo radiologic scans ( CT-scan, or MRI  and bone scintigraphy ) 
10. Able and willing to give written informed consent according to local guidelines  
 
4.3. Exclusion C riteria 
Subjects who meet ANY of the following criteria at screening will be excluded from trial entry:  
1. Any treatment with investigational drugs, chemotherapy or immunotherapy within [ADDRESS_455652] dose of investigational treatment. Pall iative radiotherapy (1x8 Gy 
dose) is allowed before and during the study , but not in the week prior to start of study 
treatment .  
2. Subjects who have had prior treatment with taxanes . 
3. Subjects with symptomatic brain metastases. Subjects asymptomatic in the a bsence of 
corticosteroids and anticonvulsant therapy for ≥[ADDRESS_455653] been completed ≥[ADDRESS_455654] 
be stable with verification by [CONTACT_9661] (e.g. brain MRI or CT completed at screening, 
demonstrating no current evidence of progressive brain metastases). Subjects are not 
permitted to receive anti -epi[INVESTIGATOR_364744]. Subjects with a history of leptomeningeal met astases are not eligible.  
4. Current malignancies other than mCRPC with exception of adequately treated basal or 
squamous cell carcinoma of the skin , or adequately treated non -muscular invasive bladder 
cancer.  
5. Absence of highly effective method of contraception as of cycle one day one (C1D1). Men 
enrolled in this trial must agree to use a highly effective contraceptive method throughout the 
study.  
6. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100  mm Hg)  
7. Grade ≥ 2 motor or sensor y neuropathy symptoms (as defined by [CONTACT_30828] 5.0)  
8. Known hypersensitivity to any of the study drugs or excipi[INVESTIGATOR_364745] , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455655], CYP3A, OATP1B1, OATP1B3 and MRP2 modulating drugs 
such as Ca+ - entry blockers (verapamil, dihydropyrid ines), cyclosporine, quinidine and 
grapefruit juice, concomitant use of HIV medications, other protease inhibitors, (non) 
nucleoside analogues, or St. John’s wort  
10. Bowel obstruction or motility disorder that may influence the resorption of drugs as judged 
by [CONTACT_1963]  
11. Major surgical procedures within 21 days prior to providing informed consent  
12. Active acute or chronic infection, which is not controlled by [CONTACT_364781] (at the 
discretion of the treating physician)  
13. Known positivity for Human Immunodeficiency Virus HIV -1 or HIV -2 type  
14. Patients with known active infection of hepatitis B, C, or E (patients who are anti -HBC 
positive but HBsAg negative are eligible to participate in this study)  
15. Clinically significant (i.e. acti ve) cardiovascular disease defined as stroke, tra nsient ischemic 
attack (TIA), myocardial infarction, unstable angina , or congestive heart failure within  ≤ [ADDRESS_455656] trial treatment  
16. Evidence of any other medical conditions (such as treatment -resistant peptic ulcer disease, 
erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, or 
pulmonary embolism within 4 weeks of randomization, or psychiatric illness, drug or alcohol 
abuse, physical examination or labo ratory findings) that may interfere with the planned 
treatment, affect subject compliance or place the subject at high risk of treatment -related 
complications  
17. Legal incapacity  
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455657] (Trial Drug)  
5.1.1.  Description of the IMP  
Modra Pharmaceuticals  developed a spray -dried solid dispersion formulation of docetaxel 
pressed in to tablets (ModraDoc006 10 mg tablets), containing 10 mg docetaxel. The formulation 
excipi[INVESTIGATOR_364746] K30, sodium dodec yl sulphate, lactose monohydrate, 
croscarmellose , silica colloidalis anhydrica and magnesium stearate. All excipi[INVESTIGATOR_364747] (oral capsules and tablets).  
The stability studies of ModraDoc006 10 mg are ongoing and according to relevant International 
Council of Harmonization (ICH) guidelines. Interim data shows that ModraDoc006 [ADDRESS_455658] 18 months at room temperature and 
protected from light. Shelf life will  be set based on ICH Q1E guideline.  
5.1.2.  Formulation , preparation and labelling  of ModraDoc006  
ModraDoc006 is manufactured and pack aged at the pharmacy Netherlands Cancer Institute 
according to good manufacturing practice (GMP) regulations. Final clinical label ling will be 
conducted by a clinical logistics service organisation. Ritonavir is commercially available as 
100 mg tablets for oral consumption (Norvir ®). This tablet has been granted market approval in 
1996 in the EU (EU/1/96/016/005) by [CONTACT_364800] 2010 in the [LOCATION_003] (NDA 
022417).  Norvir ® bottles will be overlabelled with appropriate clinical label. Both drugs will be 
distributed by a clinical logistics service organisation.  
Plasma concentrations of ritonavir after administra tion of a single 100 mg dose tablet are similar 
to the 100 mg soft gelatine capsule under fed conditions, although the absorption of the tablet 
may be more efficient 52. Norvir ® tablets and Norvir ® capsules have not been compared under 
fasting conditions.  
All clinical labels will comply with GMP  regulations  and local regulatory requirements  and will 
state that the drug is for clinical use only and should be kept out of reach of children.  
5.1.3.  Preparation and labelling of i.v. docetaxel  
All labels will comply with good manufacturing practice regulations and will state that the drug is 
for clinical use only and should be kept out of reach of children. Information regarding the patient, 
for example enrolment number, contents, expi[INVESTIGATOR_5695], d osing instructions as well as a space for the 
date of dispensing will be included on the labels.   
5.2. Drug accountability  
Modra Pharmaceuticals will provide  the study drugs ModraDoc006 , ritonavir (Norvir ®) and i.v. 
docetaxel . All other medications will be tak en from the Pharmacy’s own stock at the 
investigational site. The study drugs  will be stored and handled according to the manufacturer’s 
instructions. The site will acknowledge receipt of the study drugs indicating shipment content 
and condition. Damaged s upplies will be quarantined and replaced. Until dispensed to the 
patients, all study drugs will be stored in a secure locked area, accessible to authorised personnel 
only. The Investigator agree s to use the study drugs only in accordance with this study  protocol.   
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455659]  (medication diary)  that will be reviewed in an outpatient setting. In 
addition, during the first cycle on Day 3 and Day 10 (+/ - 1 day), patients will be contact[CONTACT_364801] o n compliance.  
Patients will be instructed to re turn any unused tablets during  each visit , including empty boxes, 
to enable the site staff to ch eck compliance. Tablets  that are not taken will not be reallocated but 
returned to the pharmacy.  
5.3.1.  Accountability Procedures  
Accurate records of all study drugs  (ModraDoc006, ritonavir  and i.v. docetaxel ) dispensed to the 
investigational site are to be maintained,  including the amount (number of vials) and lot 
numbers,  according to site -specific Standard Operating Procedures (SOPs). Records will include 
overall accountability of the bulk product shipped to the investigational sites, and details of the 
dosing vials dispensed to patients  for traceability . Drug accountabil ity will be monitored 
throughout the study.  
Upon termination of the study, and after inventory by a Modra Pharmaceuticals monitor or 
designated representative, all study drug s are to be returned to Modra Pharmaceuticals or 
designee in the original vials u nless there is agreement to destroy it on site. The site must supply 
a copy of their study drug destruction policy to Modra Pharmaceuticals before authorisation for 
destruction will be considered . Full documentation of study drug destruction will be provid ed for 
the Trial Master File.  
5.4. Administration  of i.v. docetaxel  
5.4.1.  Dose and Schedule of i.v. docetaxel according to standard of care  
All patients in Cohort 1  will be treated with i.v. docetaxel 75 mg/m2 as a one -hour infusion on 
day [ADDRESS_455660] of care 77 (see Figure 4:). Per the FDA label  for docetaxel,  
premedication with dexamethasone is required in order to reduce the incidence and severity of 
fluid retention as well as the severity of hypersensitivity reactions.” 77. The recommended 
premedication regimen is oral dexamethasone [ADDRESS_455661] and every  subsequent cycle, the patient will receive i.v. 
docetaxel.  This regime n will be continued 3 -weekly until disease progression (specifically meant 
as radiographic disease progression , not biochemical or PSA progression only), unacceptable 
toxicity, or discontinuation for any other reason.  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    47  
 
Figure 4: Study schedule cohort 1  
Week  1 2 3 
Day 1       8       15      
Docetaxel i.v.  x                    
Prednisone  
twice daily  x x x x x x x x x x x x x x x x x x x x 
ADT*   
Patients will be treated with i.v. docetaxel on day 1 every 21  days with prednisone 5 mg twice daily every day. *Patients will also 
be treated with androgen deprivation therapy (ADT) according to the standard of care, for example gosereline (Zoladex) 10.[ADDRESS_455662] Characteristics (SPC) 78. 
One dose reduction of i.v. docetaxel  is allowed from 75 mg/m 2 to 60 mg/m 2 (see Table 44).  If a 
patient requires more than the allowed dose -reduction, study treatment needs  to be discontinued . 
Patients should permanently discontinue study treatment for all grade 4 toxicities with the 
exception of:  laboratory values which resolve to CTCAE < grade 1, alopecia, or inadequately 
treated nausea, vomiting, or diarrhea . 
 
Table 4: Dose modifications for i.v. docetaxel  
Treatm ent Standard dose  First  dose reduction  
i.v. docetaxel  75 mg/m²  60 mg/m²  
 
5.5. Administration of ModraDoc006/r  
5.5.1.  Dose and Schedule of ModraDoc006/r  
All patients in Cohort 2  will take ModraDoc006 /r orally bi -daily on day 1 of every week  (see 
Figure 5), in the morning and in the afternoon on an empty stomach , either 1 hour before or 2 
hours after meals  (see Table 55). The time allowed between morning and afternoon dosage is at 
least [ADDRESS_455663] in an outpatient set ting. ModraDoc006 is administered simultaneously with 200 mg 
ritonavir in the morning and 100 mg ritonavir in the afternoon and a glass of tap water 
(approximately 150 mL). Patients will report their medication intake and possible symptoms on a 
personal re gistration list that will be reviewed in an outpatient setting.  In case of vomiting after 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455664] and every  subsequent weekl y cycle, the patient will receive 
ModraDoc006/r. This regime will be continued weekly until disease progression (specifically 
meant as radiographic disease progression , not biochemical or PSA progression only), 
unacceptable toxicity, or discontinuation for  any other reason. There is no maximum duration of 
ModraDoc006/r administration.  
Figure 5:  Study schedule  cohort 2   
Week  1 2 3 
Day 1       1       1      
 Morning  Evening   Morning  Evening   Morning  Evening   
ModraDoc006  x x       x x       x x      
Ritonavir  x x       x x       x x      
Prednisone  
twice daily  x x x x x x x x x x x x x x x x x x x x x x x 
ADT*   
Patients will be treated with ModraDoc006 and ritonavir twice a day, once every week and with prednisone 5 mg twice daily 
every day.  *Patients will also be treated with androgen deprivation therapy (ADT) according to the standard of care, for 
example gosereline (Zoladex) 10.8 mg s.c. every 12 weeks.  
 
Table 5: ModraDoc006/r t reatment  
Schedule: Once weekly (on the same day)  
Treatment  Dosing  Administration  
ModraDoc006  
 
 
Ritonavir  20 mg in the morning  
20 mg in the evening  
 
200 mg in the morning  (i.e. 2*100 mg)  
100 mg in the evening  oral tablets of 10 mg each  
 
 
oral tablet s of 100 mg each  
 
Note : Patients enrolled under protocol amendment 1 , who are dosed with 30 mg of ModraDoc006 
combined  with 200 mg ritonavir in the morning and 20 mg of ModraDoc006 combined  with 100 
mg ritonavir in the evening, will , at the investigator ’s discretion, be able to continue at this dose . 
5.5.2.  Premedication and supportive care  for ModraDoc006/r  
 
Anti-emetic therapy  
As anti -emetic therapy, all patients will be given bi-daily a 5HT3 antagonist  prior to oral 
ModraDoc006/r administration during the fir st two weeks  (see Table 66). In subsequent cycles, 
5HT3 antagonist premedication may be given if indicated. All patients should be provided by [CONTACT_364802] , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    49 site with a home prescription for anti -emetics (metoclopramide 10 mg maximum 4 times daily) 
and should receive instructions on how to use this medication in case nausea/vomitin g occurs at 
home. In case metoclopramide (or domperidone) proves insufficient, a 5HT3 antagonist may be 
taken on days of study medication, granisetron [ADDRESS_455665] step only and at a low dose of 1 mg, because as has been 
explained in Appendix VIIII, concomitantly used ritonavir may increase exposure to 
dexamethasone.   
In case of vomiting after intake, the patient should not take any new study drug.  
Table 6: Premedication before ModraDoc006/r  
Premedication (standard during first two cycles , there after according to standard practice of the 
treating physician)  
Treatment  Dose  Day Administration  
Granisetron  (preferred)  1 mg  morning dose , one hour before treatment  
evening  dose, one hour before treatment  oral tablet  
Ondansetron * 8 mg morning dose, two hours before treatment  
evening dose, two hours before treatment  oral tablet  
*If ondansetron is prescribed, it has to be taken at least 2 hours in advance of the study treatment to avoid 
drug-drug interactions . 
Table 7: Anti -emetic therapy  
Step 1  Step 2  Step 3  
Metoclopramide  (preferred)  
4 dd 10 mg as needed  
or 
Domperidone  
4 dd 10 mg as needed  Granisetron  (preferred)  
2 dd 1 mg  
or 
Ondansetron * 
2 dd 8 mg  Dexamethasone  
1 dd 1 mg, increase as needed  
or 
Lorazepam  
1 dd 1 mg, increase as needed  
*If ondansetron is prescribed, it has to be taken at least 2 hours in advance of the study treatment to avoid 
drug-drug interactions.  
Supportive care for diarrhea  
All patients should be provided by [CONTACT_364803] a home 
prescription for loperamide, with instructions on how to use this medication in case diarrhea 
occurs at home. Of note, loperamide is not allowed on the day of administration of 
ModraDoc006/r, due to metabolis m by [CONTACT_2750]3A isoenzyme.  
In case of diarrhea and the presence of nausea and/or vomiting, treatment with metoclopramide 
should be altered to a 5HT3 antagonist.  
Instructions on AE management and dose modifications for diarrhea are provided in Table 88. 
Patients will be instructed that if they miss a day’s dose, they must not double up the next dose 
but skip this dose instead and resume the dosing schedu le as planned. If a dose or doses are 
missed, the reason(s) and the number of doses not taken will be noted and recorded in the eCRF, 
just as all administered doses are documented.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    50 Table 8: Diarrhea - Supportive treatment and Dose Modifications  
CTCAE Grade  Adverse Event Management  Dose Modification  
Uncomplicated 
diarrhea¹  
Grade 1 or Grade 2  
 Diet:  Stop all lactose -containing products; 
eat small meals, BRAT diet (bananas, 
apples, rice, toast) is recommended.  
 
Hydration:  8 to 10 large glasses of clear 
liquids per day (e.g., Gatorade or broth).  
 
Medication (Grade 2):  
- stop metoclopramide, in case of 
nausea/vomiting: start ondansetron or 
granisetron.  
 
- Loperamide³, initially 4 mg, followed by 
2 mg every 4 hours or after every unformed 
stool, to a maximum of 16 mg/ day. 
Continue until diarrhea -free for 12 hours.  
Loper amide is NOT allowed on the day of 
administration of ModraD006/r.  
 
Diarrhea > 24 hours: Loperamide 2 mg 
every two hours to a maximum of 16 mg/ 
day. Consider adding oral antibiotics.  
Diarrhea > 48 hours: Loperamide 2 mg 
every two hours to a maximum of 16 m g/ 
day. Add budesonide or other 2nd line 
therapi[INVESTIGATOR_014] (octreotide, or tincture of opi[INVESTIGATOR_1890]) 
and oral antibiotics.  Grade 1  (despi[INVESTIGATOR_364748]) : No dose 
reduction , unless unacceptable  to 
patient  or medically concerning . 
 
Grade 2  (despi[INVESTIGATOR_364748]) :  
Hold or omit 4 ModraDoc006/r 
until recovery to ≤ grade 1 . 
Restart with a dose reduction of 
ModraDoc006/r . 
Any complicated 
diarrhea²  
Grade 3 or Grade 4  
 Clinical evaluation is mandatory.  
 
Stop metoclopramide, in case of 
nausea/vomiting: start ondansetron or 
granisetron.  
 
Loperamide³ : initially 4 mg, followed by 
2 mg every 4 hours or after every unformed 
stool, to a maximum of 16 mg/ day. 
Continue until di arrhea -free for 12 hours.  
2nd line therapi[INVESTIGATOR_364749]. Loperamide is NOT 
allowed on the day of administration of 
ModraD006/r.  
 
Hydration:  IV fluids should be administered 
if clinically indicated.  
 
Antibiotics  (oral or IV) should be 
administered if clinically indicated.  
 ≥ Grade 3  (despi[INVESTIGATOR_364748]):   
Hold or omit 4 ModraDoc006/r 
until recovery to ≤ grade 1, and 
then restart with a dose reduction 
of ModraDoc006/r if in the best 
interest of the patient.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    51 CTCAE Grade  Adverse Event Management  Dose Modification  
Interventions should be continued until 
the patient is diarrh ea-free for ≥ 24 
hours.  
Intervention may require hospi[INVESTIGATOR_364750] -threatening 
complications.  
¹ Uncomplicated diarrhea is defined by [CONTACT_364804][INVESTIGATOR_007], nausea/vomiting ≥ Grade 2, 
decreased performance status, pyrexia, sepsis, neutropenia ≥ Grade 3, frank bleeding, and/or dehydration requiring 
IV fluid substitution.  
² Complicated diarrhea is defined by [CONTACT_190772][INVESTIGATOR_007], nausea/vomiting ≥ Grade 2, 
decreased performance status, pyrexia, sepsis, neutropenia ≥ Grade 3, frank bleeding, and/or dehydration requiring 
IV fluid substitution.  
³ Loperamide should be made available prior to the start of study treatment so that loperamide administration can 
begin when indicated. Loperamide is NOT allowed on the day of administration of ModraDoc006/r.  
4 Hold or omit = Hold dose in case of Day 1; Omit dose in ca se of Day 8 or Day 15. Patients should be assessed 
weekly until recovery. Up to a maximum of 28 days in between doses is permitted.  
5.5.3.  Dose Modifications  of ModraDoc006/r  
Toxicities leading to dose modification are defined as any of the following occurring during the 
treatment despi[INVESTIGATOR_364751] I nvestigator assessed as possibly, probably 
or definitely related to ModraDoc006/r  (see Table 99 for hema tological  toxicities and   
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    52 Table  10 for non -hema tological toxicities ): 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    53 Table 9: Dose modifications for ModraDoc006/r in case of hema tological toxicity  
NCI Common Toxicity Criteria: Hema tologic al toxicity  
Toxicity  Definition  Dose modification  
Anaemia  Grade 1 -4 No dose reduction, but blood transfusions or other 
medical intervention aimed at resolving bleeding 
focus, when present, are allowed as needed.  
Neutropenia  Grade 1 -2 No intervention or dose reduction.  
Grade 3 without 
fever (< 38.5 ᵒC) Hold or omit* ModraDoc006/r and repeat blood 
count twice weekly until resolution to CTCAE < 
grade 2 . Resume at the same dose -level when ANC 
≥ 1.0 x10⁹/L. 
Grade 3 with fever (
≥ 38.5 ᵒC) or 
Grade 4  Hold  or omit*  ModraDoc006/r and repeat blood 
count every other day until resolution to CTCAE < 
grade 2 . Resume when ANC ≥ 1.0 x10⁹/L with a 
dose reduction if in the best interest of the patient.  
Thrombocytopenia  Grade 1  No intervention or dose reduction.  
Grade 2  Hold  or omit*  ModraDoc006/r and repeat blood 
count after one week. Resume treatment at the same 
dose-level when platelets ≥ 75 x10⁹/L. 
Grade 3  Hold  or omit*  ModraDoc006/r and repeat blood 
count twice weekly until resolution to CTCAE < 
grade 2 . Resume treatment at the same dose -level 
when platelets ≥ 75 x10⁹/L. If grade 3 is associated 
with bleeding, hold ModraDoc006/r and repeat blood 
count after one week. Resume treatment when 
platelets ≥ 75 x10⁹/L with a dose reduction of 
ModraDoc006 if in the best interest of the patient.  
Grade 4  Hold  or omit*  ModraDoc006/r and repeat blood 
count every other day until grade 3. Resume when 
platelets ≥ 75 x10⁹/L with a dose reduction if in the 
best interest of the patient.  
All gradin g will be done according to CTCAE v 5.0 (Appendix III). 
*Hold or omit = Hold dose in case of Day 1; Omit dose in case of Day 8 or Day 15. Patients should be assessed weekly 
until recovery. Up to a maximum of 28 days in between doses is permitted.  
 
If a second epi[INVESTIGATOR_8738] ≥ grade 3 hema tological toxicity occurs  after dose reduction , patients will 
be taken off study.  
 
 
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    54 Table 10: Dose modifications for ModraDoc006/r in case of non -hema tological toxicity  
NCI Common Toxicity Criteria: Non -Hema tological toxicity  
Toxicity  Definition  Dose modification  
Diarrhea  Grade 1 -4 See Table 88 
Nausea and vomiting  
(failing optimal 
dopamine antagonist, 
5HT3 antagonist, 
dexamethasone, or 
benzodiazepi[INVESTIGATOR_127245])  Grade 1  No intervention or dose reduction.  
≥ Grade 2 Hold  or omit*  until recovery to ≤ grade 1, up to [ADDRESS_455666] of the patient.  
Mucositis  Grade 1  
 
Grade 2-3 Dose reduce if G1 mucositis appears in Cycle 1 or 2.  
No intervention or dose reduction in Cycle 3 or more.  
Hold  or omit*  until recovery to ≤ grade 1, up to 21 
days, and then restart with a dose reduction.  
Peripheral neuropathy  Grade 1  No intervention or dose reduction.  
Grade 2  No intervention or dose reduction, but if 
unacceptable to patient or medically concerning, then 
treatment should be discussed with PI.  
≥ Grade 3  Permanent discontinu ation of  study  treatment .. 
Fatigue  Grade 1  No intervention or dose reduction.  
Grade 2  Dose reduce if G2 fatigue appears in Cycle 1 or 2.  
If unacceptable to patient or medically concerning, 
then hold or omit* until recovery to ≤ grade 1, up to 
[ADDRESS_455667] of the patient . 
Grade 3  Hold or omit* until recovery to ≤ grade 1, up to [ADDRESS_455668] of the patient.  
Other non -
hema tological toxicity  Grade 1  No intervention or dose reduction.  
Grade 2  Dose reduce if G2 appears in Cycle 1 or 2.  
If unacceptable to patient or medically concerning, 
then hold or omit* until recovery to ≤ grade 1, up to 
[ADDRESS_455669] of the patient.  
Grade 3  
 Hold  or omit* until non -hema tological toxicity has 
resolved to ≤ grade 1, up to [ADDRESS_455670] of the 
patient.  
Any non -hema tological 
toxicity   Grade 4  Permanent discontinuation of study treatment, except 
in case of laboratory values which resolve to CTCAE 
≤ grade 1 , alopecia, or inadequately treated nausea, 
vomiting, or diarrhea . 
All gradin g will be done according to CTCAE v 5.0 (Appendix III). 
*Hold or omit = Hold dose in case of Day 1; Omit dose in case of Day 8 or Day 15. Patients should be assessed weekly 
until recovery. Up to a maximum of 28 days in between doses is permitted.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    55  
In case of grade 4 toxicities , patients should permanently discontinue study treatment with the 
exception of:  laboratory values which resolve to CTCAE ≤ grade 1, alopecia, or inadequately 
treated nausea, vomiting, or diarrhea.  
Patients who develop grade 3 -4 peripheral neuropathy should permanently discontinue study.  
One dose reduction of ModraDoc006/r as described in Table 1111 is allowed. If a patient 
requires more than the allowed dose -reduction, study treatment needs to be discontinued.  
 
Table 11: Dose modifications for ModraDoc006/r  
Dose  Standard dose  Dose reduction  
Morning dose  
ModraDoc006  20 mg  20 mg  
Ritonavir  200 mg  200 mg  
Evening dose  
ModraDoc006  20 mg  10 mg 
Ritonavir  100 mg  100 mg  
 
 
Note:  For p atients enrolled under protocol amendment 1 , two dose reductions of ModraDoc006/r 
will be allowed . In these patients, i f a second epi[INVESTIGATOR_8738] ≥ grade 3 hema tological toxicity occurs, 
treatment will be stopped until toxicity resolves to ANC ≥ 1.0 x10 ⁹//L and/or platelets ≥ 75 
x10⁹/L. If a second  epi[INVESTIGATOR_8738] ≥ unacceptable grade 2 or grade 3 non -hema tological toxicity 
occurs, trea tment will be stopped until toxicity resolves to ≤ grade 1. When treatment is resumed, 
patients will receive a second dose reduction of ModraDoc006, according to the dose reduction 
scheme  in Table 12. If a third  epi[INVESTIGATOR_8738] ≥ grade 3 hema tological toxicity or ≥ unacceptable 
grade 2 or grade 3 non -hema tological  toxicity occurs, patients will be taken off study.  
 
Table 12: Dose modifications for ModraDoc006/r  under  amendment [ADDRESS_455671]  
dose reduction  Second  
dose reduction  
Morning dose  
ModraDoc006  30 mg  20 mg 20 mg  
Ritonavir  200 mg  200 mg  200 mg  
Evening  dose 
ModraDoc006  20 mg  20 mg  10 mg 
Ritonavir  100 mg  100 mg  100 mg  
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    56 5.6. End of T reatment  
In this trial, end of treatment (EOT) is defined as the moment at which trial treatment is 
permanently discontinued.  
Patient s are scheduled to continue to receive treatment with ModraDoc006/r  until any of the 
following occurs:  
• Unacceptable toxicity (even after the allowed  dose modification  has been applied, 
refer to Section  6.8) 
• Progressive disease  as defined in RECIST v1.1  (Appendix IV) and/or PCWG3  
(Appendix V) 
• Initiation of any other anti -cancer treatment  
• Inability  or unwillingn ess of the patient  to comply with trial procedures  
• Significant protocol violations, as judged by [CONTACT_737]  
• Withdrawal of consent by [CONTACT_102]  
• Changes in the medical status of the patie nt such that the I nvestigator believes that the 
safety of the patient will be compromised  
• Patient lost to follow -up 
• Death  
The Investigator  is ultimately responsible for the safety and wellbeing  of the  patient . If at any 
time participation in this protocol  is detrimental to the patient 's health, the patient may be taken 
off treatment or of f trial.  
The CRO must be notified a nd the reason(s) for treatment withdrawal/ trial drop-out should be 
documented in the electronic Case Report From (e CRF ). 
5.7. Prior and C oncomi tant T reatments  
All prior therapi[INVESTIGATOR_014] (beginning  and stopped within  4 weeks prior to , and/or ongoing at the time of  
the screening visit until C ycle 1 Day 1) and concomitant treatment, blood products, as well as 
interventions (e.g. analgesic use, radiotherapy) received by [CONTACT_364805]. This includes start and stop date, dose, 
unit, frequency, route of administration and indication.  
The following rules should be considered  when prescribing other treatments prior to or during  
the patient’s participation in the trial: 
• Ancillary treatments will be given as medically indicated; they should be recorded in 
the patient ’s medical  chart and on the appropriate eCRF . 
• Radiotherapy may be given concomitantly for control of bone pain or other reas ons, 
however may not be given within one week prior to start of the trial treatment . If 
possible, not all evaluable lesions should be included in the irradiated field. If this 
cannot be real ised, the patient  will be removed from the trial and will not be evaluable 
for response from that moment on. Any lesion within the irradiated area cannot be 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    57 used as a parameter for response assessment. The area should therefore be as small as 
possible.  
• Patient s will not re ceive other anticancer treatments or other investigational agents 
from start of trial treatment until last trial treatment.  
• Prior treatment with ADT is allowed. Treatment with ADT such as an agonist of 
luteinising -hormone -releasing hormone may be continued  in participants who are 
receiving it.   
• Patients are allowed to take bisphosphonate drugs if they commenced treatment at 
least two months before registration and they continued them as per the 
manufacturer’s guidelines or as per institutional practice. Pat ients not taking 
bisphosphonate treatment are not permitted to start such therapy until they have 
completed [ADDRESS_455672] use of growth factors (G -CSF, epo) is not allowed , unless a ≥ grade 4  febrile 
neutropenia , neutropenic infecti on or a ≥ grade 4 anemia has occurred in the previous 
treatment cycle. In this  case, if in alignment with local practice, G -CSF or epo 
prevention in subsequent cycles is  indicated, this will be allowed for IV docetaxel 
(cohort 1) only . According to the FDA  label G -CSF is recommended in case of 
accidental overdose of docetaxel Injection  as it reads in paragraph 10 of the 
PRESCRIBING INFORMATION: “ Anticipated complications of overdosage 
include: bone marrow suppression, peripheral neurotoxicity, and mucositis . Patients 
should receive therapeutic G -CSF as soon as possible after discovery of overdose." 77 
There is no experience with overdose of ModraDoc006/r and in case of such accident 
the sponsor should be notified without delay to discuss supportive measures to ensure 
optimal safety of the involved patient.  
Prohibited  concomitant therapy within [ADDRESS_455673] dose of ModraDoc006/r or i.v. 
docetaxel until after completion of study treatment (i.e., after EOT  visit) is defined as follows (a 
list of commonly used drugs of below drug types is provided in Appendix VIIII): 
• Systemic chemotherapy , or any other investigational agent  within the last [ADDRESS_455674] dose of ModraDoc006/r , or i.v. docetaxel . Single dose palliative 
radiation (1*8Gy) for pain relieve is allowed during the study, but not within one 
week prior to start (these lesions are not to be included as target lesions) .  
• Corticosteroids  and anticonvulsive treatment  for brain metastasis are prohibited 
and should have been discontinued at least [ADDRESS_455675] dose of 
ModraDoc006/r , or i.v. docetaxel . 
Drugs that show interaction with ModraDoc006/r, or i.v. docetaxel , need to have been stopped at 
least 5 times the terminal half-life (accordin g to SPC) or [ADDRESS_455676], in order to 
prevent interaction with the drug  (see also Appendix VIIII): 
• CYP3A4 inducers / inhibitors : all stro ng inducers and inhibitors of CYP3A4 may 
not be used during this trial, since this might prevent  uptake or could result in 
significant toxicity  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    58 • CYP3A4 substrates : all substrates  of CYP3A4 should be used with great caution. If 
administration of a CYP3A4 substrate is deemed necessary, dose -reductions of this 
drug might be needed.  
• OATP1B1, OATP1B3 inhibitors : all other strong inducers and inhibitors of 
OATP1B1 and OATP1B3 may not b e used during this trial, since this might prevent 
uptake or could result in significant toxicity.  
• OATP1B1, OATP1B3 substrates : all substrates of OATP1B1 and OATP1B3 should 
be used with great caution. If administration of an OATP1B1 or OATP1B3 substrate 
is deemed necessary, dose -reductions of this drug might be needed.  
• P-glycoprotein (P -gp, ABCB1, MDR1) inducers/inhibitors : all other strong 
inducers and inhibitors of P -gp may not be used during this trial, since this might 
prevent uptake or could result i n significant toxicity.  
• P-glycoprotein (P -gp, ABCB1, MDR1) substrates :  
Loperamide is widely used to treat acute and chronic diarrhea, irritable bowel 
syndrome, and faecal incontinence. Despi[INVESTIGATOR_364752] a full agonist at the 
opi[INVESTIGATOR_2480] μ -receptor, i t is not associated with the induction of typi[INVESTIGATOR_364753]. It acts only peripherally because it is a substrate for the MDR1 efflux 
protein P -gp in the blood –brain barrier. Despi[INVESTIGATOR_364754] -term use of 
loperamide most likely d oes not significantly affect the PK of ModraDoc006/r or 
the central toxicity of the therapy, patients may NOT take loperamide on the day 
of ModraDoc006/r administration . On other days, loperamide is allowed, if 
needed.  
all other substrates of P -gp should b e used with great caution. If administration of a P -
gp substrate is deemed necessary, dose -reductions of this drug might be needed.  
• MRP2 (ABCC2) inducers/inhibitors : all other strong inducers and inhibitors of MRP2 may 
not be used during this trial, since this might prevent uptake or could result in significant 
toxicity.  
• MRP2 (ABCC2) substrates : all substrates of MRP2 should be used with great caution. If 
administratio n of a MRP2 substrate is deemed necessary, dose -reductions of this drug might 
be needed.  
Dietary limitations  
Grapefruit , grapefruit  juice,  other grapefruit products and St. John’s wort are not to be used 
during this trial because of the interaction with CYP3A4  (see Appendix VIIII). 
5.8. Contraception  
Patients with a female partner of childbearing potential will be informed that taking the stud y 
medication may involve unknown risks to the foetus , if pregnancy were to occur during the 
study. In order to participate in the study,  they must adhere to the study contraception 
requirements during the study from the time of screening until [ADDRESS_455677] dose of 
study medication. Adequate contraceptive methods are: condom, male sterilization, other barrier 
contraceptive measures preferably in combination with condoms , true abstinence.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    59 If a female partner of a patient inadvertently becomes pregn ant while on treatment, a Pregancy 
Report  will need to  be filled out . Every effort will be made to obtain permission to follow the 
outcome of the pregnancy and report the condition of the foetus or newborn  to the sponsor . A 
Health Report of the infant will need to be filled out at 4 weeks of age . 
5.9. Drug accountability  
For the shipment, receipt, disposition, return and destruction of the investigational medicinal 
products the procedures are depi[INVESTIGATOR_364755].  
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455678] been divided into screening, visits during treatment , safety 
assessments and clinical efficacy assessments. Appendix I provides an overview of all 
assessments to be carried out throughout the trial. 
6.1. Trial Assessment Specifications  
The following Table  13 provides an overview of the specifications of each of the assessments. 
All regular laboratory safety assessments will be analysed at the local hospi[INVESTIGATOR_136966]. All 
additional lab assessme nts (i.e. outside regular visits) , may be performed at local labs (at the 
discretion of the treating physician). See also Appendix I. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    61 Table  13: Trial Assessments  
Assessment  Specification  
Physical examination 
(incl. Height  in cm  & 
Weight  in kg ) Includes the following: head /neck/oral cavity , respi[INVESTIGATOR_2133]/chest, 
cardiovascular system/ heart, abdomen, skin, lymph nodes, extremities and 
(at the Investigator’s discretion) genitourinary system/pelvis. The 
Investigator (or qualified designee) should evaluate all items of the 
examination eith er as normal or abnormal , and in case of the latter, whether 
clinically significant or not.   Information about the physical examination 
must be present in the source documentation at the investigational site. 
Significant findings that are present prior to the signing of the ICF must be 
included on the Medical History eCRF. Significant findings which meet the 
definition of an AE, must be recorded on the AE eCRF.  
Medical History & 
Demographics  • Medical history : patient  demographics, current medical conditions , 
including those symptoms related to the advanced cancer condition leading 
to trial participation and any associated symptoms thereof.  
• Prior anti -neoplastic medications, radiotherapy, and surgeries .  
• Dates of initial diagnosis of primary cancer and advan ced/metastatic 
disease . 
• Medication history for the past 4  weeks  prior to signing Informed Consent .  
WHO Performance 
Status  Assessment using scale of 0 to 5 (Appendix II) prior to ModraDoc006/r  or 
i.v. docetaxel administration. Only patients with a WHO Performance Status 
score of 0 , 1 or 2 are allowed to enter the trial. A score of  ≥3 during 
treatment  is not a criterion for withdrawing the patient from the trial . 
HRQoL  assessment  Health Related Quality of Life (HRQoL) endpoints will be assessed by 
[CONTACT_364785], FACT -P and FACT -taxane  and EQ -5D-5L questionnaires at 
baseline and at the end of cycle 3 , 6 and 10 , or at End of Treatment (EOT) if 
this would occur earlier ; HRQoL assessment by [CONTACT_364806] 3, 6 and 10, or at End of 
Treatment (EOT) if this would occur earlier  (Appendix VII). 
Electrocardiogram 
(ECG) &  
Vital signs  A single 12 -lead ECG will be made as per local practice and assessed by [CONTACT_3786] (or qualified designee)  at screening , week 6 and EOT . The 
ECGs should be assessed at the investigational site as soon as possible after 
recording and prior to ModraDoc0 06/r or i.v. docetaxel administration.  
Vital signs (blood pressure, temperature and heart rate) will be obtained at all 
visits and should be taken pre -dose. Blood pressure may be measured in a 
sitting position.  
Hema tology 1  Includes the following: h aemoglobin, hema tocrit, red blood cell count, w hite 
blood cell count  and differential ( including neutrophil, lymphocyte, 
monocyte, basophil and eosinophil counts) and platelet count.  
Biochemistry 1 Includes the following: s odium  (Na), potassium  (K), calcium  (Ca), glucose,  
urea, creatinine, total bilirubin, alkaline phosphatase, gamma -glutamyl 
transferase ( GGT ), aspartate aminotransferase (AS AT), alanine 
aminotransferase (AL AT), lactate dehydrogenase  (LD) , total protein, 
albumin . Creatinine clearance is calculated using the Cockcroft -Gault or 
MDRD formula.  
Urinalysis [ADDRESS_455679] the following: protein, 
glucose, blood, pH, and ketones. If dipstick findings are abnormal according 
to local reference ranges, then a microscopic evaluation may be performed to 
assess the abnormal findings.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    62 Assessment  Specification  
Tumor marker 1 PSA according to the assessment scheme ( Appendix I). Please record in the 
eCRF.  
(S)AEs  Assessed at screening and then continuously until follow -up visit.  Grading of 
(S)AEs will be according to CTCAE v 5.0. 
Concomitant 
medications/procedures  Will be assessed at screen ing and then at each visit until follow -up visit . 
Compliance  Triage by [CONTACT_364807] 1, Day 3 and 10 f or compliance assessment of  
administration of ModraDoc006/r  (cohort 2 only) and optimal supportive 
treatment  (cohort 1 and 2)  
CT/MRI / Bone  Scans  Patient s will undergo repeated tumor imaging to evaluate disease progression 
per PCWG3 (Appendix V) and assess tumor responses per RECIST v1.1  
(Appendix IV). RECIST v1.[ADDRESS_455680] 24 weeks (i.e. during  week 9, 17 and 25) timepoint beginning after 
Cycle 1, thereafter every 12 weeks and at End Of Treatment (EOT) of 
ModraDoc006/r  or i.v. docetaxel . Scans will include the thorax , abdomen 
and pelvis (preferably CT -scans with appropriate slice thickness per R ECIST  
v1.1). In case CT is contraindicated (e.g. due to contrast allergy), then an 
MRI of the abdomen needs to be performed with a chest CT without contrast.  
The modality selected should be the same throughout the study .  
1All laboratory tests to be done at the local lab of the institution  
6.2. Screening Visit(s) and Registration of Patient s 
6.2.1.  Screening  Visit(s)  
At the screening visit, the trial will be explained to the patient  and informed consent will be 
obtained before any trial procedures are conducted. This procedure should be thoroughly 
described in the source documents. Screening may be performed over more than one day as long 
as all tasks are completed within the max imum allow able visit window of 14  days. 
Screening/baseline laboratory assessments done within [ADDRESS_455681] ModraDoc006/r or i.v. 
docetaxel administration  do not need to be repeated at Day 1. All procedures as described in the 
Schedule of Assessments ( Appendix I) should be completed and patient  eligibility should be 
confirmed before trial treatment can take place. Patient s who do not meet all inclusion criteria or 
who meet any of the exclusion criteria are not eligible for the trial. As soon as a patient  is 
deemed ineligible during the screening phase, all further trial evaluations will be cancelled for 
this patient . Patient  numbers assigned to patient s who fail screening will not be reused.  Patients 
failing the screening assessments will be replaced.  
Re-screening may be allowed on a case -by-case basis. In the case of out -of-range laboratory 
results during the screening period, a re -test may be allowed within the screening period. The 
Investigator must contact [CONTACT_364808] -screening case.  
In case of a re -screening  after the initial screening period , a new ICF must be signed by [CONTACT_364809] (sub-)Investigator, a new patient  number will b e assigned , and all screening 
assessments must be repeated . 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    63 6.3. Patient  Registration  and Randomization  
Patient s considered eligible for the trial may only enter the trial after the patient  has been 
properly informed about the study and the I nformed Consent Form has been signed .  
Eligible patients  will be registered in the electronic CRF for details about  the patient’s 
randomized treatment arm and the patient ’s trial number.  
6.4. Treatment Visit(s)  
Evaluations and procedures for all visits are shown in the  Assessment Schedule ( Appendix I). 
Cohort 1 i.v. docetaxel:  
I.v. docetaxel will be administered Day [ADDRESS_455682] by [CONTACT_364810], 
death, or termination of the trial by [CONTACT_1034]. The duration of patient  participation may 
therefore vary  per patient .  
 
Cohort 2  ModraDoc006/r : 
Each treatment cycle is a time -period of 21 days. ModraDoc0 06/r will be administered Day 1 of 
each week  (i.e. Day 1, 8 and 15 of each cycle) . Safety will be monitored  at day [ADDRESS_455683] cycle and  once every cycle  thereafter , i.e. once every 21 days. In the absence of 
progressive disease (PD) or unacc eptable toxicity, patients may receive additional cycles of 
treatment. It should be the intention to treat a patient in all cycles at the dose level assigned at 
cycle 1 day 1.  
 
6.5. End of Treatment  Visit   
Patient s are scheduled to continue to receive treatment with  ModraDoc006/r , or i.v. docetaxel , 
until any of the reasons as specified in Section  6.[ADDRESS_455684] ModraDoc006/r 
or i.v. docetaxel administration .  
6.6. Follow -up Visit  
Following withdrawal from treatment, patient s should visit the hospi[INVESTIGATOR_307] [ADDRESS_455685] 
ModraDoc006/r or i.v. docetaxel administration .  
Patient s that withdraw from  the trial due to withdrawal of consent, inability or unwillingness of 
the patient  to comply with trial procedures or  lost to follow -up are considered as trial drop-outs 
and will not have to perform this  follow -up visit. 
All patient s with any  remaining adverse events at this  30-day follow -up visit should be followed 
as indicated in Section  7.2.1  (Adverse Events).  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    64 6.7. Assessment of Safety  
Safety will be assessed by [CONTACT_122959], weight, vital signs, performance 
status, laboratory evaluations ( hema tology, biochemistry and urinalysis), electrocard iograms 
(ECG), and recording of concurrent illness/therapy and adverse events.  
An overview  of the assessments to be performed during each visit  is provided in  Table 14. For 
more detailed information about the assessments itself, please refer to Table  13.  
 
 
Table 14: Overview of Safety A ssessments  
Moment in trial Required safety assessment  
Screening/ Baseline   
Note: ≤ [ADDRESS_455686] dose. These can 
therefore also be performed on day 1 of cycle  
1 before administration of ModraDoc006/r  or 
i.v. docetaxel . • Physical examination  
• Weight  
• Vital signs  
• WHO  performance status  
• Hema tology  
• Biochemistry  
• Urinalysis  
• ECG  
• Recording concurrent illness/therapy  
• Recording AE  
Once every  cycle, i.e. once every 21 days, 
within 3 days before administration   
 
Note: before ModraDoc006/r  or i.v. docetaxel 
administration.  
*Baseline measurements ≤ 3 days before 
administration  can also be used for this.  
** For patients with grade 3 -4 neutropenia 
and/or thrombocytopenia blood counts should 
be determined  twice weekly (grade 3) or  
every other day (grade 4) until resolution to 
CTCAE < grade 2.  • Physical examination  
• Weight  
• Vital signs   
• WHO  performance status * 
• Hema tology */** 
• Biochemistry * 
• Recording concurrent illness/therapy  
• Recording AE  
Cycle 1, Day 3 and Day 10  
Note: window of +/ - 1 day allowed  • Recording AE  
• Compliance  
End of treatment  • Physical examination  
• Weight  
• Vital signs  
• WHO  performance status  
• Hema tology  
• Biochemistry  
• Urinalysis  
• ECG  
• Recording concurrent illness/therapy  
• Recording AE  
30-day follow up  • Physical examination  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    65 Moment in trial Required safety assessment  
• Weight  
• Vital signs  
• WHO  performance status  
• Hema tology  
• Biochemistry  
• Recording concurrent illness/therapy  
• Recording AE  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    66 6.8. Withdrawal, Discontinuation and Replacement of Patient s 
6.8.1.  Withdrawal  
Patients should be withdrawn from the trial, if the patient:  
• Withdraws consent . It is recommended that the Investigator attempts to perform EOT 
visit evaluations on the date  a patient withdraws consent;  
• Is non -compliant with the trial treatments;  
• Is non -compliant with the trial visits and procedures;  
The primary reason for patient wit hdrawal will be noted on the eCRF. The Investigator should 
attempt to follow withdrawn patients until resolution of any AEs, or at least [ADDRESS_455687] 
dose of ModraDoc006/r, or i.v. docetaxel.  
Upon withdrawal, no further dosing, or follow -up visi ts should be performed for these patients. 
Investigators shall make reasonable attempts to contact [CONTACT_364811] -to-follow -up patients for evaluation 
of overall response and/or PFS.  
6.8.2.  Discontinuation  
Patients should discontinue treatment with ModraDoc006/r  or i.v. docetaxel , if: 
• The patient  has clinically significant lab abnormalities or A Es that, in the 
Investigator’s judgment, would preclude continued treatment .  
• Patients should permanently discontinue study treatment for all grade 4 toxicities with 
the exception of:  laboratory values which resolve to CTCAE < grade 1, alopecia, or 
inadequately treated nausea, vomiting, or diarrhea . 
• Patients who develop grade 3 -4 peripheral neuropathy should permanently 
discontinue study . 
• Any other reason including  withdr awal of consent.  
If a patient fails to return for a scheduled visit/follow up, attempts should be made to contact [CONTACT_364812] a (serious) adverse event ((S)AE).  
Likewise, if a patient declares his/her wis h to discontinue from the study, e.g. for personal 
reasons, an attempt should be made to establish that the true reason is not an AE (bearing in 
mind that the patient is not obliged to state his/her reasons). If the study drug therapy is 
prematurely discon tinued, the primary reason for discontinuation must be recorded in the eCRF 
and all efforts will be made to complete and report the observations as thoroughly as possible.  
A complete final evaluation following the patient’s withdrawal should be made, and any A Es 
followed up until resolution or a period of [ADDRESS_455688] dose of ModraDoc006/r or i.v. 
docetaxel has elapsed, whichever is the shorter.  
6.8.3.  Replacement of Patient s  
• Patients who fail to receive any administration of docetaxel i.v./ oral ModraD oc006/r  
• Patients who fail to undergo any efficacy assessment after baseline measurement  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    67 • Patients who discontinue due to toxicity related to study drug will NOT be replaced.  
6.9. Assessment of Efficacy  
6.9.1.  Clinical efficacy assessments  
Preliminary clinical efficacy will be assessed according to  RECIST v1.1 and PCWG3 criteria  
(Appendix IV and Appendix V). An overview of the schedule of preliminary clinical efficacy 
assessments is pro vided in Table  15. 
Table  15:  Overview of C linical Efficacy Assessments  
Moment in trial Required assessment  
Baseline  
Note: Radiological assessment needs to be 
done < 28 days prior to start of intake of study 
medication   • CT-scan (or MRI-scan if CT contraindicated)   
• Tumor  marker PSA * 
• Bone scintigraphy  
Prior to e very cycle  • Tumor markers PSA*  
After e very [ADDRESS_455689] 24 weeks  (i.e. 
during  week 9, 17 and 25) , thereafter every 
12 weeks # – 4-6 weeks later again if PR/CR 
for confirmation    (interval of minimally 4 
weeks)  • CT-scan (or MRI -scan if CT contraindicated) #  
• Bone scintigraphy  
End of Treatment  
 • CT-scan (or MRI -scan if CT contraindicated)   
• Tumor  markers  PSA* 
• Bone scintigraphy  
# In this randomized  comparative trial, the scheduled assessments should not be affected by [CONTACT_121243], drug   
holidays or any other events that might lead to imbalance in a treatment arm in the timing of disease assessment.   
*Tumor  marker : PSA. Please record in eCRF w hen measured during the course of the study.  
 
In order to evaluate efficacy, appropriate imaging procedures to accurately assess the tumor  stage 
need to be performed.  
All lesions identified at screening/baseline will be consistently followed using the uni que lesion 
number assigned at screening/baseline . All tumor  measurements are to be obtained using the 
same diagnostic procedure used at screening/baseline .  
Each time  a tumor  assessment is made, standard RECIST v 1.1 and PCWG3 criteria  are to be 
applied . All response s need to be  documented in the patient  eCRF . 
If there is a reduction in tumor  size consistent with a complete or partial response (CR or PR), 
tumor  assessment will be repeated after 4-[ADDRESS_455690] be followed during and after treatment (i.e. target lesions as well as non -target 
lesions)  until progression of disea se or subjects’ end of study .  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    68 6.9.2.  Determination of Radio graphic Disease Progression  
 
The consensus guidelines of the Response Evaluation Criteria in Solid Tumors, version 1.1 
(RECIST 1.1) (Appendix IV) and the Prostate Cancer Clinical Trials Working Group 3 
(PCWG3) (Appendix V) have been taken in to consideration for the determination of 
radiographic disease progression. Radiographic disease progression is defined by [CONTACT_393] 1.1 
for soft tissue disease, or the appearance of two or more new bone lesions on bone scan (                
PCWG3). The docume ntation required for the determination of radiographic disease progression 
is listed in Table 16. 
 
Table 16:  Protocol -Specified Documentation for Radiographic Evidence of Disease 
Progression  
Date  
Progression  
Detected 
(Visit) a Criteria for Progression  Criteria for Confirmation  
of Progression 
(requirement  
and timing)  Criteria for  
Documentation of Disease  
Progression on  
Confirmatory Scan  
Week 9  Bone lesions: 2 or more  
new lesions compared to  
baseline  bone scan by  
[CONTACT_43877]3.  Timing: at least 6 weeks  
after progression identified or  
at Week 17 visit .b Two or more new bone  
lesions on bone scan  
(compared to Week 9  
scan)  
Soft tissue lesions:  
Progressive disease on CT  
or MRI by [CONTACT_393] 1.1  Confirmation required for  
soft tissue disease (scan of  
same modality as  
demonstrated progression) b Confirmation of  
progressive soft tissue  
disease by [CONTACT_393] 1.1  
Week 17  Bone lesions: Two or  
more new lesions on bone  
scan compared to Week 9  
bone scan . Timing: at least 6 weeks  
after progression identified or  
at Week 25 visit. Required  
for bone lesions observed on  
bone scan b Persistent c or increase in  
number of bone lesions  
on bone scan compared  
to Week 17 scan  
Soft tissue lesions:  
Progressive disease on CT  
or MRI by [CONTACT_393] 1.1  No confirmatory scan  
required for soft tissue  
disease progression.  n/a 
Week 25 and  
Later  
 Bone lesions: Two or  
more new lesions  
compared to Week 9 bone  
scan.  Timing: at least 6 weeks  
after progression identified.  
Required for bone lesions  
observed on bone scan b Persistent c or increase in  
number of lesions on  
bone scan compared to  
prior scan  
Soft tissue lesions:  
Progressive disease on CT  
or MRI by [CONTACT_393] 1.1  No confirmatory scan  
required for soft tissue  
disease progression  n/a 
a Progression detected by [CONTACT_364813] [ADDRESS_455691]/MRI at an unscheduled visit prior to Week [ADDRESS_455692] be present at that next available scan 
(confirmation scan).  
n/a, not applicable.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    69 7. ADVERSE EVENTS  
All adverse events in this trial will be collected and processed in accordance with ICH -GCP and 
national and local laws and regulations. In line with these, the Investigator  is responsible for 
reporting Serious Adverse Events (SAEs) to the CRO  within the appropriate timelines (see 
below). If required, t he Investigator  is also responsible for notifying the appropriate local  ethics 
committee of SAE s per the guidelines of the Institution and in accordance with aforementioned  
laws and regulations.  
7.1. Definitions  
7.1.1.  Adverse Event  (AE)  
An adverse event (AE) is any untoward medical occurrence in a patient  administered a 
pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment. An AE can there fore be any unfavo urable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product. Whe n 
there are reasonable grounds for suspi[INVESTIGATOR_364756] 
(i.e. there are facts or arguments to suggest a causal relationship), it must be considered as 
adverse drug reaction  (ADR) . 
Worsening of the patient ’s cond ition for which the trial treatment is being used, is not considered 
an AE.  
All AEs reported by [CONTACT_364814].  AEs  
should be followed until resolution or until judged to be permanent . Assessments  should be made 
at each visit. Information about common side effects already know about the IMP can be found 
within the IB or will be communicated between IB updates in the form of Investigator 
Notifications.  
The investigator should also instruct each subj ect to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician believes might 
reasonably be related to the study treatment.  
Each AE will be described by:  
• Description of the event  
• Its durat ion (start and end dates)  
• The severity Grade (according to  CTCAE v5.0  criteria  for toxicity; Section [IP_ADDRESS] ) 
• Its relationship to the study drugs separately  (Section  [IP_ADDRESS] ) 
• Treatment of the e vent 
• The outcome  
• Consequences  (actions taken)  for study medication  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    70 7.1.2.  Adverse Drug Reaction  (ADR)  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered as adverse drug reactions (ADRs). The phrase “responses to medicinal product” 
means that a causal relationship between a medicinal product and an adverse event is at least a 
reasonable possibility, i.e., a relationship cannot be ruled out.  ADRs are also referred to as 
toxicity . 
7.1.3.  Unexpected Adverse Dru g Reaction  
An unexpected adverse drug reaction is an adverse drug reaction of which the nature or severity 
is not consistent with the availab le product information, e.g.  IB for an unapproved investigational 
product. ADRs that are more specific or more seve re than described in the Investigator ’s 
brochure should also be considered unexpected.  
7.1.4.  Serious Adverse Event  (SAE)  
A SAE is an occurrence that at any dose  of any of the following : 
• Results in death. If death results from (progression of) the disease, it should be  
reported as an event (SAE) itself; or  
• Is life threatening (the patient  was at risk of death at the time of the event; it does not 
refer to an event that hypothetically might have cause d death if it were more severe); 
or 
• Requires patie nt hospi[INVESTIGATOR_364757]; or  
• Results in persistent or sign ificant disability/incapacity; or  
• Is a congenital anomaly/birth defect  in case of pregnancy outcome of partner . 
Any event that does not meet the above criteria may also be considered by [CONTACT_364815] , based on appropriate medical and scientific judgment. This includes important medical 
events that may not be immediately life -threatening , or result in  death or hospi[INVESTIGATOR_11956] , but may 
jeopard ise the patient  or may require intervention to prevent one of the other outcomes listed in 
the definition above.  
Severity grade for adverse events   is based on an organ toxicity grading scale as described in 
CTCAE  v5.0 (Appendix III), provided separately in the Investigator  File. The relationship 
between the administration of trial drug and the occurrence of the adv erse event is described as 
belonging to one of only two categories, either suspected by [CONTACT_364816] . 
7.1.5.  Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  
Any SAE for which there is a reasonable possibility that it is related to the study drug and where 
the nature or severity is not consistent with the product information mentioned in the IB or the 
study p rotocol .  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455693] contributed  should be notified to the CRO  at 
once (within 24 hours of lear ning of the event) in case of toxic death. The CRO  will notify the 
Sponsor  immediately.  
7.2. Monitoring, Reporting, and Documentation of A dverse Events  
7.2.1.  Monitoring of AEs 
Patients will be monitored for AEs from ICF Signature  [INVESTIGATOR_107990] [ADDRESS_455694] ModraDoc006/r  or 
i.v. docetaxel administration .  
In addition, for all patient s with any remaining SAEs  at the 30-day follow -up visit, regardless of 
its relationship to trial medication, AE information need to be collected every 3 weeks , until:  
• the symptom subsides  or stabilizes ;  
• any clinically relevant abnormal laboratory val ue has returned to baseline;  
• there is a satisfactory explanation other than the trial medication fo r the change(s) 
observed; or  
• death, in which case an autop sy report should be supplied to the CRO , if performed.  
AEs occurring  [ADDRESS_455695] be 
recorded only if they are considered (in the opi[INVESTIGATOR_273554]) unexpected and related to  
ModraDoc006/r , or i.v. docetaxel . 
7.2.2.  Documentation of AEs 
All AEs are to be evaluated for duration, intensity and relationship to (associat ion with) the trial 
treatment or alternatively due to other causes.  
All non-laboratory  AEs (problems, complaints, signs, and symptoms and clinically relevant 
laboratory abnormalities ), both those observed by [CONTACT_364817] s, must be recorded on the AE page in the eCRF, as well as i n the 
patient’s  medical record using standard medical terminology , regardless of causality. Required 
information includes  the type of adverse event, an estimate of its severity, date and time of 
occurrence, date of resolution, actions required, and an asse ssment of its causal relationship to 
trial medication. AEs resulting from concurrent illnesses, reactions to concurrent medications, or 
progression of disease states are also to be recorded. Progression of disease itself is not 
considered to be an AE.  
All AEs must be recorded on the AE page in the eCRF, as well as in the patient’s  medical record. 
If an AE occurred after signing informed consent, but the patient  withdraws trial participation 
before trial treatment, the AE should be recorded on the Screening Log (instead of on the AE 
page in the eCRF).  
[IP_ADDRESS].  Severity of Adverse Events  
Each AE is to be classified and graded according to CTC AE criteria  (v5.0, Appendix III). A 
copy of these will be provided in the Investigator  File. Dates of onset and resolution, including 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    72 dates at which the grade of an AE changes, are to be recorded in the patient  file. If no CTC 
grading is available, the severity of an AE is graded as follows:   
• Mild:  the event causes discomfort without disruption of normal daily activities.  
• Moderate:  the event causes discomfort that affects normal daily activities.  
• Severe:  the event makes the patient  unable to perform normal daily activities or significantly 
affects the  clinical status.  
• Life-threatening:  the patient  was at risk of death at the time of the event , or the event caused 
death.  
[IP_ADDRESS].  Relationship to Trial  Treatment  
Relationship with the study drug is generally caused by [CONTACT_364818] (docetaxel), and therefore due to the combination  of ModraDoc006 and ritonavir.  In 
rare cases relationship may be attributed to only one of both drugs (i.e. Modr aDoc006 alone or 
ritonavir alone), if suspected it is advised to  discuss  with sponsor.  
The relationship of an adverse event to trial medication will be recorded on the CRF and defined 
as following:  
• Not R elated:  the event is definitely not associated with trial drug administration , but is judged 
clearly and incontrovertibly to be due to causes other than the trial medication.  
• Unlikely:  an event that follows such a temporal sequence from administration of the trial 
medication that a relationship is not likely , and is likely to be due to cause s such as (known 
characteristics of) the patient ’s clinical state or other treatment.  
• Possibly : an event that follows a reasonable temporal sequence from administration of the trial 
medication, but that may be due to another cause.  
• Probably : an event that follows a reasonable temporal sequence from administration of the 
trial medication, and that is not easily explained by [CONTACT_364819] t’s clinical state or other treatment.  
• Definitively : an event that follows an established temporal sequence from administration of 
the trial medication (e.g. re -challenge), or that cannot be explained by [CONTACT_364820].  
7.2.3.  Reporting of Serious Adverse Events  
Information on SAEs, like all AEs, will be collected from the time of Inform Consent Form 
Signature [INVESTIGATOR_107990] [ADDRESS_455696] only be reported when they are considered (in 
the opi[INVESTIGATOR_689]) unexpected and related to ModraDoc006/r , or i.v. docetaxel .  
All AEs that meet the criteria for SAE  require the completion of a  trial-specific SAE  Form  (or 
Additional Safety Inf ormation (ASI) Form) . This applies to all SAEs , whether or not they were 
considered to be related to the trial treatment.  
The Investigator  must report all SAEs to the CRO  immediately, i.e. within 24 hours ( in the 
eCRF ) of learning of their occurrence . For  this reporting, an SAE Form (provided in the 
Investigator  File) needs to be completed  in English . Follow -up information about a previously 
reported SAE  must also be reported to the CRO  within [ADDRESS_455697] be provided on an ASI Form.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455698] also be entered on the relevant  Medical History page of the eCRF.  
The SAE report should provide a detailed description of the AE and should include anonym ised 
copi[INVESTIGATOR_364758]. Autopsy results, if applicable, should 
also be sent to the CRO  as soon as they become available. Copi[INVESTIGATOR_1309] e ach report will be kept in 
the Investigator  File.  
All SAEs will need to be followed activ ely until resolution or stabilis ation. The above is also 
applicable to follow -up SAE information.  
The CRO , on behalf of Sponsor , is required by [CONTACT_364821] a written 
safety report: 1) all fatal or life -threatening S[LOCATION_003]Rs  within seven (7) calendar days of initial 
notification; and 2) all other S[LOCATION_003]Rs within fifteen (15) calendar days of initial notification.  
7.2.4.  Pharmacovigilance Contact [CONTACT_364822]:   Covance Clinical & Periapproval Services Limited  
Street:   Osprey House, Maidenhead Office Park, Westacott Way  
Postal code:  SL6 3QH  
Place:   Maidenhead  
Country:  United Kingd om 
Tel:    +44 (0)1628 548000  
Fax:   +44 (0)1628 540028  
E-mail:  [EMAIL_6533]  
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    74 8. STATISTICAL METHODS  
The full statistical methodology and presentation of data will be described in a Statistical 
Analysis Plan separate from this protocol.  
All data collected in this trial will be documented using summary tables, figures, and patient  data 
listings. Continuous variables will be summarized using descriptive statistics ( N, mean, standard 
deviation, quartiles, median, minimum and maximum). Catego rical variables will be summarized 
using counts and percentages .  
8.1. Data Analysis  Considerations  
Analysis Populations:  
• Safety Population (SAF): All subjects receiving at least one dose of trial medication in 
either study arm will be included in the evaluatio n of safety.  
• Efficacy Population (Full Analysis Set (FAS)): All subjects who received at least one 
dose of  i.v. docetaxel ( Cohort 1) or one full cycle of ModraDoc006/r ( Cohort 2) and have 
at least one post -baseline tumor  assessment (+PSA levels) will be i ncluded in the 
evaluation of efficacy and the QoL evaluation.  
• Per Protocol (PP) population includes all subjects in the FAS population with the 
exclusion of subjects who are not compliant to study treatment or have at least one major 
protocol deviation that will affect the interpretation of efficacy.  
Safety Analysis:  
Safety data will be summarized for the safety population.   
 
Efficacy Analysis:  
Radiographic Progression -Free Survival : Defined as time from randomization to the first 
objective evidence of radiologic progression or death due to any cause after treatment 
discontinuation, whichever occurs first will be assessed , per PCWG3 criteria . 
 
Objective Response Rate:  The best overall soft tissue response as assessed by [CONTACT_1697] s 
using RECIST 1.1 will be summarized. Only patients with measurable soft tissue disease at 
screening (i.e., at least [ADDRESS_455699] 1.1) will be included in this analysis. Tumor 
response for target lesions will be assessed at baseline and spec ified time points throughout the 
study. The tumor response will be evaluated according to RECIST version 1.1. The calculation 
of ORR as primary endpoint is based on disease status as determined by [CONTACT_364788].  
 
Disease Control Rate:  Defined as propo rtion of patients who have achieved complete response, 
partial response and stable disease  using RECIST 1.1 . 
 
Duration of Response:  Defined as time from documentation of tumor response using RECIST 
1.[ADDRESS_455700] objective evidence of radiologic progress ion. 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    75 Radiographic Progression -Free Survival at 6 months:  Defined as probability of rPFS at [ADDRESS_455701] objective evidence of radiologic 
progression or death due to any cause.  
 
Time To Progression:  Defined as t ime from randomization to the first objective evidence of 
radiologic progression  
 
PSA Response:  Confirmed PSA responses will be defined as ≥50% reductions in PSA from  
baseline to lowest postbaseline PSA result, with a consecutive assessment conducted at least 3 
weeks later required to confirm the PSA response. PSA response ≥50% will be calculated by 
[CONTACT_364823] 1 
postbaseline assessment. The analysis of the tumor marker PSA will be performed on the 
efficacy population as per PCWG3 criteria 81. The variables will be evaluated using appropriate 
descriptive statistics for each assessment point and for t he changes from baseline.  
 
PSA Progression -Free Survival / Time to PSA Progression:  PSA progression according to 
PCWG3 criteria is defined as the first PSA increase that is ≥25% and ≥2 ng/mL, either above the 
nadir (if PSA decline after baseline) or from b aseline beyond 12 weeks (if no PSA decline from 
baseline), and which is confirmed by a second value ≥ [ADDRESS_455702] Skeletal -Related Event:  Time from randomization to first skeletal -related event 
will be assessed. A skeletal -related event i s defined as radiation therapy or surgery to bone, 
pathologic bone fracture, spi[INVESTIGATOR_13377].  
 
Health Related Quality of Life Endpoints:  
FACT Quality of Life:  The FACT global, FACT -P and FACT -taxane data will be summarized 
descriptively by [CONTACT_364824]. 
 
Treatment Satisfaction Questionnaire for Medication:  TSQM data will be summarized 
descriptively by [CONTACT_15449].  
 
EQ-5D-5L Quality of Life : The EQ -5D-5L data will be summarized descriptively by [CONTACT_364825].  
 
Planned Data Analysis : 
All data collected in this trial will be documented using summary tables, figures, and patient data 
listings.  
• Continuous variables will be summarized using descriptive statistics (N, mean, 
standard deviation, quartiles, median, minimum, and maximum).  
• Categorical variables will be summarized using counts, frequencies and percentages.  
• ORR will be reported as proportion of subjects per cohort who have presented 
response at fixed time intervals and separately at the end of trial . 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    76 • Response rates and 95% CIs will be calculated for the ORR and DCR by [CONTACT_6490]  
• PSA values will be reported as percentage change from baseline every cycle and as 
absolute change in PSA over time from baseline to best response .  
• Differences between the  cohorts will be compared using parametric techniques for 
continuous variables (only in case of severe deviations of normality will the 
Wilcoxon -Mann Whitney test be used) and Fisher’s exact test for categorical 
variables.   
PFS, TTP-DOR, PSA-PFS and time t o PSA progression will be summarized using Kaplan -Meier 
estimates and differences will be determined via the log -rank test. Univaria te Cox proportional 
hazards models, and multivaria te models may be constructed to evaluate the effect of 
confounding variabl es on PSA -PFS, PFS and time to PSA progression.  All tests will be two -
sided and considered significant at  P<0.05.  With the design that compares treatment with 
ModraDoc006/r versus standard i.v. docetaxel, the treatment outcome will be estimated and used 
as the basis for the design of the future pi[INVESTIGATOR_16076].  
8.2. Population for A nalysis  
For analysis of trial results, the following populations will be defined and analysed : 
8.2.1.  Safety analysis  
To be considered evaluable for safety, patients should have received at l east one administration 
of ModraDoc00 6/r or i.v. docetaxel (all administrations on day 1).  
8.2.2.  Population evaluable for radiological response  
To be considered evaluable for radiological response:  
• Patients should have received at least 6 weekly administrations of ModraDoc006/r or 
[ADDRESS_455703] three -weekly cycles of i.v. docetaxel  
• Patients should have measurable lesions according to RECIST v 1.1 
• Response should be evaluated according to RECIST v 1.[ADDRESS_455704] response. ORR will be summarised with 
95% confidence intervals. PFS  and time -to-event endpoints  will be summar ised and illustrated 
graphically using a Kaplan -Meier plot. Median survival and associated 95% confidence interval 
will be provided for each time to event endpoint. The proability of event free and 95%  
Confidence interval at [ADDRESS_455705] ratio and 95% confidence interval will be provided based on Cox proportional 
hazards model s. Tumor  sizes (volumes) will be summarised  by [CONTACT_364826].  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    77 8.4. Safety  
Toxicity will  be scored according to the CTC AE v5.0.  (see Appendix III). Individual safety d ata, 
as well as the absolute and relative incidence of toxicities, will be presented in tables. The worst 
grades of these toxicities will be given for all patients who were evaluable for toxicity 
measurements. These toxicities will be scored from the momen t the patients received their first 
dose of study medication until end of treatment. The toxicities might be classified and presented 
in different tables, based on the nature of the toxicities ( hema tological or non -hema tological) or 
the causality of the to xicities (treatment related,  or all observed toxicities).  
The number of adverse  events (AEs) that start or worsen after first dose of study drug will be 
summarised , as well as related AEs, AEs of each severity (CTCAE grade), SAEs, deaths, related 
SAEs, an d discontinuations due to AEs. AEs and SAEs will further be summarised by [CONTACT_53428].  
The AEs and SAEs  by [CONTACT_11702] , grade (according to CTCAE v. 5.0), and relationship to the 
study drug, will be presented in a table.  
Specif ically, the incidence will be tested of:  
• grade 3 -4 neutropenia  with weekly ModraDoc 006/r as compared to the standard 
treatment with i.v. docetaxel  
• febrile neutropenia  with weekly ModraDoc 006/r as compared to the standard 
treatment with i.v. docetaxel  
• toxicity -related hospi[INVESTIGATOR_364759] 006/r as compared to 
the standard treatment with i.v. docetaxel  
• grade 3 -4 diarrhea  with weekly ModraDoc 006/r as compared to the standard 
treatment with i.v. docetaxel  
• grade 3 -4 fatigue  with weekly ModraDoc 006/r as compared to the standard 
treatment with i.v. docetaxel  
• grade 3 -4 neuropathy  with weekly ModraDoc 006/r as compared to the standard 
treatment with i.v. docetaxel  
• grade 3 -4 treatment -related allergic reactions  with weekly ModraDoc 006/r as 
compared to the standard treatment with i.v. docetaxel.  
Other safety data will be summarised by [CONTACT_364827].  
8.5. Interim Analysis  
No formal interim analysis is planned.  However, after in total 50% of evaluable patients have 
been treated efficacy endpoints  will be reviewed in both treatment arms to obtain a first 
impression about the effect  of ModraDoc006/r and standard i.v. docetaxel.  
    
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455706] to validation according to the Data Validation and 
Medical Review Plans , in order to ens ure the information in the eCRF is complete, consistent 
and accurate. The clinical trial site staff are responsible for resolving data queries issued by 
[CONTACT_42029], Medical Monitor(s) and Data Management team  at the CRO . A system audit tr ail will 
maintain a reco rd of initial entries and changes made; reasons for change; time and date of entry; 
and user name [CONTACT_364864].  
Prior to the database lock, the eCRF must be completed and electronically signed by [CONTACT_364828] r or authorized delegate from the clinical trial site staff. A complete eCRF 
package will be transferred to Sp onsor , and the I nvestigator will receive a copy at the end of the 
trial. 
All external data will be electronically transferred to the CRO  for further data handling.  
Quality control audits of all key safety and efficacy data in the database will be  made prior to 
locking the database. Protocol deviations will be  monitored throughout the trial and a final 
assessment of major/minor deviations w ill be  made at the end of the trial.  
9.2. Data R eview  
This trial will be monitored by [CONTACT_364829] , and may also be 
audited/inspected by [CONTACT_2024] , Sponsor , or by [CONTACT_364830]/or authority . By [CONTACT_364831] , the Investigat or agrees to fully co -operate with compliance checks by [CONTACT_364832].  
CRA s will conduct regular monitoring visits . The CRA  may be accompanied by a representative 
of Sponsor  on that occasion. Amo ngst other  things,  the following will be reviewed during  those 
visits:  
• Trial progress;  
• Compliance with the Protocol ; 
• Consent procedures, including date of consent and signatures;  
• Medical history, concomitant medication;  
• Completion of CRFs and verification of data against the source data;  
• Adverse events;  
• Storage, dispensing and accountability of trial medication;  
• Archiving of trial documentation.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    79 It is the Investigator ’s responsibility to assure that adequate time for these visits will be made 
available by [CONTACT_12552]/her and other trial personnel.  
It is a prerequisite of the Investigator ’s participation in this trial that the CRA  has direct access to 
source data for data verif ication. All information on eCRFs must be traceable to these source 
documents in the patient 's file (permission will be sought from the patient  as part of the consent 
process). Direct access to source documents will also be required for representatives of the 
Sponsor  and for regulatory authorities.  
The audit or inspection may include, for example, a review of all source documents, drug 
records, original clinical medical notes, some or all of the facilities used in the trial. 
In addition, participation and personal information will be treated as strictly confidential to the 
extent the applicable law permits, and will not be made publicly available.  
9.3. Medical Coding  
Coding of prior and concomitant medications will be performed using World Health 
Organization (W HO) Drug Dictionary. AEs and medical history will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA ). 
9.4. Quality Control and Quality Assurance  
The Sponsor or its designee will perform the quality assurance and quality control activities for 
this trial. However, responsibility for the accuracy, completeness and reliability of the trial data 
presented to the Sponsor lies with the Principal or qualified Investigator generating the data . 
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    80 10. ADMINISTRATIVE ASPECTS  
10.1. Maintenance of Patient  Records  
The P rincipal Investigator  will maintain adequate records, including flow sheets, laboratory 
reports, signed patient  consent forms, drug disposition records, and information on AEs, patient  
treatment discontinuation and reasons for treatment discontinuation. All records will be signed 
and dated by [CONTACT_737] . All records are to be retained for a period of 15 years following the 
date the entire clinical investigation is completed, terminated or discontinued . 
10.2. Investigator  Site File (ISF) 
At trial initiation, each Investigator will be provided with an Investigator Site File (ISF) 
containing information as specified in Section 8.2 -4 of ICH GCP 79. It is the Investigator's 
responsibility to keep the Investigator Site File up to date.  
10.3. Handling of Investigational Product  
The trial medication  must be received by a designated person at the trial site, handled and stored 
safely and properly, and kept in a secured location to which only the Investigator, Pharmacist 
and designated assistants have access. Upon receipt , the trial medication and all supplies should 
be stored according to the instructions specified on the drug labels.  
Medication labels will comply with the legal requirements of the country. In addition, t hey will 
include storage c onditions for the drug , but no information about the trial. 
For drug accountability, the Investigator must maintain an accurate record of the shipment and 
dispensing of trial drug.  
The trial medication must be used only as directed in the Protocol  and for patient s enrolled in 
this trial. 
For more information, see Section  5.3. 
10.4. Drug A ccountability  
Each time trial medication  is dis pensed to a patient , this must be recorded on a drug 
dispensing/accountability log . Copi[INVESTIGATOR_364760]. 
At regular intervals the CRA (s) will perform a ‘drug recon ciliation visit’, verifying if all trial 
medication  that has been  shipped to the institute can be accounted for by [CONTACT_364833], 
dispensing and destruction.  
Unused study drug that is not  dispensed may only  be destroyed following authoris ation by a 
representative of the CRO , and destruction shall be  fully documented. Alternatively, th e study 
drug may be returned to Sponsor . 
At the end of the trial, it must be possible to reconcile delivery records with records of usage and 
destroyed or returned stock. It is essential that the Investigator or institut e account for all trial 
treatment , and that any discrepancies are explained and documented.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455707] the completeness, 
accuracy, and/or reliability of the trial data , or that might significantly affect a patient 's rights, 
safety, or well -being. This includes deviations related to patient  eligibility, informed consent, 
study drug dosing errors , or failing to perform assessments required to interpret the primary 
endpoint. Additional categories may be identified as deemed necessary by [CONTACT_1689].  
All protocol deviations will be reported by [CONTACT_364834]-involved personnel . The 
protocol deviations will be reviewed by [CONTACT_1689]. The Medical Monito r determines 
whether a deviation is major or not. Major deviations are reported to the Sponsor as part of 
regular reporting. Important protocol deviations will be summarized in the clinical trial report. In 
accordance with applicable regu latory authority m andates, the I nvestigator is responsible for 
reporting protocol deviations to the IRB/ IEC.  
In case of a deviation, the Investigator enters a comment in the source documents , and the non -
compliance will be documented in a Monitoring Visit Report by [CONTACT_2689] . All non -compliance 
will be followed up and reported to RA and IEC as per local regulations.  
In parallel, corrective and/or preventive actions will be undertaken and documented, including 
any retraining of the Investigator and site staff.  
No waivers for inclusion or exclusion criteria will be given.  
10.6. Procedures for Protocol  Amendments  
Should any change be required to the approved Protocol , a Protocol  Amendment will  be 
prepared . Any amendment  is to be approved by [CONTACT_364835] . 
Upon approval, t he final Protocol  amendment will be incorporated into the Protocol . In case of a 
substantial Protocol  amendment, it must be submitted to the IEC/IRB and competent authorities, 
detailing the reasons necessit ating the amendment. Approval by [CONTACT_18369]/IRB and competent 
authorities is required for all substantial amendments, in accordance with international and local 
regulations. Notwithstanding the need for approval before implementation of formal Protocol  
amendme nts, the Investigator  is expected to take any immediate action required for the safety of 
any patient  included in this trial, even if this action represents a deviation from the Protocol .  
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    82 11. ETHICAL AND LEGAL CONSIDERATIONS  
The Investigator will ensure tha t this trial is conducted in full conformance with the principles of 
the “Declaration of Helsinki” (64th WMA General Assembly, Fortaleza, Brazil, October 2013) 
or with the laws and regulations of the country in which the research is conducted, whichever 
affords the greater protection to the individual. The trial must fully adhere to the principles 
outlined in “Guideline for Good Clinical Practice” ICH Tripartite Guideline , or with local law if 
it affords greater protection to the patient . As this trial is conducted in the EU/EEA countries, the 
Investigator will ensure compliance with the EU Clinical Trial Directive [2001/20/EC].  
11.1. Regulatory Authority / Independent Ethics Committees  
The protocol and any accompanying material provided to the patient  (such as patient information 
sheets or descriptions of the trial used to obtain informed consent , as well as any recruitment 
materials or compensation given to the patient ) will be submitted to the  Regulatory Authority  
(RA) and Independent Ethics Committees ( IEC).  
Approval from the committee must be obtained before starting the trial and  should be 
documented in a letter to the Investigator specifying the date on which the committee met and 
granted the approval.  
Any modifications made to the protocol after receipt o f the RAs/IECs approval must be re -
submitted in the European Economic Area ( EEA ) member states in accordance with local 
procedures and regulatory requirements.  
11.2. Site Review  
The Investigator  will submit this Protocol, the site-specific  informed consent form,  and any 
required documents for site review and approval.  A letter confirming approval must be 
forwarded to the CRO  prior to initiation of this trial at each Investigational site .  
Prior to trial start, the Investigator  is required to sign a Protocol  signa ture page confirming 
his/her agreement to conduct the trial in accordance with these documents and all of the 
instructions and procedures found in this Protocol  and to give access to all relevant data and 
records to CRA s, auditors, and regulatory authoriti es as required. Investigator s ascertain they 
will apply due diligence to avoid Protocol  deviations.  
The Investigator  will make appropriate reports on the progress of this trial to the CRO  in 
accordance with applicable government regulations and their agree ment with the CRO .  
11.3. Informed C onsent  
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, the 
Data Protection Directive (Directive 95/46/EC), and local regulations. The Investigator will 
prepare the informed consent fo rm (ICF) and provide the documents to the RA and IEC for 
approval.  
Before enrolment in the trial, the Investigator or an authorized member of the investigational 
staff must explain to potential trial patient s and/or his legal representative the aims, methods, 
reasonably anticipated benefits, and potential hazards of the trial, and any discomfort 
participation in the trial may entail. Patient s will be informed that their participation is voluntary 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455708] the care the patient  will receive for the treatment of his disease. 
Patient s will be told that alternative treatments are available if they  refuse to take part and that 
such refusal will not prejudice future treatments. Finally, they will be told by [CONTACT_364836] a patient  identification register  
and their medical records for the purposes of long -term follow -up if needed , without violating 
the confidentiality of the patient , to the extent permitted by [CONTACT_6983](s) or regulation.  
By [CONTACT_364837] -contact [CONTACT_364838], or to obtain information about his or her vital status.  
The patient  will be given sufficient time to read the ICF , and the opportunity to ask questions. 
After this explanation and before entry into the trial, consent should be appropriately recorded by 
[CONTACT_106201] ’s personally dated signature [CONTACT_364865]’s personally dated 
signature. After obtainin g the consent, a copy of the ICF must be given to the patient .  
If the patient  is unable to read or write, an impartial witness should be present for the entire ICF 
process (which includes reading and explaining all written information) and should personal ly 
date and sign the ICF after the oral consent of the patient  is obtained.  
Copi[INVESTIGATOR_364761] , and the original will be maintained with the 
patient ’s records. If new safety information results in significant changes in t he risk/benefit 
assessment, the ICF should be reviewed and updated as necessary. All patient s should be 
informed of the new information and give their consent to continue the trial. 
11.4. Confidentiality  
By [CONTACT_364839], the Investigator affirms to the CRO  that all information regarding this 
trial and  ModraDoc006/r  will be maintained in strict confidence. Such information can be 
communicated to the Investigator's local review and approval authority under an appropriate 
understanding of confidentiality . Updated General Data Protection Regulations (GDPR) 
procedures are covered in the ICF and in site agreements.  
Every effort will be made to maintain the anonymity and confidentiality of patient s during this 
clinical trial. However, because of the experime ntal nature of this treatment, the Investigator 
agrees to allow representatives of the CRO , the Sponsor , as well as authorized employees of the 
regulatory authorities , to inspect the facilities used in this trial as well as to review, for purposes 
of verif ication, the hospi[INVESTIGATOR_364762] s enrolled into this trial. A statement to 
this effect is to be included in the patient  consent form.  
11.5. Insurance  
Insurance is detailed in the Investigator  contracts.  
The Investigator/institution is requ ired to have adequate current insurance to cover claims for 
negligence  and/or malpractice according to applicable national regulations. The Sponsor will 
provide insurance coverage for the clinical study as required by [CONTACT_364840].  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    84 11.6. Publ ication Policy  
Both the use of data and the publication policy are detailed within the clinical trial agreement.  
The Investigator should be aware that intellectual property rights (and related matters) generated 
by [CONTACT_364841] e clinical trial will be subject to the terms of a 
clinical trial agreement that will be agreed upon between the institution and the Sponsor or 
designee. With respect to such rights, the Sponsor or designee will solely own all rights and 
interest in any ma terials, data, and intellectual property rights developed by [CONTACT_364842], subject to the terms of any such agreement. In order to 
facilitate such ownership, the relevant party will be required to assig n all such inventions either 
to the relevant institution or directly to the sponsor or their designee, as will be set forth in the 
clinical trial agreement.  Further specifics are detailed in the study contract.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    85 Appendix I: Assessments  
Trial procedures  Baseline  
 Cohort 1:  
Docetaxel 75 mg/m² iv  
Once every 3 weeks  
(cycle = 21 days with infusion on day 1)  
Premedication with oral dexamethasone 8mg, [ADDRESS_455709] of care.  
Prednisone 2dd 5 mg continuously  
 
Cohort 2:   
ModraDoc006/r 20/20mg + 200/100mg  
Once every week twice daily  
(cycle = 21 days with ModraDoc006/r intake on day 1, 8, 15)  
Prednisone 2dd 5 mg continuously  
 
 ≤ Day 28  Cycle 1  Subsequent 
Cycles  EOT***  FU****  
Day 1*  Day 3 **  Day 10 **  Day 1*   
Visit outpatient clinic  X X   X X X 
Compliance 
assessments    X X    
Informed Consent  X       
Randomi zation  1 X       
In-/exclusion criteria  X X      
Demographic Data  [ADDRESS_455710]-scan /MRI 9 X     X X13 
Bone scintigraphy 9 X     X X13 
PSA X X   X X X 
Safety assessments 10 X X X X X X X 
Concomitant 
medication 11 X X   X X X 
HRQoL 
questionnaires and  
EQ-5D 12 X    X12 X X 
* Assessments may be performed within 3 days  of day 1  
**Day 3 and 10 (+/- 1 day) safety (AEs) a nd compliance assessments via triage by [CONTACT_364843] 1 only  
*** End Of Treatment  (EOT) visit as soon as possible after discontinuation  
**** Follow Up visit (FU) [ADDRESS_455711] administration of ModraDoc006/r or i.v. docetaxel   
 
1. Randomi zation ≤ 3 days;  Demographic data: age, ethnic origin  
2. Medical History: (including details of malignancy, stage of cancer, radiotherapy and other therapi[INVESTIGATOR_014], with start and 
stop dates of therapy, number of cycles, cumulative doses, (cancer related) surgery etc., if applicable)).  
3. Physical examination: WHO Performance Status, weight in kg, height in c m (height: baseline only).  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    86 4. Vital Signs: blood pressure, pulse rate and temperature.  
5. Hematology : hemoglobin , hematocrit , RBC, WBC with differential (differential should include: neutrophil, 
lymphocyte, monocyte, basophil and eosinophil counts), platelet cou nt. 
6. Clinical Chemistry: ASAT, ALAT, GGT, LD, alkaline phosphatase, total and direct bilirubin, Na, K, Ca, Mg, 
glucose, urea, total protein, albumin, serum creatinine,.  
7. Urinalysis: dipstick for  protein, glucose, blood, pH, and ketones.  
8. Creatinine Clearance:  will be measured using Cockcroft -Gault formula  or MDRD formula . 
 
For items 3) – 8): Assessments  during screening less than 3 days  before dosing need not to be repeated at day 1 of 
Cycle 1.  
 
9. Tumor  assessment (following PCWG3) by [CONTACT_364844]/ radiological assessment (i.e. 
CT/MRI + bone scan)  at baseline (≤ 28 days prior to administration  of study medication) , every [ADDRESS_455712] 
24 weeks  (i.e. during  week 9, 17 and 25) , thereafter every 12 weeks  and at End of Treatment (EOT) , according to 
the RECIST v1.[ADDRESS_455713] v1.1. Of note: In this randomi zed comparative 
trial, the scheduled assessments should not be affected by [CONTACT_121243], drug holidays or any other events that 
might lead to imbalance in a treatment arm in the timing of disease assessment  (see Table  15 in par.  6.9 for further 
details) .  
10. Toxicity assessments: baseline signs and symptoms and all related and unrelated adverse events will be assessed 
using the NCI -CTCAE criteria Version 5.0, including start and stop dates, severity, relationship to study drug, 
outcome and action taken.  
11. Concomitant medication: including start and stop dates, dose, frequency, route of administration and indication.  
12. Baseline, at the end of cycle 3 , 6 and 10 or at EOT  (if this would occur earlier ): FACT global, FACT -P and 
FACT -taxane, Treatment Satisfaction (excluding baseline) and EQ -5D-5L questionnaire.  
13. Imaging to be performed in the Follow Up visit, in case of unconfirmed PR or CR.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    87 Appendix II: WHO Performance Status S cale 
KARNOFSKY  ZUBROD -ECOG -WHO  
Status  Scales     Status  
Normal, no complaints  100 0 Normal activity  
Able to carry on normal activities  
Minor signs of symptoms of disease  90 1 Symptoms, but nearly ambulatory  
Normal activity with effort  80   
Cares for self. Unable to carry on normal 
activity or to do active work  70 2 Symptomatic, but in bed <50% of the day  
Requires occasional assistance, but able to 
care for most of his needs  60   
Requires considerable assistance and 
frequent medical care  50 3 Needs to be in bed >50% of the day, but not 
bedridden  
Disabled, requires special care and 
assistance  40   
Severely disabled. Hospi[INVESTIGATOR_364763]  30 4 Unable to get out of bed  
Very sick. Hospi[INVESTIGATOR_364764]. Active 
supportive treatment necessary  20   
Moribund  10   
Dead  
 0 5 Dead  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    88 Appendix III: Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 
The descriptions and grading scales found in the revised N ational Cancer Institute (NCI)  
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for 
adverse event (A E) reporting. All appr opriate treatment areas should have access to a copy of the  
CTCAE v5.0 . A copy of the  CTCAE v5.0  can be downloaded from the CTEP web site:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
Quick Reference  
The NCI CTCAE  is a descr iptive terminology which can be utilized for Adverse Event (AE) 
reporting. A grading (severity) scale is provided for each AE term.  
Components and Organization  
System Organ Class (SOC), the highest level of the Medical Dictionary for Regulatory Activitie s 
(MedDRA) hierarchy, is identified by [CONTACT_364845], aetiology , or purpose 
(e.g. SOC Investigations for laboratory test results). CTCAE terms are grouped by [CONTACT_364846]. Within each SOC, AEs are listed and accompanied by [CONTACT_364847] 
(Grade).  
CTCAE Terms  
An Adverse Event (AE) is any unfavourable  and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medical 
treatment or procedure that may or may not be considered related to the medical treatment or 
procedure. An AE is a term that is a unique representation of a specific event used for medical 
documentation and scientific analyses. Each CTCAE v 5.0 term is a MedDRA LLT (Lowest 
Level Term).  
Definiti ons  
A brief definition is provided to clarify the meaning of each AE term.  
Grades  
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of severity for each AE based on this general guideline:  
• Grade 1 Mild: asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
• Grade 2 Moderate:  minimal, local or non -invasive intervention indicated; limiting 
age-appropriate instrumental ADL  (Activities of Daily Livi ng).  
• Grade 3 Severe or medically significant but n ot immediately life -threatening:  
hospi[INVESTIGATOR_3111]; dis abling; limiting 
self-care ADL .  
• Grade 4 Life -threatening consequences:  urgent intervention indicated.  
• Grade 5 Death related to AE.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    89 Appendix IV: RECIST  v1.[ADDRESS_455714] v 1.1 document 80. 
https://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf  
A summary is provided below.  
Definitions  
At baseline, tumor  lesions/lymph nodes will be categor ised measurable or non -measurable as 
follows:  
• Measurable : Tumor  lesions m ust be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size 
of: 
[ADDRESS_455715] -scan (CT -scan slice thickness no greater than 5 mm).  
10 mm calliper  measurement by [CONTACT_461] ( lesions that cannot be accurately 
measured with callipers  should be recorded as non -measurable).  
[ADDRESS_455716] X -ray.  
Malignant lymph nodes: To be co nsidered pathologically enlarged and measurable, a 
lymph node must be P15 mm in short axis when assessed by [CONTACT_4654] -scan (CT -scan 
slice thickness recommended to be no greater than 5 mm). At baseline and in 
follow -up, only the short axis will be measured and fol lowed.  
• Non-measurable : Non-measurable are all other lesions, including small lesions 
(longest diameter <10 mm or pathological lymph nodes with P10 to <15 mm short 
axis) as well as truly non -measurable lesions. Lesions considered truly non -
measurable inclu de leptomeningeal disease, ascites, pleural or pericardial effusion, 
and inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses /abdominal  organomegaly identified by [CONTACT_364848].  
Specifications by [CONTACT_364849] M easurements  
• Measurement of lesions : All measurements should be recorded in metric notation, 
using callipers  if clinically assessed. All baseline evaluations should be performed as 
close as possible to the trea tment start and never more than 4 weeks before the 
beginning of the treatment.  
• Method of assessment : The same method of assessment and the same technique 
should be used to character ise each identified and reported lesion at baseline and 
during follow -up. Imaging based evaluation should always be done rather than 
clinical examination unless the lesion(s) being followed cannot be imaged but are 
assessable by [CONTACT_461].  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    90 • Clinical lesio ns: Clinical lesions will only be considered measurable when they are 
superficial and P10mm diameter as assessed using callipers  (e.g. skin nodules). For 
the case of skin lesions, documentation by [CONTACT_347069] a ruler to 
estimate the size o f the lesion is suggested. As noted above, when lesions can be 
evaluated by [CONTACT_51752], imaging evaluation should be 
undertaken since it is more objective and may be reviewed at the end of the trial. 
• Chest X -ray: Chest CT is preferred o ver chest X -ray, particularly when progression 
is an important endpoint, since CT is more sensitive than X -ray, particularly in 
identifying new lesions. However, lesions on chest X -ray may be considered 
measurable if they are clearly defined and surrounded  by [CONTACT_6776].  
• CT, MRI : CT is the best currently available and reproducible method to measure 
lesions selected for response assessment. This guideline has defined measurability of 
lesions on CT -scan based on the assumption that CT slice thickness is [ADDRESS_455717] slice thickness greater than 5 mm, the minimum size for a 
measurable lesion should be twice the slice thickness. MRI is also acceptable in 
certain situations (e.g. for body scans).  
• Ultrasound:  Ultrasound is not useful in ass essment of lesion size and should not be 
used as a method of measurement. Ultrasound examinations cannot be reproduced in 
their entirety for independent review at a later date and because  they are operator 
dependent, it cannot be guaranteed that the same t echnique and measurements will be 
taken from one assessment to the next. If new lesions are identified by [CONTACT_364850], confirmation by [CONTACT_12154]. If there is concern 
about radiation exposure at CT, MRI may be used inste ad of CT in selected instances.  
• Endoscopy, laparoscopy:  The utilis ation of these techniques for objective tumor  
evaluation is not advised. However, they can be useful to confirm complete 
pathological response when biopsies are obtained or to determine rela pse in studies 
where recurrence following complete response or surgical resection is an endpoint.  
• Tumor  markers:  Tumor  markers alone cannot be used to assess objective tumor  
response. If markers are initially above the upper normal limit, however, they mus t 
normal ise for a patient  to be considered in complete response. Because tumor  markers 
are disease specific, instructions for their measurement should be incorporated into 
protocols on a disease specific basis. Specific guidelines for both CA -125 response 
(in recurrent ovarian cancer) and PSA response (in recurrent prostate cancer), have 
been published.  In addition, the Gynaecologic  Cancer Intergroup has developed 
CA125 progression criteria which are to be integrated with objective tumor  
assessment for use in first -line studies in ovarian cancer.  
• Cytology, histology:  These techniques can be used to differentiate between PR and 
CR in rare cases if required by [CONTACT_990] (for example, residual lesions in tumor  types 
such as germ cell tumor s, where known residual benign tumor s can remain). When 
effusions are known to be a p otential adverse effect of treatment (e.g. with certain 
taxane compounds or angiogenesis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment can be 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    91 considered if the measurable tumor  has met criteria for response or stable disease in 
order to differentiate between response (or stable disease) and progressive disease.  
Assessment of O verall Tumor  Burden and Measurable Disease  
To assess objective response or future progression, it is necessary to estimate the overall tumor  
burden at baseline and use this as a comparator for subsequent measurements. Only patient s with 
measurable disease at baseline should be included in protocols  where objective tumor  response is 
the primary endpoint. Measurable disease is defined by [CONTACT_202864]. In studies where the primary endpoint is tumor  progression (either time to progression or 
proportion with progression at a fixed date), the protocol must specify if entry is restricted to 
those with measurable disease or whether patient s having non -measurable disease only are also 
eligible.  
Baseline Documentation of ‘Target’ and ‘Non -Target’ Lesions  
When more than one mea surable lesion is present at baseline , all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved organs 
should be identified as target lesions and  will be re corded and measured at baseline. Th is means 
for instance,  where patient s have only one or two organ sites involved a maximum of two and 
four lesion s respectively will be recorded . Target lesions should be selected based on  their size 
(lesions with the longest diameter), be representative of  all involved organs, but in addition 
should be those that lend themselves to reproducible repeated measurements. It may be the case 
that, on occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next large st lesion, which can be measured reproducibly,  should be selected.  
Lymph nodes merit special mention since they are normal anatomical structures that  may be 
visible by [CONTACT_33490] . As noted in Section  [ADDRESS_455718] in which the image is obtained (for CT -scan this is almost always the 
axial plane; for MRI the plane of acquisition may be axial , sagittal  or coronal). The smaller of 
these measures is the short axis. For example, an abdominal node which is reported as being 20 
mm· [ADDRESS_455719] ed as the node measurement. All other pathological nodes 
(those with short axis P10 mm but <15 mm) should be considered non -target lesions. Nodes that 
have a short axis <10 mm are considered non -pathological and should not be recorded or 
followed. A sum of  the diameters (longest for non -nodal lesions, short axis for nodal lesions) for 
all target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes 
are to be included in the sum, then as noted above, only the short axis is add ed into the sum. The 
baseline sum diameters will be used as reference to further character ise any objective tumor  
regression in the measurable dimension of the disease. All other lesions (or sites of disease) 
including pathological lymph nodes should be id entified as non -target lesions and should  be 
recorded at baseline. Measurements are not required and these lesions should be followed as 
‘present’, ‘absent’, or in rare cases ‘unequivocal progression’,  (more details to follow). In 
addition, it is possible to record multiple non-target  lesions involving the same organ as a single 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455720] form (e.g. ‘multiple enlarged pelvic lymph nodes’ or ‘multiple liver 
metastases’).  
Response Criteria  
Evaluation of Target Lesions  
Complete Response (CR):  Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <10 mm.  
Partial Response (PR):  At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the ba seline sum diameters.  
Progressive Disease (PD):  At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on trial (this includes the baseline sum if that is the smallest 
on trial). In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered 
progression).  
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR, nor sufficient incr ease to 
qualify for PD, taking as reference the smallest sum diameters while on trial. 
Evaluation of Non-Target Lesions  
Complete Response (CR):  Disappearance of all  non-target lesions and normalis ation of tumor  
marker level. All lymph nodes must be non -pathological in size (<10mm short axis).  
Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or maintenance of tumor  
marker level above the normal limits.  
Progressive Disease (PD):  Unequivocal progression (see comments below) of existing non -
target lesions. (Note: the appearance of one or more new lesions is also considered progression).  
Evaluation of Best Overall Response  
The best overall response is the best response recorded from  the start of the trial treatment until 
the end of treatment considering  any requirement for confirmation. On occasion a response may 
not be documented until after the end of therapy so protocols should be clear if post -treatment 
assessments are to be cons idered in determination of best overall response. Protocols must 
specify how any new therapy introduced before progression will affect best response 
designation. The patient ’s best overall response assignment will depend on the findings of both 
target and non-target disease and will also take into consideration the appearance of new lesions. 
Furthermore, depending on the nature of the trial and the protocol requirements, it may also 
require confirmatory measurement. Specifically, in non -randomized  studies w here response is 
the primary endpoint, confirmation of PR or CR is needed to deem either one the ‘best overall 
response’. This is described further below.  
Confirmatory Measurement/Duration of Response  
Confirmation  
In non -randomized  studies where response i s the primary endpoint, confirmation of PR and CR 
is required to ensure responses identified are not the result of measurement error. This will also 
permit appropriate interpretation of results in the context of historical data where response has 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    93 tradition ally required confirmation in such studies. However, in all other circumstances, i.e. in 
randomized  studies (Phase  II or III) or studies where stable disease or progression are the 
primary endpoints, confirmation of response is not required since it will n ot add value to the 
interpretation of trial results. However, elimination of the requirement for response confirmation 
may increase the importance of central review to protect against bias, in particular in studies 
which are not blinded. In the case of SD,  measurements must have met the SD criteria at least 
once after trial entry at a minimum interval (in general not less than 6 –8 weeks) that is defined in 
the trial protocol.  
Duration of Overall Response  
The duration of overall response is measured from the  time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded on trial). The duration of overall complete response is measured from the time 
measurement criteria are first met for CR until the first date that recurrent disease is objectively 
documented.  
Duration of Stable Disease  
Stable disease is measured from the start of th e treatment (in randomized  studies, from date  of 
randomization ) until the criteria for progression are met, taking as reference the smallest sum on 
trial (if the baseline sum is the smallest, this is the reference for calculation of PD). The clinical 
relev ance of the duration of stable disease varies in different studies and diseases. If the 
proportion of patient s achieving stable disease for a minimum period of time is an endpoint of 
importance in a particular trial, the protocol should specify the minimal time interval required 
between two measurements for determination of stable disease.  
Note:  The duration of response and stable disease as well as the progression -free survival are 
influenced by [CONTACT_150065] -up after baseline evaluation. It is not in the scope of this 
guideline to define a standard follow -up frequency. The frequency should consider  many 
parameters including disease types and stages, treatment periodicity and standard practice. 
However, these limitations of the precision of  the measured endpoint should be considered  if 
comparisons between studies are to be made.  
Progression -Free Survival/Proportion Progression -Free  
This guideline is focused primarily on the use of objective response endpoints for Phase  II 
studies. In some circumstances, ‘response rate’ may not be the optimal method to assess the 
potential anticancer  activity of new agents/regimens. In such cases ‘progression -free survival’ 
(PFS) or the ‘proportion progression -free’ at landmark time points, might be considered 
appropriate alternatives to provide an initial signal of biologic effect of new agents. It i s clear, 
however, that in an uncontrolled trial, these measures are subject to criticism since an apparently 
promising observation may be related to biological factors such as patient  selection and not the 
impact of the intervention. Thus, Phase  II screening studies utilizing these endpoints are best 
designed with a randomized  control. Exceptions may exist where the behaviour  patterns of 
certain cancers are so consistent (and usually c onsistently poor), that a non -randomized  trial is 
justifiable. However, in these cases it will be essential to document with care the basis for 
estimating the expected PFS or proportion progression -free in the absence of a treatment effect.
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    94 Appendix V: PCWG3 Recommendations   
 
Reference 81: 
Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration -Resistant 
Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working 
Group 3 (PCW G3). Journal of Clinical Oncology. 2016;34:1402 -1418  
 
Appended:  
 
PCWG3 Table 2 : Standard Baseline Disease Assessments Recommended by [CONTACT_43877]3 in 
Comparison With PCWG2 Recommendations  
 
PCWG3 Table 3 : Criteria for Progression at Trial Entry by [CONTACT_364851]3 Table 4 : Suggested Frequency of Assessment for Commonly U sed Measures in 
Metastatic Prostate Cancer Clinical Trials  
 
PCWG3 Table 5: Suggested Outcome Measures for Clinical Trials in Metastatic Prostate 
Cancer: Re port by [CONTACT_364851]3 Figure 3 : Swimlanes illustrating the patient experience in a trial    
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    95 PCWG3 Table 2: Standard Baseline Disease Assessments Recommended by [CONTACT_43877]3 in 
Comparison With PCWG2 Recommendations  
 
 
  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    96 PCWG3 Table 3: Criteria for Progression at Trial Entry by [CONTACT_364852] , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    97 PCWG3 Table 4: Suggested Frequency of Assessment for Commonly Used Measures in 
Metastatic Prostate Cancer Clinical Trials  
 
 
 
  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    98 PCWG3 Table 5: Suggested Outcome Measures for Clinical Trials in Metastatic Prostate 
Cancer: Report by [CONTACT_364852] , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    99 PCWG3 Table 5: Suggested Outcome Measures for Clinical Trials in Metastatic Prostate 
Cancer: Report by [CONTACT_364853]  (continued)  
 
 
  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    100 PCWG3 Table 5: Suggested Outcome Measures for Clinical Trials in Metastatic Prostate 
Cancer: Report by [CONTACT_364853]  (continued)  
 
 
  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    101 PCWG3 Figure 3: Sw imlanes illustrating the patient experience in a trial  
 
Fig 3. Swim  lanes  illustrating  the patient  experience  on a trial. For early -phase  trials,  the swimmers  plot is used  to track  individual  patients  on a trial, including  
time on and off therapy,  adverse  events,  progression  events,  and the point  at and the reason  for which  therapy  is stopped.  Progression  in individual  disease  
manifestations  and other  signiﬁcant events  are recorded,  including  those  that did not lead to trial discontinuation  and those  that did. Pragmatically,  each  line 
shows  the duration  on therapy.  Note  that this particular example  depi[INVESTIGATOR_27039]  a trial in progress.  NLCB,  no longer  clinically  beneﬁting;  PSA,  prostate -speciﬁc  antigen;  
rPFS,  radiographic  progression -free survival;  SAE,  serious  adverse  event. 
 

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    102 Appendix VII: Quality of life Q uestionnaires  
 
FACT -global  
Please circle or mark one number per line to indicate your response as it applies to the past [ADDRESS_455721] 7 days . 
 
 SOCIAL/FAMILY WELL -BEING  
 Not 
at all  A little 
bit Some -
what  Quite 
a bit Very 
much  
 
GS1 I feel close to my friends
 ................................ ................................ ..........................   0 1 2 3 4 
GS2 I get emotional support from my family
 ................................ ................................ ..........................   0 1 2 3 4 
GS3 I get support from my friends
 ................................ ................................ ..........................   0 1 2 3 4 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455722] my illness
 ................................ ................................ ..........................   0 1 2 3 4 
GE4 I feel nervous
 ................................ ................................ ..........................   0 1 2 3 4 
GE5 I worry about dying
 ................................ ................................ ..........................   0 1 2 3 4 
GE6 I worry that my condition will get worse
 ................................ ................................ ..........................   0 1 2 3 4 
 
 
 
 GS4 My family has accepted my illness
 ................................ ................................ ..........................   0 1 2 3 4 
GS5 I am satisfied with family communication about my 
illness
 ................................ ................................ ..........................    
0  
1  
2  
3  
4 
GS6 I feel close to my partner (or the person who is my main 
support)
 ................................ ................................ ..........................    
0  
1  
2  
3  
4 
Q1 Regardless of your current level of sexual activity, please 
answer the following question. If you prefer not to answer it, 
please mark this box and go to the next section.       
GS7 I am satisfied with my sex life
 ................................ ................................ ..........................   0 1 2 3 4 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455723] 7 
days. 
 
 FUNCTIONAL WELL -BEING  
 Not 
at all  A little 
bit Some -
what  Quite 
a bit Very 
much  
 
GF1 I am able to work (include work at home)
 ................................ ................................ ..........................   0 1 2 3 4 
GF2 My work (include work at home) is fulfilling
 ................................ ................................ ..........................   [ADDRESS_455724] accepted my illness
 ................................ ................................ ..........................   0 1 2 3 4 
GF5 I am sleepi[INVESTIGATOR_102641]
 ................................ ................................ ..........................   0 1 2 3 4 
GF6 I am enjoying the things I usually do for fun
 ................................ ................................ ..........................   0 1 2 3 4 
GF7 I am content with the quality of my life right now
 ................................ ................................ ..........................   0 1 2 3 4 
 
 
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455725] -P (prostate)  
 
Please circle or mark one number per line to indicate your response as it applies to the past [ADDRESS_455726] and maintain an erection
 ................................ ................................ ..........................   0 1 2 3 4 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455727] trouble walking
 ................................ ................................ ..........................   0 1 2 3 4 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455728] my hands or nails look
 ................................ ................................ ..........................   0 1 2 3 4 
 
 
 
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    108  
TSQM 76 (Version 1.4)  
Treatment Satisfaction Questionnaire for Medication  
Instructions: Please take some time to think about your level of satisfaction or dissatisfaction 
with the medication you are taking in this clinical trial. We are interested in your evaluation of 
the effectiveness, side effects, and convenience of the medi cation over the last two to three 
weeks, or since you last used it. For each question, please place a single check mark next to the 
response that most closely corresponds to your own experiences.  
 
1. How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your 
condition?  
□1  Extremely  Dissatisfied  
□2  Very Dissatisfied  
□3  Dissatisfied  
□4  Somewhat Satisfied  
□5  Satisfied  
□6  Very Satisfied  
□[ADDRESS_455729] the medication relieves your symptoms?  
□1  Extremely Dissati sfied  
□2  Very Dissatisfied  
□3  Dissatisfied  
□4  Somewhat Satisfied  
□5  Satisfied  
□6  Very Satisfied  
□7  Extremely Satisfied  
 
 
 
 

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    109 3. How satisfied or dissatisfied are you with the amount of time it takes the medication to start 
working?  
□1  Extremely Dissatisfied  
□2  Very Dissatisfied  
□3  Dissatisfied  
□4  Somewhat Satisfied  
□5  Satisfied  
□6  Very Satisfied  
□7  Extremely Satisf ied  
 
4. As a result of taking this medication, do you experience any side effects at all?  
□1 Yes 
□0 No (if No, then please skip to Question 9)  
 
5. How bothersome are the side effects of the medication you take to treat your condition?  
□1  Extremely Bothersome  
□2  Very Bothersome  
□3  Somewhat Bothersome  
□4  A Little Bothersome  
□5  Not at All Bothersome  
 
6. To what extent do the side effects interfere with your physical health and ability to function 
(i.e., strength, energy levels, etc.)?  
□1  A Great Deal  
□2  Quite a Bit  
□3  Somewhat  
□4  Minimally  
□5  Not at All  
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    110 7. To what extent do the side effec ts interfere with your mental function (i.e., ability to think 
clearly, stay awake, etc.)?  
□1  A Great Deal  
□2  Quite a Bit  
□3  Somewhat  
□4  Minimally  
□[ADDRESS_455730] medication side effects affected your overall satisfaction with the 
medication?  
□1  A Great Deal  
□2  Quite a Bit  
□3  Somewhat  
□4  Minimally  
□5  Not at All  
 
9. How easy or difficult is it to use the medication in its current for m?  
□1  Extremely Difficult  
□2  Very Difficult  
□3  Difficult  
□4  Somewhat Easy  
□5  Easy  
□6  Very Easy  
□7  Extremely Easy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    111 10. How easy or difficult is it to plan when you will use the medication each time?  
□1  Extremely Difficult  
□2  Very Difficult  
□3  Difficult  
□4  Somewhat Easy  
□5  Easy  
□6  Very Easy  
□7  Extremely Easy  
 
11. How convenient or inconvenient is it to take the medication as instructed?  
□1  Extremely Inconvenient  
□2  Very Inconvenient  
□3  Inconvenient  
□4  Somewhat Convenient  
□5  Convenient  
□6  Very Convenient  
□7  Extremely Convenient  
 
12. Overall, how confident are you that taking this medication is a good thing for you?  
□1  Not at All Confident  
□2  A Little Confident  
□3  Somewhat Confident  
□4  Very Confident  
□5 Extremely Confident  
 
 
 
 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    112 13. How certain are you that the good things about your medication outweigh the bad things?  
□1  Not at All Certain  
□2  A Little Certain  
□3  Somewhat Certain  
□4  Very Certain  
□5 Extremely Certain  
 
14. Taking all things into account, how satisfied or dissatisfied are you with this medication?  
□1  Extremely Dissatisfied  
□2  Very Dissatisfied  
□3  Dissatisfied  
□4  Somewhat Satisfied  
□5  Satisfied  
□6  Very Satisfied  
□7  Extremely Satisfied  
 
 
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455731] severe problems washing or dressing myself   
  
I am unable to wash or dress myself     
  
 
USUAL ACTIVITIES  (e.g. work, study, housework, family or  leisure activities)  
I have no problems doing my  usual activities   
  
I have slight problems doing my usual activities   
  
I have moderate problems doing my usual activities   
  
I have severe problems doing my usual activities   
  
I am unable to do my usual activities    
  
 
PAIN / DISCOMFORT  
I have no pain or discomfort      
  
I have slight pain or discomfort     
  
I have moderate pain or discomfort     
  
I have severe pain or discomfort     
  
I have extreme pain or discomfort     
  
 
ANXIETY / DEPRESSION  
I am not anxious or depressed     
  
I am slightly anxious or depressed     
  
I am moderately anxious or depressed    
  
I am severely anxious or depressed     
  
I am extremely anxious or depressed     
  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    114  
EQ-5D-5L 
 
  

Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    115 Appendix VIII: Structured Risk Analysis  
 
Potential issues of concern  
a. Level of knowledge about mechanism of action  
As described in paragraph 1, the mechanism of action of docetaxel is well known.  
 
b. Previous exposure of human beings with the test product(s) and/or products with a similar 
biological mechanism  
As described in paragraph 1 , the study drug has been tested i n two prior phase I trials and one  
ongoing phase I trial. The safety of docetaxe l as i.v. formulation  in the patient population is well 
known.  
 
c. Can the primary or secondary mechanism be induced in animals and/or in ex -vivo human cell 
material?  
The mechanism of action of docetaxel has been studied in cell material, animal and severa l 
human clinical studies.  
 
d. Selectivity of the mechanism to target tissue in animals and/or human beings  
As described in paragraph [ADDRESS_455732]  
As described in paragraph 7.9 , the efficacy of docetaxel as oral treatment will be evaluated by 
[CONTACT_364854], according to the international guidelines.  
 
f. Pharmacokinetic considerations  
As described in paragraph 1 , the pharmacokinetic  parameters of ModraDoc006/r have been  
evaluated in the prior phase I trials. Based on the observed pharmacokinetic parameters and the 
clinical experience in the prior phase I trials, the toxicity of ModraDoc006/r is expe cted to be 
lower and the efficacy is expected to be comparable or even superior to i.v. docetaxel treatment.  
 
g. Study population  
IV docetaxel treatment is well known. The toxicity of ModraDoc006/r is expected to be lower 
and the efficacy is expected to be  non-inferior or even superior  to i.v. docetaxel treatment.  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    116 h. Interaction with other products  
Besides CYP3A inducting or inhibiting products, no relevant interactions with other products are 
known for ModraDoc006/r in the study population . However, in vi ew of potential interactions a 
list of drugs and compounds either to be given with caution or not to be given together with 
ModraDoc006/r is provided in Appendix VIIII.  
 
i. Predictability of effect  
Based on the observed pharmacokinetic parameters and the clinical experience in the prior phase 
I trials, the toxicity of ModraDoc006/r is expected to be lower and the efficacy is expected to be 
comparable or even superior to i.v. docetaxel treatment . 
 
j. Can effects be managed?  
As described in  paragraph 8 , all toxicities will be closely  monitored and treated.  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    117 Appendix VIII I: Drug-Drug Interactions  
Substrates  
 
These drugs need to be used with great caution since the 
inhibition of CYP3A4 by [CONTACT_364855]3A4 are not allowed 
to be used concomitantly 
with the study drug  Inducers  
 
These i nducers of 
CYP3A4 are not allowed 
to be used co ncomi tantly 
with the study drug  
Anti-arrhythmics:  
quinidine  
alprazolam  
digoxin  
midazolam  
triazolam  
Immune Modulators:  
cyclosporine  
tacrolimus  
Antihistamines:  
astemizole  
chlorpheniramine  
terfenadine  
Calcium Channel  
Blockers:  
amlodipi[INVESTIGATOR_364765] -arrhythmic 
Agents:  
flecainide  
propafenone  
Antipsychotic Agent:  
lurasidone  
Lipid lowering Agents:  
simvastatin  
atorvastatin  
rosuvastatin  Other Agents:  
alfuzosin  
aripi[INVESTIGATOR_364766]:  
indinavir  
nelfinavir  
saquinavir  
 
Anti-microbial agents:  
clarithromycin  
itraconazole  
ketoconazole  
nefazodone  
telithromycin  
erythromycin  
fluconazole  
chloramphenicol  
ciprofloxacin  
norfloxacin  
voriconazole  
 
Cardiac agents:  
verapamil  
diltiazem  
cimetidine  
amiodarone  
 
Other agents:  
fluvoxamine  
 
Fruits  
star fruit  
grapefruit juice  HIV Antivirals:  
efavirenz  
nevirapi[INVESTIGATOR_364767]:  
barbiturates  
carbamazepi[INVESTIGATOR_364768]. John's wort  
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    118 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
OATP1B1 by [CONTACT_364856]1B1 are 
not allowed to be used concomitantly 
with the study drug  Inducers  
 
These inducers of OATP1B1 are not 
allowed to be used co ncomitantly 
with the study drug  
 
ambrisentan  
atorvastatin  
atrasentan  
bilirubin  
bosentan  
docetaxel  
empagliflozin  
enalapril  
ezetimibe  
fexofenadine  
fluvastatin  
glyburide  
glecaprevir  
grazoprevir  
irinotecan  
lovastatin  
methotrexate  
olmesartan  
paritaprevir  
phalloidin  
pi[INVESTIGATOR_364769]   
N/A 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    119 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
OATP1B3 by [CONTACT_364856]1B3 are 
not allowed to be used concomitantly 
with the study drug  Inducers  
 
These i nducers of OATP1B3 are not 
allow ed to be used co ncomitantly 
with the study drug  
 
atorvastatin  
atrasentan  
bilirubin  
bosentan  
demethylphalloin  
digoxin  
docetaxel  
empagliflozin  
enalapril  
estradiol -17β-glucuronide 5 –25 
estrone -3-sulfate  
fexofenadine  
fluvastatin  
irinotecan  
glecaprevir  
grazoprevir  
methotrexate  
olmesartan  
paclitaxel  
paritaprevir  
phalloidin  
pi[INVESTIGATOR_364770] (T4)  
valsartan  
velpatasvir  
voxilaprevir   
ataza navir 
clarithromycin  
cobicistat  
cyclosporine  
daclatasvir  
erythromycin  
glecaprevir  
lopi[INVESTIGATOR_054]/ritonavir  
paritaprevir  
pi[INVESTIGATOR_364771]   
N/A 
 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455733]. John's Wort  
tipranavir  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    121 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
P-glycoprotein by [CONTACT_364857] P -glycoprotein 
are not allowed to be used 
concomitantly with the study drug  Inducers  
 
These i nducers of P -glycoprotein 
are not al lowed to be used 
concomitantly with the study drug  
fluvastatin  
fosamprenavir  
glecaprevir  
grazoprevir  
imatinib  
indacaterol  
indinavir  
itraconazole  
ivermectin  
lapatinib  
ledipasvir  
levomilnacipran  
linagliptin  
loperamide  
losartan  
lovastatin  
maraviroc  
methotrexate  
morphine  
nelfinavir  
nilotinib  
ombitasvir  
paclitaxel  
paliperidone  
paritaprevir  
phenytoin  
pi[INVESTIGATOR_364772] t  
tacrolimus  
tamoxifen   
telaprevir  
ticagrelor  
velpatasvir  
verapamil  
vorapaxar  
voxilaprevir  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    122 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
P-glycoprotein by [CONTACT_364857] P -glycoprotein 
are not allowed to be used 
concomitantly with the study drug  Inducers  
 
These i nducers of P -glycoprotein 
are not al lowed to be used 
concomitantly with the study drug  
ritonavir  
rivaroxaban  
saquinavir  
saxagliptin  
silodosin  
simvastatin  
sirolimus  
sitagliptin  
sofosbuvir  
tacrolimus  
ticagrelor  
telaprevir  
tetracycline  
tipranavir  
tolvaptan  
topotecan  
umeclidinium  
vecuronium  
velpatasvir  
verapamil  
vilanterol  
vinblastine  
vincristine  
voxilaprevir  
 
 
 
 
 
 
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    123 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
MRP -2 by [CONTACT_364858] -2 are not 
allowed to be used concomitantly 
with the study drug  Inducers  
 
These inducers of MRP -2 are not 
allowed to be used co ncomitantly 
with the study drug  
 
acetaminophen  
adefovir  
ampi[INVESTIGATOR_364773] , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    124 Substrates  
 
These drugs need to be used with 
great caution since the inhibition of 
MRP -2 by [CONTACT_364858] -2 are not 
allowed to be used concomitantly 
with the study drug  Inducers  
 
These inducers of MRP -2 are not 
allowed to be used co ncomitantly 
with the study drug  
vinflunine  
vinorelbine  
 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    125 12. REFERENCES  
1. Hassanipour -Azgomi S, Mohammadian -Hafshejani A, Ghoncheh M, Towhidi F, 
Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their 
relationship with the Human Development Index worldwide. Prostate Int. 2016;4(3):118 -
124. 
2. Heidenrei ch A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: 
Treatment of advanced, relapsing, and castration -resistant prostate cancer. European 
urology. 2014;65(2):467 -479. 
3. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelin es on prostate cancer. part 1: 
screening, diagnosis, and local treatment with curative intent -update 2013. European 
urology. 2014;65(1):[ADDRESS_455734] ED. Characterising the castration -resistant prostate cancer 
population: a systema tic review. International journal of clinical practice. 
2011;65(11):1180 -1192.  
5. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The 
development of risk groups in men with metastatic castration -resistant prostate cancer 
based on ri sk factors for PSA decline and survival. European journal of cancer. 
2010;46(3):517 -525. 
6. Armstrong AJ. Docetaxel for advanced prostate cancer: how early to start? Lancet 
Oncology. 2015;16:[ADDRESS_455735]-line long -term hormone therapy in prostate cancer (STAMPEDE): survival results 
from an adaptive, multiarm, multistage, platform randomi sed controlled trial. Lancet 
(London, England). 2016;387([ZIP_CODE]):1163 -1177.  
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. The New England journal of medicine. 
2004;351(15):[ADDRESS_455736] ine compared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. The New England 
journal of medicine. 2004;351(15):1513 -1520.  
10. Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without 
lenalidomide in che motherapy -naive patients with metastatic castration -resistant prostate 
cancer (MAINSAIL): a randomi sed, double -blind, placebo -controlled phase 3 trial. The 
Lancet Oncology. 2015;16(4):417 -425. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    126 11. Kelly WK, Halabi S, Carducci M, et al. Randomized, double -blind, placebo -controlled 
phase III trial comparing docetaxel and prednisone with or without bevacizumab in men 
with metastatic castration -resistant prostate cancer: CALGB [ZIP_CODE]. Journal of clinical 
oncology : official journal of the American Society of Cli nical Oncology. 
2012;30(13):1534 -1540.  
12. Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomi sed, placebo -controlled study of 
docetaxel in combination with zibotentan in patients with metastatic castration -resistant 
prostate cancer. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2013;31(14):1740 -1747.  
13. Meulenbeld HJ, van Werkhoven ED, Coenen JL, et al. Randomi sed phase II/III study of 
docetaxel with or without risedronate in patients with metastatic Castration Resistant 
Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of 
cancer (Oxford, England : 1990). 2012;48(16):[ADDRESS_455737] -line therapy for metastatic castration -resistant prostate cancer. Annals of 
oncology : official journal of the European Society for Medical Oncology. 
2012;23(7):1803 -1808.  
15. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel a nd 
placebo for men with advanced castration -resistant prostate cancer (SWOG S0421): a 
randomi sed phase 3 trial. The Lancet Oncology. 2013;14(9):893 -900. 
16. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with 
docetaxel and  prednisone for treatment of men with metastatic castration -resistant prostate 
cancer (VENICE): a phase 3, double -blind randomized  trial. The Lancet Oncology. 
2013;14(8):[ADDRESS_455738]-Line Therapy 
for Patients With Metastatic Castration -Resistant Prostate Cancer: A Randomized Phase III 
Trial -FIRSTANA. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2017;35(28):3189 -3197.  
18. Araujo JC, T rudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with 
metastatic castration -resistant prostate cancer (READY): a randomized , double -blind phase 
3 trial. The Lancet Oncology. 2013;14(13):[ADDRESS_455739] B, Sweeney CJ. Management of Metastatic Hormone -Sensitive Prostate Cancer. 
Current Urology Reports. 2015;16(3).  
20. Gietema JA, Oosting SF. [Docetaxel for metastatic prostate cancer: early is better]. 
Docetaxel voor gemetastaseerd prostaatcarcinoom. 2016;160(0):D215 -D215.  
21. Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate 
cancer : recommendations of the St Gallen Advanced Prostate Cancer Consensus 
Conference ( APCCC ) 2015. 2015:1 -16. 
22. Graff JN, Beer TM. Should docetaxel be administered earlier in prostate cancer therapy? 
Expert Review of Anticancer Therapy. 2015;15(9):977 -979. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    127 23. Gravis G, Fizazi K, Joly F, et al. Androgen -deprivation therapy alone or with docetaxel in 
non-castrate metastatic prostate cancer (GETUG -AFU 15): A randomized , Open -label, 
Phase 3 trial. The Lancet Oncology. 2013;14(2):149 -158. 
24. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic 
prostate cancer in the docetaxel era: Data from 917 patients in the control arm of the 
STAMPEDE Trial (MRC PR08, CR[LOCATION_006]/06/019). European urology. 2015;67(6):1028 -
1038.  
25. Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology 
(Williston Park, NY). 2015;29(12):956 -962. 
26. Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate -sensitive prostate cancer. 
Prostate Cancer Prostatic Dis. 2016;19(2):139 -144. 
27. Sweeney CJ, Chen Y -H, Carducci M, et al. Chemohormonal Therapy in Metastatic 
Hormone -Sensitive Prostate Cancer. New England Journal of Medicine. 2015;373(8):[ADDRESS_455740] of care in men with localised or metastatic, hormone -sensitive prostate cancer: A 
systematic review and meta -analyses of aggregate data. The Lancet Oncology. 
2016;17 (2):243 -256. 
29. Beer TM, Pi[INVESTIGATOR_364774], Lowe BA, Henner WD. Phase II study of weekly docetaxel in 
symptomatic androgen -independent prostate cancer. Annals of oncology : official journal of 
the European Society for Medical Oncology. 2001;12(9):1273 -1279.  
30. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single -agent weekly 
docetaxel in hormone -refractory, symptomatic, metastatic carcinoma of the prostate. 
Seminars in oncology. 2001;28([ADDRESS_455741] 15):8 -15. 
31. Malhotra A, Welch D, Rosenbaum P, Poiesz BJ. Efficacy and Toxicity of Every 2 Weeks 
Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate 
Cancer: A Retrospective Analysis. American journal of clinical oncology. 2016;39(3):266 -
270. 
32. Nakai Y, Nishimura K, Nakayama M , et al. Weekly, low -dose docetaxel combined with 
estramustine for Japanese castration -resistant prostate cancer: its efficacy and safety profile 
compared with tri -weekly standard -dose treatment. International journal of clinical 
oncology. 2014;19(1):165 -172. 
33. Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic 
metastatic hormone -refractory prostate carcinoma. Cancer. 2003;98(8):1627 -1634.  
34. Petrioli R, Pozzessere D, Messinese S, et al. Weekly low -dose docetaxel in ad vanced 
hormone -resistant prostate cancer patients previously exposed to chemotherapy. Oncology. 
2003;64(4):300 -305. 
35. Ferrero JM, Foa C, Thezenas S, et al. A weekly schedule of docetaxel for metastatic 
hormone -refractory prostate cancer. Oncology. 2004;6 6(4):281 -287. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    128 36. Kojima T, Shimazui T, Onozawa M, et al. Weekly administration of docetaxel in patients 
with hormone -refractory prostate cancer: a pi[INVESTIGATOR_364775]. Japanese 
journal of clinical oncology. 2004;34(3):137 -141. 
37. McKeage K. Docetaxel: A review of its use for the first -line treatment of advanced 
castration -resistant prostate cancer. Drugs. 2012;72(11):[ADDRESS_455742], Harmenberg U, Joensuu T, et al. 2 -Weekly versus 3 -weekly 
docetaxel to treat castration -resistant advanced prostate cancer: a randomized , phase 3 trial. 
The Lancet Oncology. 2013;14(2):[ADDRESS_455743] of prednisone on toxicities 
and survival in metastatic castration -resistant prostate cancer : A systematic review and 
meta -analysis of randomized clinical trials. Critical reviews in oncology/hematology. 
2014;90(3):253 -261. 
40. Ndibe C, Wang CG, Sonpavde G. Corticosteroids in the management of prostate cancer: a 
critical review. Current treatment options in oncology. 2015;16(2):6.  
41. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of 
metastatic prostatic cancer with low -dose prednisone: evaluation of pain and quality of life 
as pragmatic indices of response. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 1989;7(5):[ADDRESS_455744] of prednisone on prostate -
specific antigen in patients with hormone -refractory prostate cancer. Urology. 
1998;52(2):252 -256. 
43. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: 
implications for the  management of androgen -independent prostate cancer. Urology. 
1996;47(1A Suppl):61 -69. 
44. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate 
specific antigen levels and clinical response to low dose dexamethasone for hormon e-
refractory metastatic prostate carcinoma. Cancer. 1995;76(1):96 -100. 
45. Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute 
to the response rate of docetaxel and estramustine in androgen independent prostate cancer. 
The Journal of urology. 2000;163(3):834 -837. 
46. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic 
Hormone -Sensitive Prostate Cancer. The New England journal of medicine. 
2015;373(8):737 -746. 
47. Schellens JHM, Malingré MM, Kruijtz er CMF, et al. Modulation of oral bioavailability of 
anticancer drugs: From mouse to man. European Journal of Pharmaceutical Sciences. 
2000;12(2):103 -110. 
48. Banna GL, Collovà E, Gebbia V, et al. Anticancer oral therapy: Emerging related issues. 
Cancer tr eatment reviews. 2010;36(8):595 -605. 
49. Borner M. Answering Patients' Needs: Oral Alternatives to Intravenous Therapy. The 
oncologist. 2001;6([ZIP_CODE]):12 -16. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    129 50. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative 
chemotherapy. Journal of Clinical Oncology. 1997;15(1):[ADDRESS_455745] together in restricting the oral bioavailability of 
paclitaxel. Interna tional journal of cancer. 2013;132(10):2439 -2447.  
52. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopi[INVESTIGATOR_054]/ritonavir provides 
similar bioavailability to the soft -gelatin capsule formulation with less pharmacokinetic 
variability and diminis hed food effect. Journal of Acquired Immune Deficiency Syndromes. 
2007;44(4):401 -410. 
53. Kessler H, Brun S, King M, Al E. Analysis of safety data from ABT -378/ritonavir in two 
Phase II clinical trials. Presented at the XIII international AIDS conference: AIDS 2000 
Durban, South Africa. 2000;July 9 -14. 
54. Marechal JD, Yu J, Brown S, et al. In silico and in vitro screening for inhibition of 
cytochrome P450 CYP3A4 by [CONTACT_364859]. 
Drug Metabolism & Disposition. 2006;34: 534-538. 
55. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel 
in mice resulting from extensive first -pass metabolism is boosted by [CONTACT_364860]. Cancer 
research. 2002;62(21):6158 -6164.  
56. de Weger VA, Stuurman FE, Hendrik x J, et al. A dose -escalation study of bi -daily once 
weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. 
European journal of cancer (Oxford, England : 1990). 2017;86:217 -225. 
57. de Weger V.A. SFE, Mergui -Roelvink M., Nuijen  B., Huitema A.D.R., Beijnen J.H., 
Schellens J.H.M., Marchetti S. A phase I dose -escalation trial of bi -daily (BID) weekly oral 
docetaxel as ModraDoc006 in combination with ritonavir. 2016; 
https://oncologypro.esmo.org/Meeting -Resources/ESMO -2016/A -phase -I-dose-escalation -
trial-of-bi-daily -BID-weekly -oral-docetaxel -as-ModraDoc006 -in-combination -with-
ritonavir . 
58. Baker SD, Zhao M, Lee CKK, et al. Comparative Pharmacokinetics of Weekly and ev ery-
three -weeks docetaxel. Clinical cancer research. 2004;10(410):1976 -1983.  
59. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of 
docetaxel in phase II studies in patients with cancer. Journal of clinical oncology : official  
journal of the American Society of Clinical Oncology. 1998;16(1):187 -196. 
60. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population 
pharmacokinetic model for docetaxel (Taxotere): model building and validation. Journal of 
phar macokinetics and biopharmaceutics. 1996;24(2):153 -172. 
61. Bruno R, Vivier N, Veyrat -Follet C, Montay G, Rhodes GR. Population pharmacokinetics 
and pharmacokinetic -pharmacodynamic relationships for docetaxel. Investigational new 
drugs. 2001;19(2):163 -169. 
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  [ADDRESS_455746]. Population 
pharmacokinetics of intravenously and orally administered docetaxel with or without co -
administration of ritonavir in patients with advanced cancer. British journal of clinic al 
pharmacology. 2010;69(5):465 -474. 
63. Kaplan SS, Hicks CB. Safety and antiviral activity of lopi[INVESTIGATOR_054]/ritonavir -based therapy in 
human immunodeficiency virus type 1 (HIV -1) infection. The Journal of antimicrobial 
chemotherapy. 2005;56(2):273 -276. 
64. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels 
and side -effects: Implications for therapeutic drug monitoring. Aids. 1999;13(15):2083 -
2089.  
65. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine c ompared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. New England 
Journal of Medicine. 2004;351(15):1513 -1520.  
66. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II 
clinical trials in androgen -independent prostate cancer: recommendations from the 
Prostate -Specific Antigen Working Group. Journal of clinical oncology : official journ al of 
the American Society of Clinical Oncology. 1999;17(11):3461 -3467.  
67. Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of 
metastatic castration -resistant prostate cancer: state of the science. Prostate cancer and 
prosta tic diseases. 2016;19(2):111 -121. 
68. Clark MJ, Harris N, Griebsch I, Kaschinski D, Copley -Merriman C. Patient -reported 
outcome labeling claims and measurement approach for metastatic castration -resistant 
prostate cancer treatments in the [LOCATION_002] and  European Union. Health and quality of 
life outcomes. 2014;12:104.  
69. Moul JW, Dawson N. Quality of life associated with treatment of castration -resistant 
prostate cancer: a review of the literature. Cancer investigation. 2012;30(1):1 -12. 
70. Schmid S, Om lin A, Blum D, Strasser F, Gillessen S, Rothermundt C. Assessment of 
anticancer -treatment outcome in patients with metastatic castration -resistant prostate 
cancer -going beyond PSA and imaging, a systematic literature review. Annals of oncology 
: official j ournal of the European Society for Medical Oncology / ESMO. 
2015;26(11):[ADDRESS_455747] of enzalutamide 
on quality of life in men with metastatic castration -resistant prostate cancer aft er 
chemotherapy: additional analyses from the AFFIRM randomi sed clinical trial. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO. 
2015;26(1):[ADDRESS_455748] skeletal -related 
event, pain, and quality of life in men with castration -resistant prostate cancer: results from 
the randomi sed, phase 3 AFFIRM trial. The Lancet Oncology. 2014;15(10):1147 -1156.  
Modra Pharmaceuticals  Clinical Trial Protocol , Amendment 2   Final Version V3.0  
ModraDoc006/r  M18MDP  31 Mar 2020  
Confidential    131 74. Banna GL, Collova E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. 
Cancer treatment reviews. 2010;36(8):595 -605. 
75. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of 
taxane therapy in oncology: the functional assesment of cancer therapy -taxane (FACT -
taxane). Cancer. 2003;98(4):822 -831. 
76. Atkinson MJ, Sinha A, Hass SL, et al. Validatio n of a general measure of treatment 
satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a 
national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.  
77. FDA. Taxotere label FDA. 2013; 
https://www.accessda ta.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf . Accessed 
03-09-2018.  
78. EMA. Taxotere EPAR. 2005; https://www.ema.europa.eu/documents/product -
information/taxotere -epar-product -information_en.pdf . Accessed 27 -09-2018.  
79. Anonymus. GUIDELINE FOR G OOD CLINICAL PRACTICE. 1996; 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6
_R1_Guideline.pdf . Accessed 26 -09-2018.  
80. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumor s: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, 
England : 1990). 2009;45(2):[ADDRESS_455749] ant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical 
Trials Working Group 3 (PCWG3). Journal of  Clinical Oncol ogy. 2016;34:1402 -1418 . 
 
 